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Gynaecological malignancy is a common diagnosis that is highly amenable to
effective treatment. Unfortunately the incidence of thrombosis, together with its
morbidity and mortality, remains significant in this patient group. Patients with
thrombosis have also been shown to have a worse prognosis. Thromboprophylaxis
can reduce the incidence of thrombosis and may potentially also improve outcomes.
Primary thromboprophylaxis could be indicated in patients considered to be at high
risk of thrombosis. However empirical thromboprophylaxis is not without its risks as
cancer patients also have a significant risk of bleeding. Primary thromboprophylaxis
cannot at present be recommended for all patients with gynaecological malignancy.
We are currently unable to assess whether or when a thrombosis is likely to happen.
The ability to identify patients at a high risk of thrombosis would allow a more
tailored approach to primary thromboprophylaxis that could translate into improved
outcomes.
Microparticles are postulated to be important participants in many
pathophysiological processes, including haemostasis and thrombosis. There is also
increasing evidence that microparticles influence cancer cell survival, invasiveness
and metastasis. There are several publications in peer reviewed literature reporting
increased numbers of circulating plasma microparticles in patients with malignancy
and other prothrombotic conditions. It is hypothesised that microparticles may be
directly involved in the pathogenesis of thrombosis and in cancer cell survival and
progression, and hence may have a direct effect on overall prognosis and outcome.
Measuring the number of circulating plasma microparticles could potentially help
identify cancer patients at increased risk of thrombosis that may benefit from primary
thromboprophylaxis, which in turn could potentially lead to improved overall
outcomes.
I set out to quantify and compare the number of circulating plasma microparticles in
patients with gynaecological malignancy and a control group of women with no
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malignancy. I also wanted to establish whether measuring the number of plasma
microparticles would identify patients at an increased risk of thrombosis.
Research on microparticles is currently hampered by the lack of a standardised
method for the identification and quantification of microparticles, mainly due to their
small size. There are several pre-analytical variables that may influence the number
of microparticles identified. These include the isolation methods, the labelling
antibodies and the assays used to quantify microparticles, amongst others. Use of
different laboratory techniques by different investigators makes the meaningful
comparison of results in the published literature difficult.
Flow cytometry is the technique most commonly used to quantify microparticles. I
set up a laboratory assay based on light-scattering flow cytometry to identify and
quantify microparticles. Platelet free plasma was prepared from citrated blood,
monoclonal antibodies were used to label microparticles, and a flow based method
used to quantify the absolute number of microparticles in the patient plasma by flow
cytometry.
There is currently still debate as to whether microparticle assays need to be done on
fresh plasma samples or whether they can be meaningfully done on frozen samples.
In the first twenty patients I compared the results obtained from fresh plasma with
the results from a separate aliquot of the same plasma sample that had been stored
frozen at -80°C. The number ofmicroparticles detected after a freeze/thaw cycle did
not correlate with the results obtained from fresh plasma. In view of this I analysed
all patient samples on fresh plasma within two hours of collection. All patient
samples in my study have been handled in an identical manner to ensure that results
from different patients are comparable.
I recruited 67 women with gynaecological malignancy and a control group of 42
women without malignancy. I measured the total number of circulating platelet-
derived microparticles, leucocyte-derived microparticles, endothelial-cell derived
microparticles, tissue factor positive microparticles and annexin V positive
microparticles. There was no statistically significant difference in the number of
circulating microparticles between the patients with gynaecological malignancy and
the women without malignancy. Five (7.5%) of the patients with gynaecological
malignancy were diagnosed with a venous thrombotic event during the study follow
up period (median of 11 months, range 5-17 months). The number of plasma
microparticles in the latter patients was indistinguishable from that in gynaecological
cancer patients without thrombosis and in the control group. However, because only
a small number of patients (five) were diagnosed with a thrombosis, it has not been
possible to ascertain whether such patients truly do not have raised levels of
microparticles, or whether a larger study might demonstrate a difference.
In order to establish whether my study cohort is representative of gynae-oncology
patients in the South East of Scotland Cancer Network (SCAN), I identified all
patients diagnosed with a gynaecological malignancy in SCAN during 2009 (period
of study recruitment). I compared the characteristics of this group of patients with
my study cohort and found that my study cohort was highly representative of the
overall population of patients with gynaecological malignancy in SCAN with a
similar frequency of the different gynaecological malignancies and a similar
incidence of thrombosis.
There are a number of limitations to this study. There is still no universally accepted
definition of what constitutes a microparticle. The assay 1 have used, while
standardised for this study, is not universally used by all investigators measuring
microparticles. Although flow cytometry is the commonest technique used to
measure microparticles, the accuracy of the assay is called into question given the
small size of the microparticles being measured. Further this is a single centre study,
and although all the patients recruited had been diagnosed with gynaecological
malignancy, given the variable nature and prognosis of the different types of
gynaecological cancers, the patients recruited are in fact a diverse group. Recruiting
patients with a specific type of gynaecological cancer only would have led to a more
uniform group of patients that are more readily comparable. The overall number of
patients diagnosed with a venous thromboembolic event, while representative of the
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overall population in SCAN diagnosed with gynaecological cancer, is too small to be
able to draw any firm conclusions regarding the usefulness of measuring
microparticles as a prothrombotic marker or otherwise, particularly given the
different incidence of venous thrombotic events in the different types of
gynaecological cancer.
As far as I can establish this is the first study looking at microparticles specifically in
patients with gynaecological malignancy. Keeping the limitations of the study in
mind, I did not find a difference in the number of plasma microparticles in patients
with gynaecological malignancy compared to a control group of women with no
cancer. Further, microparticles cannot at present be used to help identify patients
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Using the Shapiro-Wilk test, the variables measured in this study (microparticle
numbers, markers of haemostatic activation and haematological and renal
parameters) were found not to be normally distributed. Values are therefore
expressed as the median and the interquartile range (IQR). Comparisons between
two independent groups of patients were carried out using the Mann Whitney U test,
while comparisons between three or more independent groups were carried out using
the Kruskal Wallis test. Multivariate analysis was also carried out to allow for age
adjustment.
The correlation between different variables has been assessed using Spearman's
nonparametric correlation coefficient (r). Paired samples were compared using the
Wilcoxon Signed Ranks test. All reported probability values are two-tailed.
Statistical significance was defined as a p value of < 0.05. Analyses were performed
with the statistical package SPSS version 17.0 (SPSS Inc, Chicago, IL, USA).
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Gynaecological malignancies consist of ovarian cancer (which includes fallopian
tube cancer and primary peritoneal cancer), endometrial cancer, cervical cancer,
vaginal cancer and vulval cancer. Together they are the third[l] commonest (after
breast and colorectal cancer) diagnosis of cancer in women in the developed world
(second commonest in the developing world), with the overall incidence worldwide
being approximately 1 million women per annum[2]. Gynaecological cancers are
highly amenable to effective treatment. The 10 year survival rate varies according to
the specific type of gynaecological malignancy, being 75% for endometrial cancer,
62% for cervical cancer and 36% for ovarian cancer[3].
The management of individual patients with gynaecological cancer varies according
to the specific cancer site (i.e. ovarian, cervix, vaginal, vulval, endometrial), its
histological subtype (e.g. squamous carcinoma, mucinous carcinoma), the clinical
stage and any co-morbidities the patient may have. Treatment normally includes any
or all of surgery, chemotherapy and radiotherapy (external beam radiotherapy and/or
brachytherapy)[4].
Unfortunately VTE (DVT and/or pulmonary embolism) remains a complication in
this patient group, occurring either as a presenting feature or as a complication of
treatment or disease progression[5-10]. The management of VTE events in cancer
patients has improved significantly over recent years; however VTE remains the
second commonest cause of death in this group of patients[5].
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1.1.2 VTE in cancer patients
1.1.2.1 Incidence of VTE
Cancer patients have a 4-5 fold (in some studies up to 7-fold)[l 1-15] increased risk
of VTE. Patients with cancer represent approximately 15-20% of all patients
presenting with a VTE[13-15], and 20% of all cancer patients will experience a VTE
at some point[16]. The highest incidence of VTE is reported in patients with
malignancies of the ovary, pancreas and glioblastomas^, 17, 18]. The risk of VTE
is highest in the first year after the malignancy is diagnosed, reflecting both the
presence of a malignancy and its treatment; in the first 3 months the risk is increased
53-fold, and then declines thereafter. By 2 years after the diagnosis of cancer the
relative risk of VTE decreases considerably, but remains higher than that of the
general population, and it is only after 15 years that the risk subsides[7, 11, 19]. This
seems to be true both for patients with only a lower limb DVT and for patients with a
pulmonary embolism with/without lower limb DVT. Most thrombotic events
involve the venous system, although arterial thromboembolism has also been
reported[20-22].
The risk of VTE is also linked to the extent of disease. The relative risk of VTE in
patients with metastasis is increased 58-fold compared to patients with no
malignancy, a much higher risk than for patients with cancer but no metastases (4-
fold)[ll]. The presence of metastases is associated with a hypercoagulable state as
the haemostatic system plays an important role in the ability of solid tumours to
metastasise (see section 1.1.2.3, page 6).
Unfortunately there is little in the way of prospective data assessing the incidence of
VTE events in cancer patients through systematic screening; the estimates available
are derived from autopsy series, epidemiological surveys, and prospective
chemotherapy trials. The quoted incidence of VTE events in patients with
gynaecological malignancy is very variable: 13.6-27% of ovarian cancer
patients[23], 9.8-57% of patients with endometrial cancer[8, 24, 25] and 0-34% of
patients with cervical cancer[9]. The rate of pulmonary embolism is reported to be
1-2.6%, and goes up to 6.8% in post-operative ovarian cancer patients[6].
^ In a significant proportion of patients with gynaecological malignancy clinically
silent VTE is detectable prior to any treatment; please refer to Table 1.1 [8, 26]. Such
asymptomatic VTE present prior to surgery may progress and become symptomatic
postoperatively, partly contributing to the high incidence ofVTE in the postoperative
period in patients with gynaecological cancer. Clinically asymptomatic DVT has
been found in as many as 25% of patients with ovarian cancer and 9.9% of patients
with endometrial cancer. However there are several studies that have documented an
>
even higher incidence of postoperative VTE in patients with endometrial cancer[24,
27-29], so that the incidence of asymptomatic VTE prior to surgery is unlikely to
fully account for the high incidence of VTE postoperatively in such patients[8]. In











Table 1.1: Incidence of clinically silent venous thromboembolism (VTE) prior to
treatment in patients with gynaecological malignancy[8]. Deep vein thrombosis
(DVT), pulmonary embolism (PE).
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1.1.2.2 Pathophysiology of VTE
Despite the strong association between malignancy and VTE, the pathophysiological
basis of this relationship remains uncertain. Virchow's triad of endothelial damage,
blood stasis, and hypercoagulable state leading to VTE remains valid today[30]. In
patients with gynaecological malignancy thrombosis occurs as a result of the
interaction ofmany different variables including a) patient specific factors, b) tumour
related factors and c) extrinsic factors related to the treatment of the tumour (surgery,
chemotherapy, radiotherapy).
The patient specific factors that contribute to the risk of thrombosis are many and
variable, including older age, increased BMI, immobility, genetic prothrombotic
defects (such as factor V Leiden and antithrombin deficiency[20]), sepsis, smoking,
hypertension and diabetes.
The tumour related prothrombotic factors are also many and variable. They include
the physical characteristics of the tumour such as the size and site of any pelvic
masses that may be compressing (causing blood stasis) and damaging the
endothelium of blood vessels, as well as the characteristics of the tumour cells and
the tumour microenvironment. Tumour cells can up-regulate coagulation factors,
down-regulate the fibrinolytic system, and express cytokines or regulatory proteins
associated with clot formation[31]. Tumour cells can also secrete coagulation factors
themselves (e.g. TF, thrombin) so that monocytes and endothelial cells in the tumour
microenvironment can also promote thrombosis[20, 32-34]. The prothrombotic state
of cancer patients is due to an imbalance between the procoagulant and anticoagulant
systems of the body, damage to the endothelium of blood vessels, and activation of
platelets[20].
Treatment of the malignancy also contributes to the prothrombotic state of cancer
patients[7, 35-40], Treatment of gynaecological cancer can include any or all of
surgery (often complex abdominal and pelvic surgery), chemotherapy and
radiotherapy. These treatment modalities lead to a prothrombotic state through the
up-regulation of procoagulant proteins, down-regulation of anticoagulants
5
(antithrombin, protein C, protein S), suppression of the fibrinolytic system, increased
platelet activation, enhanced adhesion of neutrophils and the release of cytokines and
tumour procoagulants during tumour cell lysis[6, 41-46].
1.1.2.3 Thrombosis and cancer prognosis
VTE often occurs prior to the diagnosis of cancer, and patients with cancer who are
diagnosed with a thrombotic event have a worse prognosis[19, 20, 47]. There is a
vicious cycle in which hypercoagulability facilitates the aggressive behaviour of
malignancy and vice versa. The clotting and fibrinolytic pathways influence tumour
growth[48, 49]; coagulation factors have been found to have a profound effect on
tumour cell behaviour both in in vivo and in vitro studies, enhancing tumour cell
proliferation, invasion, angiogenesis, and metastasis[20]. The prothrombotic state
found in patients with malignancy seems to affect the ability of tumour cells to
survive, proliferate and disseminate[20, 48, 49].
Thrombotic episodes are associated with significant morbidity and mortality.
Patients presenting acutely with pulmonary embolism have an overall all cause 30-
day mortality of approximately 3%[ 13, 50-53]. The natural history of thrombosis is
more aggressive in patients with underlying cancer. The mortality rate in such
patients is higher than in patients with either cancer alone or thrombosis alone[6, 7,
12, 19, 20, 54], Patients in whom cancer was diagnosed within a year of a
thrombotic event are more likely to have advanced disease and a poor prognosis than
patients with cancer but no thrombosis[19]. Survival is particularly poor when the
diagnosis of cancer is concurrent with the thrombotic event; only 12% of patients
diagnosed with cancer at the time of a DVT were alive at 1 year[7, 19], while the
overall survival for patients in whom cancer was diagnosed more than one year after
VTE was similar to that for matched (for type of cancer and age) patients without
VTE. These findings indicate that VTE in a patient with cancer suggests the presence
of advanced and biologically aggressive disease; it is unlikely that the increased
mortality in patients with malignancy and VTE is purely a complication of VTE. A
number of studies suggest that anticoagulant therapy may reduce the incidence of
cancers, hinder their progression and decrease the mortality rate[19, 20, 55-60],
although not all studies have confirmed these findings[19, 61]. The exact
mechanism by which heparin mediates antitumour or antimetastatic activity is
unclear, however these findings raise the question of whether patients with VTE and
cancer should receive more aggressive anticoagulation than other patients with VTE
but no cancer. The relatively poor prognosis of cancer diagnosed soon after VTE
also suggests that more aggressive anticoagulant therapy might be appropriate in
such patients[19]. Further studies are needed to explore the interaction between the
clotting system and cancer progression. In the future, treatment targeting activated
clotting factors may be part of a viable strategy for treating cancer.
If cancer patients at a significantly increased risk of thrombosis could be
prospectively identified the use of primary thromboprophylaxis in this subgroup of
patients could reduce the risk associated with thrombotic events, and potentially
improve the prognosis of the malignancy. Thromboprophylaxis with mechanical
compression devices and/or heparin has been shown to significantly reduce the rate
of VTE (both DVT and pulmonary embolism) in patients undergoing surgery for
gynaecological cancer[6, 62-64], which in turn translates into a reduced mortality
rate, so that thromboprophylaxis is indicated in all patients undergoing such surgery.
However there is very little data on the use of primary thromboprophylaxis in the
non-surgical setting. At present we have no way of predicting whether or when
thrombosis will occur. Laboratory markers of coagulation activation are often
elevated in patients with cancer[18] but are of little clinical use in assessing the
individual risk for thrombosis. The use of thromboprophylaxis is not without its
risks: the risk ofmajor bleeding is 2-6 fold higher in patients with cancer[l 1,12, 65-
67]. Ifwe were able to identify subgroups of patients at increased risk of thrombosis,
then treatment with primary thromboprophylaxis could be targeted.
1.2 MICROPARTICLES
1.2.1 Definition and formation of MPs
In 1949 Chargaff[68] first recognised that platelet-free plasma (PFP) contains a
precipitable factor that can accelerate thrombin generation. In 1967, Wolf noted the
presence of cell-membrane derived material in PFP (obtained by ultra-centrifugation)
capable of generating thrombin[68, 69] - electron microscopy confirmed that these
small microvesicles originated from activated platelets; at the time Wolf described
them as "platelet dust". In 1999 Combes described EMPs derived from HUVECs
after TNFa stimulation[68, 70], These MPs were detectable in both healthy
individuals and patients with prothrombotic conditions, and they expressed the same
antigens as their cell of origin. Since then there has been a lot of research carried out
to further define MPs and to try to establish their properties and functions.
MPs are described as intact phospholipid vesicles, 0.1-1.0pm in diameter[71],
released from the cell membranes of most cells (platelets, leucocytes, endothelial
cell, tumour cells) by budding of parts of the outer cell membrane[18, 72], They are
a heterogeneous group, bearing cell-specific surface antigens of their cell of origin,
and lacking a nucleus. They are distinct from apoptotic bodies and exosomes[73],
the latter being formed intracellularly and released by fusion with the cell membrane,
while apoptotic bodies are formed during the final stages of programmed cell death
and are generally larger than MPs. The release of MPs is a physiological process,
with MPs being detectable in all individuals. Their levels are reported to be higher in
females and are affected by the menstrual cycle and the circadian rhythm[73-75].
Most investigators have reported that in healthy individuals PMPs make up the
majority of MPs (70-90% of all circulating MPs), with LMPs, EMPs and RMPs
making up the remainder[71, 76, 77]. More recently Shah found that in healthy
individuals the major sources of MPs were endothelial cells and platelets,
contributing to 43.8% and 38.5% of all MPs respectively[78, 79], When one
considers the total endothelial cell surface area (average adult ~350m2), it would not
be surprising if EMPs do predominate in the circulation[78, 80], These differences
in the published literature may reflect variability in the underlying medical
conditions; however the method of sample preparation and processing is also likely
to be contributing to the variable results by different investigators. The profile of
circulating MPs does seem to alter with disease states. In patients with malignancy
TMPs can also be detected, and analysis of such TMPs could have a diagnostic and
possibly therapeutic potential. Patients with malignancy and/or thrombosis are
known to have evidence of endothelial dysfunction, vascular inflammation and a
prothrombotic state, and as might be expected elevated levels of MPs have been
reported in these conditions[18, 23, 81-83].
The number of circulating MPs depends on the balance between their rate of release
from cells and their clearance from the circulation. Cell activation results in an
increase in the rate ofMP release. The method ofMP clearance from the circulation
is less clear. Platelets have a life span of approximately 10 days, much longer than
that reported for PMPs of about 30 minutes in mice[73, 76] or less than 10 minutes in
rabbits[73, 84]. Possible mechanisms postulated to lead to the clearance of MPs
include: 1) by phospholipases[85], 2) phagocytosis after PS exposure, or 3) indirectly
such as by opsonization by proteins such as protein S and complement[86].
The rate ofMP release increases in response to several different stimuli including: 1)
cell activation or apoptosis, 2) complement mediated cell lysis and cytokines, 3)
oxidative injury and 4) other insults such as high shear stress[87, 88], An increase in
the intracellular concentration of calcium seems to be a necessary triggering event or
common pathway for vesicle release. The current knowledge on MP formation is
mainly derived from in vitro experiments, with the in vivo mechanisms involved in
MP formation still mainly unknown.
In the steady state, the cellular membrane is asymmetrical with phosphatidylcholine
and sphingomyelin found mainly in the outer layer, and PS and phosphatidyl-
ethanolamine being present in the inner layer. The enzymes flippase, floppase and
scramblase are responsible for maintaining this membrane asymmetry. During cell
activation or apoptosis, the endoplasmic reticulum releases calcium. The increase in
intracellular calcium inactivates flippase and activates floppase and scramblase,
leading to a loss of the phospholipid asymmetry of the cell membrane and to
disruption between the phospholipids and the cytoskeleton. The calcium also
activates calpain and gelsolin which cause disruption of the proteins anchored to the
cytoskeleton, leading to membrane budding and MP shedding
(microvesiculation)[73, 78, 89]; please refer to Figure 1.1, page 11. Such MPs are
rich in phosphatidylethanolamine and PS (AV binding sites) on their outer surface,
making them prothrombotic[90-94]. This is however not necessarily true of all MPs,
and partly depends on the nature of the stimulus leading to MP release. EMPs
released from activated endothelial cells have a different lipid membrane
composition to EMPs released from apoptotic endothelial cells - PS is preferentially
expressed on EMPs derived from apoptotic endothelial cells[73, 95], while EMPs













Cell activation Caff degradation of cytoskeleton
Phospholipid on outer leaf of PM
Phospholipid on inner leaf of PM
Phosphatidylserine
Figure 1.1: Schematic diagram depicting the release of microparticles (MPs). In the steady
state, the cellular membrane is asymmetrical with phosphatidylcholine and sphingomyelin
found mainly in the outer layer, and phosphatidylserine (PS) and phosphatidylethanolamine
(PE) being present in the inner layer. The enzymes flippase, floppase and scramblase are
responsible for maintaining this membrane asymmetry. During cell activation or apoptosis,
the endoplasmic reticulum releases calcium. This inactivates flippase and activates floppase
and scramblase, leading to a loss of the phospholipid asymmetry of the cell membrane and
to disruption between the phospholipids and the cytoskeleton. The calcium also activates
calpain and gelsolin which cause disruption of the proteins anchored to the cytoskeleton,
leading to membrane budding and MP shedding (microvesiculation)[73, 78, 89], Such MPs
are rich in phosphatidylethanolamine and PS on their outer surface.
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1.2.2 Function of MPs
MPs are thought to have many important roles, both physiological and pathological.
They are detectable in all individuals, whether healthy or with underlying medical
conditions, including patients with malignancy with/without thrombosis. It is
generally thought that MPs express membrane antigens specific to their cell of
origin, and function similarly to their parental cells[78]. These cell-specific antigens
are used to identify the subtypes of MPs present in circulation. However it is
important to realise that the presence of a particular cell-specific antigen on a MP
may not always identify its cell of origin.
It is postulated that soluble antigens circulating in blood derived from a specific cell
type may adhere to MPs derived from another cell type, or that MPs derived from
one cell type may fuse with the membrane of a different cell type. These cell may
theoretically subsequently release MPs carrying an "adopted" antigen[98]. Caution
is therefore required when interpreting the results of immunophenotyping
experiments. Equally the functional properties and biological role of MPs may differ
from that of their cell of origin[99].
Circulating MPs binding to cells may potentially alter the biological activity of the
recipient cell, either by 1) transferring receptors that can induce cell signalling or
even transformation[99], or 2) by transferring genetic information (mRNA) and
second messengers[100]. MPs were shown to transfer mRNA coding for CD81
between leukocytes[101] and TMPs were able to transfer mRNA to
monocytes[102]). Such binding of MP surface antigens to their specific counter-
receptor on cells allows intercellular signalling, sometimes between far removed
cells, as well as other processes, such as regulation of apoptosis, modulation of the
immune response, inflammation, angiogenesis and coagulation[98, 99], As these
properties of MPs are better understood, measuring specific markers on MPs or MP
dependent activity, rather than the total numbers of MPs, may allow new insights
into the underlying pathophysiology of diseases.
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Increased levels of circulating MPs have been reported in various medical
conditions, including malignancy, inflammatory conditions and thrombosis,
suggesting that MPs are true pathogenic markers and possibly effectors of different
disease processes[36, 78], The number, cellular origin, composition and functional
properties of the circulating MPs are postulated to reflect the underlying disease[99].
To date the main clinical application ofMP analysis has been the simple correlation
of MP level with various disease states, i.e. they serve as general indicators of cell
injury, stress, thrombosis or inflammation[87, 103], It is likely that as the
measurement ofMPs becomes standardised (see Chapter II), the results may be used
for clinical intervention. For example, it is well established that many inflammatory
conditions are associated with a thrombotic tendency, and it may be that intercellular
signalling by MPs is responsible for part of the interaction between the inflammatory
and the coagulation systems. MPs induced by in vivo stimulation of healthy
individuals with a chemotactic peptide induced the release of IL-6 and TF expression
by endothelial cells in vitro. This was associated with a TF dependent increase in the
procoagulant activity of the endothelial cells, an effect which appeared to be
mediated by LMPs[104], There are also a number of studies that have shown
increased levels of circulating TF+ve MPs, or increased procoagulant TF+ve MP
activity in patients with malignancy +/- thrombosis[l 8, 81]. It may be that
measurement of TF-bearing MPs, or MP-dependent procoagulant function, may help
in assessing the risk of thrombosis in patients with various different medical
conditions. If patients demonstrate a tendency to increased generation of total and
TF+ve MPs, and/or MP-dependent procoagulant activity, targeted therapy to block
MP generation or function, could in the future be developed to lower the thrombotic
risk.
The expression of certain surface antigens (on parental cells and subsequently on
MPs) depends on the cause of cell stimulation. Platelet and endothelial cell
stimulation leads to the rapid up-regulation of P-selectin (CD62P) on their surface.
The expression of ICAM-1 (CD54) is dramatically up-regulated by pro-inflammatory
cytokines so that the presence of CD54+ve MPs indicates inflammatory stimulation
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of leucocytes or endothelial cells[98, 105, 106] (ICAM-1 belongs to the
immunoglobulin gene super-family of receptors and is constitutively expressed at
low levels on endothelial cells, leucocytes, fibroblasts, and epithelial cells). E-
selectin (CD62E) or VCAM-1 (CD 106) are both expressed on endothelial cells (and
therefore EMPs) after stimulation by pro-inflammatory cytokines[95, 98, 107, 108],
while apoptotic stimuli of endothelial cells results in EMPs with higher levels of PS
and of constitutive endothelial cell markers such as CD31 (PECAM)[95]. The
presence of these antigens on the released MPs may determine their functional
properties.
There is now good evidence that many "soluble" mediators/markers of inflammation,
including adhesion molecules, coagulation factors and cytokines, are actually bound
to MPs[36, 87], at least in part, making MPs important circulating bioactive
effectors. For example, PECAM-1 (CD31), widely accepted as a soluble marker, can
also be detected on PMPs and EMPs by flow cytometry[87] (flow cytometry is
unable to detect truly soluble molecules); E-selectin, a frequently measured soluble
marker of endothelial stress can also be identified on EMPs by flow cytometry.
Similarly, many other "soluble" molecules, such as ICAM-1, VCAM-1, P-selectin,
TF, vWF, thrombomodulin and CD40L are now know to be at least partly MP-
bound. There is evidence that some of these do exist in true soluble form, usually
due to enzymatic cleavage from the cell membrane or by post-translational editing,
but there is equally good evidence that a significant proportion (up to 80-90%) occur
on cell-derived MPs, presumably with their transmembrane domains intact and
normally adjacent proteins present[87]. This is important for two reasons: 1) the
release of truly soluble species occurs by entirely different mechanisms from
membrane vesiculation, reflecting different pathophysiologies; 2) truly soluble
species may have functionally different properties from their MP-bound forms. It is
therefore likely that when the MP-bound markers can be clearly distinguished by
independent measurement from the truly soluble species, much clearer relationships
between the disease state and the marker in question may emerge. This further
underlines the importance of standardised MP assays - many of these "soluble"
markers are recognised as potentially valuable clinical tools.
1.3 MICROPARTICLES AND MALIGNANCY
There is increasing evidence that MPs are likely to contribute to cancer cell survival,
invasiveness and metastases, the latter through tumour micro-environmental
degradation and by promoting angiogenesis[99], MPs also seem to contribute to the
ability of cancer cells to avoid apoptosis and escape from immune surveillance - see
Figure 1.2, page 20. As evidence of the importance ofMPs accumulates, their role in
risk stratification and individualization of treatment of cancer patients is likely to
become more important. Many different groups have reported increased levels of
MPs or MP dependent procoagulant activity in patients with malignancy[99],
1.3.1 MPs and cancer cell survival
It is hypothesised that MPs contribute to cancer cell survival through several
different mechanisms. Cells are thought to release MPs as part of a protective
mechanism against intracellular stress: intracellular accumulation of caspase 3
normally leads to cell death. If MP release is inhibited, cells accumulate caspase 3
and undergo apoptosis. On the other hand, release of caspase 3-containing MPs
allows cell survival[99, 109].
Multidrug resistance of tumour cells has also been linked to the release of TMPs.
Chemo-resistant tumour cell lines express more membrane shedding-related genes
compared with chemo-sensitive cells[99, 110]. In a study by Safeaei et al[l 11] MPs
released from cisplatin resistant cancer cells contained 2.6 times more cisplatin than
MPs released from cisplatin-sensitive cells; in another study the MPs released from
tumour cells contained high levels of doxorubicin, so that TMPs seem to contribute
to tumour drug resistance]! 12].
MPs are also likely to protect tumours from complement-mediated lysis: cancer cells
can shed MPs containing the complement inhibitor membrane cofactor protein
CD46, which promotes the inactivation of complement C4b and C3b[99, 113].
Liberation of CD46 minimises the inflammation in the microenvironment of
tumours, protecting the tumour from attack by the complement system[99].
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MPs also seem to be involved in suppressing the immune response to tumours,
allowing tumour cell proliferation. TMPs from various cancers express Fas ligand,
(a ligand of CD95, death receptor Fas) which induces T-cell apoptosis, reducing the
adaptive immune response[99], MPs from lymphoblastoma cells express latent
membrane protein-I (LMP-I), another immune suppressing transmembrane protein
which inhibits leucocyte proliferation, and which could potentially explain the lack
of T-cell proliferation in patients with EBV associated tumours[99]. TMPs have also
been shown to fuse with the plasma membrane ofmonocytes, impairing the ability of
the monocytes to differentiate into antigen-presenting cells; and finally tumour cells
may also potentially escape the immune system by mimicking the host environment -
the tumour cells may fuse with non-tumour cell-derived MPs, thereby receiving
phospholipids and membrane-specific proteins that could help them to "hide" from
immune surveillance[99]. The immune-suppressive effects of TMPs may facilitate
the lymphatic dissemination of malignant cells. Activated platelets, and the PMPs
from them, probably also contribute to the haematological dissemination of tumour
cells: activated platelets express the adhesion receptor P-selectin while tumour cells
express the corresponding P-selectin ligands, such as P-selectin GP and Sialyl Lewis,
so that P-selectin bearing platelets and/or PMPs surround the tumour cells protecting
them from immune surveillance[99],
1.3.2 MPs and angiogenesis
It is hypothesised that the procoagulant role of MPs also contributes to the survival
and dissemination of tumour cells. TF +/- PS on the surface of MPs can initiate and
facilitate intravascular coagulation respectively. The fibrin formed coats the tumour
cells, protecting them from immune attacks; it also forms a matrix that supports
angiogenesis[99]. Thrombin, the final enzyme of the coagulation cascade, cleaves
several protease-activated receptors, which in turn can trigger angiogenesis. The
cancer cells in turn can potentially also induce angiogenesis by releasing MPs
containing mRNA encoding growth factors and by exposure of TF[99]. Activation
of the cytoplasmic tail of TF and subsequent downstream signalling can induce
angiogenesis[l 12, 114]. Cancer progression is highly dependent on angiogenesis -
the new vessel formation ensures an adequate supply of nutrients, oxygen and growth
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factors to the growing tumour and also facilitates tumour dissemination[l 14, 115].
TF expression on tumour cells correlates with tumour grade and progression,
probably reflecting the role of TF in angiogenesis and tumour invasiveness[l 16-119].
The data on the role ofMPs in angiogenesis is however conflicting. PMPs have been
reported to be pro-angiogenic, while LMPs and EMPs have been reported as being
both pro- and anti-angiogenic. PMPs have been found to stimulate the proliferation
of endothelial cells in a dose-dependent manner, and to inhibit their apoptosis[73,
120, 121]. At low concentrations EMPs have been found to be pro-angiogenic as a
function of their MMP activity[73, 82] (see later), remodelling of the extracellular
matrix through MMP activity being essential for angiogenesis. However at high
concentrations EMPs have been reported to be anti-angiogenic as they decrease the
formation of capillary-like structures through the production of oxygen free
radicals[122], LMPs have been reported to have either a pro-angiogenic effect
through their ability to favour nitric oxide release from endothelial cells[123], or an
anti-angiogenic effect secondary to the oxidative stress associated with a reduced
release of nitric oxide from endothelial cells[124]. The balance between such pro-
and anti-angiogenic factors may partly determine whether harmless in situ tumours
progress to frank malignancy, or not[87, 125]. MPs may well be pivotal in this
balance.
1.3.3 MPs and cancer cell invasiveness and metastasis
MPs are also likely to enhance tumour invasiveness (and metastasis) by contributing
to extracellular matrix degradation, essential for tumour growth[126], MPs carry
proteases, including matrix metalloproteinase (MMP)-2 and MMP-9, and urokinase-
type plasminogen activator (uPA). uPA catalyses the conversion of plasminogen
into plasmin. Plasmin is a serine protease: it degrades numerous components of the
extracellular matrix, including fibrin, and activates the MMP zymogens.
MMPs are a family of zinc-containing endopeptidases whose role in tumour cell
invasion, metastasis and angiogenesis has been well established[127]. MMPs have
the capacity to degrade all ECM components (basement membrane collagens) as well
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as many non-ECM substrates such as chemotactic molecules, latent growth factors,
cell-surface receptors, and cell-matrix adhesion molecules. They are mainly secreted
in a soluble proenzyme form although some (the membrane-type (MT-)MMPs) are
anchored to the cell surface[127]. Of the MT-MMPs, MT1-MMP seems to play a
major role in tumour invasion through its ability to activate pro-MMP-2. Of the
soluble MMPs, MMP-2 and MMP-9 seem to have a major role in tumour invasion as
a result of their ability to degrade type IV collagen (the main component of
subendothelial basement membranes).
There are a number of studies that show that MPs and their expression ofMMPs are
associated with cancer stage and invasiveness. Patients with gynaecological
malignancy were found to have higher levels of MPs in their ascitic fluid compared
to women with benign causes of ascites[128]. The MPs in the cancer group also
differed from the benign group in carrying active MMPs, and the MMP-2 activity of
the MPs correlated with the in vitro invasiveness of the underlying malignancy[129].
Similarly another group found higher levels of MPs in the ascitic fluid of patients
with late-stage ovarian cancer when compared with patients with early-stage ovarian
cancer[130]. They also showed that MMP-2, MMP-9 and uPA activity was mainly
concentrated within the MPs.
In breast cancer patients, high expression of MMP-2, MMP-9 and MT1-MMP has
been correlated with advanced stage disease[127]. The in vitro invasive potential of
breast cancer cell lines was enhanced by PMPs: PMPs transferred CD41 to the
surface of breast cancer cells enhancing their adhesion to endothelial cells and
potentially promoting the migration of the tumour cells to the extravascular space[82,
127]; PMPs also stimulated the production of MMPs in invasive breast cancer cells
and increased phosphorylation of signaling proteins. Similarly prostate cancer cells,
preincubated with PMPs, showed increased invasion potential. This effect was
accompanied by an increased secretion of MMP-2[131]. Application of MMP-2/9
inhibitors reversed the PMP-induced tumour cell invasion, so that PMPs seem to
promote tumour invasiveness, at least in part, by stimulation ofMMP-2 production.
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As mentioned previously, MPs are thought to be able to transfer receptors/proteins
from one cell type to another, potentially altering the biological activity of the
recipient cell. TMPs may therefore contribute to the horizontal propagation of
mutant oncogenes such as EGFRvIII, MET, HER-2, allowing cancer growth at
distant sites (metastasis)[99]. There is also evidence that TMPs are involved in
transferring the genetic information (mRNA) necessary for malignant transformation
in between cells.
1.3.4 Potential clinical application of MPs
Further knowledge of the biological functions of MPs may help shape future anti¬
cancer treatment. Inhibition of MP release is a potential target in anti-cancer
treatment since MP release by tumour cells is thought to be associated with improved
cancer cell survival and tumour growth through the various mechanisms mentioned
above. Some chemotherapeutic agents partly inhibit the mechanism of MP release,
e.g. through inhibition of the Rho/Rock pathway; inhibition of the latter pathway
resulted in smaller tumour masses in patients with glioblastoma[132].
It is also possible that MPs may in the future be used in the early detection of
malignancy. TMPs express tumour-specific markers; Smalley et al[l33] compared
the MPs in the urine of healthy individuals with the MPs in patients with bladder
cancer. The MPs in the cancer patients had higher levels of tumour related proteins,
suggesting that the protein composition of such MPs could potentially be used in the
early detection of bladder cancer.
MP analysis could potentially provide prognostic information regarding disease
progression and response to treatment. In a prospective, nonrandomised single
centre study of hormone refractory prostate cancer patients, patients with increased
levels of PMPs had a significantly shorter survival[82]. Similarly in other studies
(gastric, breast and pancreatic malignancy) patients with higher PMP levels had more
extensive disease and a shorter survival[134]. The level of PMPs has been found to
be a better predictor of metastasis than other markers such as VEGF, IL-6 and
RANTES.
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Figure 1.2: The postulated role of microparticles (MPs) in cancer cell survival,
invasiveness and metastasis. MPs are thought to allow cancer cells to avoid
detection by the immune system, resist the effects of chemotherapy, and avoid
apoptosis. MPs are also thought to contribute to the invasiveness of cancer cells and
the prothrombotic state of cancer patients.
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1.4 MICROPARTICLES and THROMBOSIS in MALIGNANCY
1.4.1 MPs and the clotting system
The specific functions of MPs in normal healthy individuals are still unclear; it is
postulated that in health MPs may play an important role in the balance of the
haemostatic system, having mainly anticoagulant properties by promoting the
generation of low levels of thrombin which activates protein C[98, 135]. The
importance of MPs for normal haemostasis is underlined by Scott syndrome[136,
137], a rare autosomal recessive disorder with an inherited defect of the enzyme
scramblase which leads to a reduced expression of PS on platelets and reduced
release of MPs. As a consequence the ability to assemble the prothrombinase and
tenase complexes, and thus activate factor X and prothrombin, is impaired leading to
a severe bleeding diathesis. PMPs and other MPs may therefore have an important
role in the normal haemostatic response to vascular injury[78],
Under normal physiological conditions the intact endothelial surface has an
important anti-thrombotic function. However upon activation endothelial cells
become prothrombotic[138]. They release EMPs expressing TF. Such EMPs (and
other MP subtypes) provide both a source of TF, as well as a catalytic surface
(anionic surface phospholipids) for the assembly of the prothrombinase and tenase
complexes[139], thus probably playing an active role in the clotting process.
TF is the physiological initiator of blood clotting[140]. It is a glycoprotein normally
expressed on the surface ofmost nonvascular cells, and after appropriate stimulation
also expressed on the surface of monocytes, neutrophils and endothelial cells) 141,
142], It is also variably expressed on the surface of tumour cells. TF binds to
circulating factor Vila anchoring the complex to the surface membrane and
dramatically increasing its proteolytic activity for factors X and IX[143]. The
hypercoagulable state of patients with malignant disease may be partly explained by
the over-expression of TF by tumour cells and cells of the tumour microenvironment
(i.e. endothelial cells, fibroblasts, and monocytes/macrophages)[144], MPs have
been identified as the main source of circulating functionally active TF[140], The
importance of TF+ve MPs for haemostasis and thrombosis in otherwise healthy
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individuals is still a matter of debate, however several groups have now reported
increased levels of TF+ve MPs or TF+ve MP-dependent activity in patients with
varying prothrombotic conditions, including malignancy[127], although it is still
unclear whether TF bearing MPs and thrombosis in cancer patients are causally
linked.
The prothrombotic potential of MPs is however not solely dependent on their
expression of TF. The protein and phospholipid composition, as well as the
orientation of the phospholipids on the surface ofMPs, depends not only on their cell
of origin but also on the stimulus resulting in MP release. MPs are thought to have
potent procoagulant properties in general, being able to passively support coagulation
on their negatively charged surface phospholipids (mainly PS). The phospholipids
have a catalytic role promoting the assembly of the tenase and prothrombinase
enzyme complexes of the clotting system on the MP membrane surface[87, 140,
145]. Their thrombogenic activity varies proportionally with their PS content. This
phospholipid surface has traditionally been thought to be provided by activated
platelets (previously known as platelet factor 3), but MPs can also support this
process, and in contrast to quiescent platelet membranes, the procoagulant activity of
PMPs is enriched and retained on the surface[135], PMPs have approximately 50 to
100-times higher procoagulant properties than an identical surface area of activated
platelets[146]. PMPs also carry FV/Va, GPIIb/IIla, GPIb/IX, are rich in membrane
receptors for coagulation factors, and (together with EMPs) carry significant amounts
of vWF (MP bound vWF is functionally more active than freely soluble vWF), all of
which contribute to their prothrombotic properties[35, 87, 121, 147-149], MPs can
also express TFPI on their surface and it is likely that the balance of procoagulant
and anticoagulant mediators on MPs determines their overall prothrombotic
potential[35, 150], It is difficult to sort out the many influences of MPs on the
coagulation system in vivo owing to its complexity, however greatly elevated levels
of circulating MPs are generally thought to have mainly a prothrombotic rather than
an antithrombotic effect.
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MPs may also be the link between thrombosis and inflammation - both EMPs and
PMPs participate in clot formation and also act as vectors of many inflammatory
mediators[26]. Complementary functional assays done in parallel with MP
identification would help to confirm the prothrombotic and/or the proinflammatory
nature of the MPs detected [8 7],
In mouse models and in in vitro studies, MPs were seen to accumulate at the site of
developing clot[l51]. They have an important role in clot formation through both
their TF-dependent and independent pathways[145]. TNFa stimulation of HUVECs
resulted in the release of TF+ve EMPs[70], Addition of increasing concentrations of
these EMPs to a coagulation assay shortened the clotting time compared to EMPs
from unstimulated HUVECs. The effect was not seen in FVI1 deficient plasma,
suggesting that the procoagulant activity of the EMPs was TF/FVII dependent. In
contrast, EMPs induced in vitro by cisplatin treatment were found to be highly
procoagulant but thrombin generation was not reduced by blocking antibodies to TF
or FVII (TF independent)[79, 152],
There is current interest in carrying out interventional studies[153] evaluating the use
of MP levels (especially TF+ve MPs) as markers of thrombogenicity, and looking at
the appropriateness of primary thromboprophylaxis in patients considered at high
risk of thrombosis by virtue of their number of circulating MPs.
1.4.2 MPs in patients with cancer and VTE
The numbers of circulating MPs and MP-dependent functions have been variably
reported to be increased in patients with VTE and/or malignancy by many different
investigators[23, 73, 81, 121, 140, 154, 155]. The results in the published literature
are variable, probably partly reflecting the lack of standardisation of MP assays,
although the variability of published results is also likely to reflect the variability of
the underlying medical conditions and their treatment (see Chapter II and Table 1.2,
page 27).
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Of all MP subtypes, PMPs have been most extensively investigated. PMPs are
mainly released from activated platelets[ 135], although some are released by
quiescent platelets, by megakaryocytes, or by apoptotic platelets[73], PMPs are
considered to be important for normal haemostasis; however they may also be
involved in pathological thromboses - e.g. high fluid shear stress in diseased small
arteries partially obstructed by compression or vasospasm may induce activation and
aggregation of circulating platelets, with shedding of procoagulant PMPs[78], Such
PMPs would promote acute arterial occlusion by providing and expanding a
phospholipid catalytic surface for the clotting cascade and concentrating surface TF.
The TF on PMPs is either derived from the platelets themselves or is transferred to
platelets (and in turn PMPs) from other cells such as monocytes[156]. Platelets store
small amounts of TF in a-granules[157], and quiescent human platelets also contain
TF pre-mRNA, which is spliced into mature mRNA in response to platelet
activation, leading to de-novo synthesis of full-length TF protein in plateletsf 158].
Whether the splicing of platelet TF pre-mRNA is altered in patients with malignant
tumours leading to increased TF+ve MPs being released is not yet known; further,
the presence of TF on circulating MPs does not necessarily mean that the TF is
functionally active[156].
Tumour cells themselves are known to over-express TF[34], There is good clinical
and experimental evidence that cancer cells can be an important source of TF+ve
MPs[159]. The number of circulating TF+ve MPs dropped significantly in 3 patients
with pancreatic carcinoma after radical pancreatectomy[18]; 50% of the TF+ve MPs
also co-expressed MUC-1, a tumour marker for pancreatic carcinoma. Other
groups[34] have also shown that the level of TF activity on tumour cells correlates
with the thrombotic risk in pancreatic cancer patients[l 16, 160], and that cancer cells
in culture shed procoagulant vesicular structures[72]. It may be that the variability of
thrombotic events in cancer patients may partly reflect the variability of MP
generation from different tumours, as well as the total tumour burden.
Hron et al[81] compared the MP levels in 20 patients with advanced colorectal
cancer with the levels in a healthy control group, and found no difference in the
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absolute number of circulating MPs (using light-scattering flow cytometry) between
the two groups (the level of PMPs and LMPs were very similar). However the
number of TF+ve MPs (mainly PMPs) in the cancer group was almost double that in
the control group, and was associated with a four-fold increase in D-dimer levels in
patients with malignancy. D-dimer, a degradation product of the fibrinolytic system,
is a sensitive marker for activation of the clotting system. Their patient group did not
have a history or recent episode of VTE, so they postulate that the increased levels of
D-dimers in their cancer patients is likely to reflect tumour related coagulation
system activation.
Zwicker et al[ 18] measured TF+ve MPs using impedance flow cytometry and found
that 60% of patients with cancer-associated VTE had detectable TF+ve MPs,
compared with 27% of patients with cancer but no VTE, a >4-fold increased risk of
thrombosis associated with detectable TF+ve MPs. They also compared a group of
patients with idiopathic VTE without cancer, with the cancer patients who had acute
VTE to determine whether the presence of TF+ve MPs was a feature of VTE or a
feature ofmalignancy. The median number of TF+ve MPs in the cancer-VTE group
was significantly greater than in both the idiopathic VTE and cancer-no VTE groups,
suggesting that the high prevalence of TF+ve MPs in patients who present with an
acute VTE is associated with cancer patients and not VTE alone.
Tesselaar et al[ 116], using a coagulation based assay, found increased TF activity,
but no difference in the absolute number of circulating TF+ve MPs measured by flow
cytometry, in PPP from patients with cancer compared with healthy controls.
Patients with malignancy and acute VTE had higher levels of MP-TF activity than
healthy subjects, cancer patients without VTE and subjects with idiopathic VTE.
This observed association between the levels ofMP-TF activity and the development
of VTE in cancer patients suggests that TF+ve MPs contribute to the development of
thrombosis in malignancy.
Hauboid et al[ 159] similarly found significantly increased levels of TF dependent
MP functional activity in a group of patients with prostate cancer, which however did
not correlate with the measured plasma TF antigen level (measured by ELISA) or
with the total number of TF+ve MPs measured by flow cytometry. Such differences
between the results of functional 159] and antigen-based MP assays have also been
reported by other investigators (see Table 1.2, page 27). MP-associated TF activity
is a quantitative estimate of the concentration of active TF in the MP preparation,
which can act as a cofactor of FVlla in FX activation, while the number of TF+ve
MPs is not a quantitative estimate of the active TF concentration, as the number of
TF molecules per MP may vary widely. Also, some of the TF antigen detected on
MPs using flow cytometry may be inactive but still detectable by the monoclonal
antibodies[l 16]. Similarly TF antigen levels detected by ELISA may not reflect the
true level of active TF present in circulation - not all the circulating TF detectable by
ELISA is active, and in the presence of high quantities of circulating plasma
membrane bound TF on MPs, the TF may not be sufficiently solubilised by an
ELISA's detergent, leading to significantly lower antigen levels being detected[159].
At present it is still unclear whether TF+ve MPs and thrombosis in cancer patients
are causally linked, especially because MPs may also support clotting through TF-
independent pathways. Circulating TF+ve MPs are not unique to cancer patients;
high levels have also been identified in a subset of non-cancer controls as well as in
individuals with idiopathic VTEs[71, 73, 161-163]. Once MP assays become
standardised the relationship between MPs and thrombosis in cancer patients is likely
to become clearer. It may be that in the future the release of MPs from activated
endothelial cells and platelets may represent a predictive assay or a therapeutic target
to prevent and limit thrombus formation.
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Table 1.2: Summary of a number of published microparticle (MP) assay results in
various patient groups. Several investigators have reported increased numbers of
circulating MPs and/or MP activity. The number of circulating MPs however often
does not correlate with the measured MP-dependent activity. Annexin V (AV),
tissue factor (TF), platelet-derived MP (PMP), leucocyte-derived MP (LMP),
endothelial-cell derived MP (EMP), venous thromboembolism (VTE), patient (pt).
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1.5 MARKERS OF HAEMOSTATIC ACTIVATION
1.5.1 Introduction
Markers of thrombin/fibrin formation and fibrinolysis are in widespread use for both
clinical and research purposes. The association of cancer and thrombosis is well
established, with thrombosis occurring prior to the diagnosis of cancer in a
significant proportion of patients. Activation of the clotting system in patients with
cancer occurs through a number of mechanisms. Cancer cells can activate the
clotting system directly through tumour procoagulant and TF[166-168], thereby
generating thrombin; or indirectly by stimulating mononuclear cells to synthesize
and express a variety of pro-coagulants[169], with the consecutive activation of
clotting factors leading to increased concentrations of thrombin and fibrin and
therefore the liberation of the corresponding markers of haemostatic activation, e.g.
D-dimers[170-174],
It is however still unclear whether the increase of such markers of haemostatic
activation reflects a cancer-induced prothrombotic state or whether it is simply an
epiphenomenon of balanced activation and inhibition of the haemostatic system in
cancer patients. Evidence of clotting system activation in cancer patients[20, 175-
177] includes a high platelet count, shortened APTT, increased levels of clotting
factors (fibrinogen, factors V, VIII, IX and XI), high D-dimers and increased
fibrinogen turnover[142]. More recently newer markers of haemostatic system
activation, TAT complex and PF1&2, have been shown to be significantly higher in
patients with both cancer and DVT than in patients with cancer but no thrombosis or
patients with thrombosis but no cancer[20, 142, 178],
1.5.2 D-dimers
D-dimer is a stable degradation product of cross-linked fibrin and reflects the body
fibrin concentration. It is a very useful haemostatic marker that can gauge ongoing
fibrin degradation[20, 175, 179, 180], Increased levels of D-dimers in plasma
suggest that fibrinolysis has been activated and that excessive levels of fibrin have
been produced. Fibrin is also important for tumour metastasis[181-183]; the
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^ formation of a fibrin matrix appears to facilitate tumour growth via the promotion of
angiogenesis, and also shields tumour cells from attack by immunocompetent
cells[ 166, 184], Increased levels of D-dimers have been correlated with tumour
extent and associated with a poor prognosis[20, 170, 175, 179, 180, 185, 186].
High D-dimer levels have been associated with VTE in a population based cohort
study[187, 188] and prospective studies have shown that D-dimer levels are
predictive of thrombotic recurrence in patients with no cancer[189, 190], Several
studies have reported increased levels of D-dimers prior to any treatment in patients
with gynaecological malignancy[191]. Satoh reported that increased levels of D-
dimer preoperatively were associated with the presence of clinically silent VTE, with
a positive predictive value of 36-44%, and a negative predictive value of 89-
^ 100%[8]. However D-dimer levels increase in the presence of several different
medical conditions including tumours, advanced age, trauma, infection and
inflammation[192] so that the main clinical value of measuring D-dimers are for
their negative predictive value to exclude VTE[170, 193]. The level of D-dimers has
not been found to be particularly helpful in predicting the risk of thrombosis in an
individual patient.
>
1.5.3 Thrombin-Antithrombin Complex and Prothrombin Fragment 1&2
The main event in blood clotting is the production of thrombin from
prothrombin[194]. Thrombin is thought to help promote cancer growth and spread
via an increase in tumour cell adhesion and by affecting angiogenesis.
Prothrombin Fragment 1&2 (PF1&2) is released when activated factor X cleaves
prothrombin to thrombin; the level of circulating PF1&2 reflects the in vivo
generation of thrombin. Once thrombin is produced it may either act on its substrates
(e.g. fibrinogen, factor V, factor VIII), or it may be inhibited by its natural antagonist
antithrombin[194] through the formation of a stable inactive enzyme-inhibitor
complex, thrombin-antithrombin (TAT). Measuring the level of circulating PF1&2
and TAT is therefore an indirect measurement of the level of activation of the
clotting system[166, 194],
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Elevated levels of PF1&2 and TAT have been investigated as a risk factor for first
and recurrent thrombotic events but studies have reported conflicting results[187,
195, 196]; compared to D-dimers the levels of TAT and PF1&2 have been found to
be far less sensitive and provide a lower negative predictive value (78-85%) for the
diagnosis of VTE. Measuring these markers of haemostatic activation has not been
found to be clinically useful as predictors of VTE in individual patients with
malignancy[142], In a preliminary study, high TAT levels successfully identified
patients at higher risk of postoperative VTE, but the positive predictive value was
only 23.3%, and these findings were not confirmed in a subsequent study[142].
Similarly neither the PF1&2 nor TAT were predictive of recurrent VTE events in
cancer patients treated with oral anticoagulation 142].
1.5.4 Clinical use of the markers of haemostatic activation
Ay et al[ 187] have found that increased levels of D-dimers and PF1&2
independently predict the occurrence of VTE in patients with cancer; however Beer
et al[ 170, 173, 186, 197, 198] and several other investigators have found that while
the markers of haemostatic system activation are increased in patients with active
tumours, the increased levels of these markers (D-dimers, TAT and PF1&2) are more
useful in assessing prognosis[166, 170] and not helpful in predicting the individual
risk of VTE[170-174, 197], High levels of these markers of haemostatic activation,
which reflect the global activation of coagulation and fibrinolysis, have been
reported in patients with malignancies both in the presence and absence of
thrombosis[187, 199-202],
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1.5.5 MPs and markers of haemostatic activation
A number of investigators have measured both the number of circulating MPs and
the level of markers of haemostatic activation (D-dimers, TAT, PF1&2) in a variety
of different patient groups. Hron et al[81] found a correlation between the number of
circulating TF+ve PMPs and the level of D-dimers; however several other
investigators have failed to show such a correlation[79, 140], This variability in
results may be due to the use of different methods to analyse MPs. Given the
postulated role MPs play in clotting activation and propagation it would be
reasonable to assume that there would be a correlation between the two. The current
variability in results with most investigators failing to show a correlation is likely to
partly reflect the lack of standardisation of MP assays. Once MP analysis becomes
standardised it may well be that a correlation between the two will be detectable; it
may also be that measuring MP-dependent activity rather than MP numbers would
better reflect the role of MPs in coagulation activation. The relationship between
MPs (and/or their function) and the markers of haemostatic activation will need to be
re-assessed once the assays for MP analysis become standardised
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1.6 STUDY HYPOTHESIS, AIMS AND OBJECTIVES
1.6.1 Hypothesis
Gynaecological malignancy is a common diagnosis with a significant proportion of
patients surviving for many years. Thrombosis remains a complication with
significant associated morbidity and mortality. Thromboprophylaxis is known to
reduce the incidence of thrombosis; however thromboprophylaxis in cancer patients
is associated with a significant risk of bleeding. It is currently unclear which
subgroup of patients with gynaecological malignancy would benefit the most from
primary thromboprophylaxis outside the surgical setting. The ability to identify
patients at a high risk of thrombosis would allow primary thromboprophylaxis to be
targeted to such patients, avoiding the use of thromboprophylaxis in patients at a low
risk of thrombosis. This would theoretically reduce the incidence of thrombosis in
patients at a high risk of thrombosis, while reducing the bleeding risk for patients at a
low risk of thrombosis. Unfortunately at present we are unable to identify such
patient subgroups.
MPs are ubiquitous, and are considered to have an important role to play in
haemostasis and thrombosis. The number of circulating MPs has been reported to be
increased in several patient groups with an underlying prothrombotic potential,
including malignancy. It may be that measuring MPs would allow the thrombotic
risk of an individual to be better assessed, potentially allowing targeted primary
thromboprophylaxis in patients considered to be at high risk of thrombosis.
I hypothesized that patients with gynaecological malignancy have increased numbers
of circulating MPs compared to women with no underlying malignancy. I wanted to
test this hypothesis and to establish whether measuring the number of MPs in such
women would allow us to identify patients at a significantly increased risk of
developing a thrombosis. To my knowledge there are no published studies
specifically reporting on the number of MPs in patients with gynaecological
malignancy.
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1.6.2 Aims and Objectives:
❖ Set up and standardise a MP assay
> Carry out a review of currently published methods for MP analysis
> Standardise blood sample collection and pre-analytical handling
> Set up a method to identify and quantify MPs
> Establish the effect of a freeze/thaw cycle on the number ofMPs measured
❖ Measure the number of circulating MPs in patients with gynaecological
malignancy and in a control group
> Recruit women with confirmed gynaecological malignancy (malignant group)
and a control group ofwomen with no underlying malignancy to measure the
number of circulating MPs
> Measure the number of circulating PMPs, EMPs, LMPs, TF+ve MPs and
AV+ve MPs, and compare the results between the malignant group and the
control group
> Establish the effect of surgery and other treatment modalities on the number
of circulating MPs
> Correlate the number ofMPs with the incidence of thrombosis
❖ Measure the level of D-dimers, TAT and PF1&2 in the malignant and
control groups
> Use ELISA to measure D-dimers, TAT and PF1&2 in the malignant group
and control group as markers of haemostatic activation
> Correlate results with numbers ofMPs and with the incidence of thrombosis
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❖ Describe the population of patients diagnosed with gynaecological
malignancy in the South East of Scotland Cancer Network (SCAN)
> Identify and describe the demographics of all women presenting with a
gynaecological malignancy in SCAN during the same time period as patient
recruitment to the study on MPs is carried out
> Establish whether the patient cohort in the MP study is representative of the
whole population of patients with gynaecological malignancy in SCAN
> Establish the incidence of the different gynaecological tumours in SCAN, and







There is currently general agreement on the importance of MPs, both as markers of
disease and also as effectors of patho-physiological processes. However, there is still
no universally agreed definition of the criteria that define a MP, and there are no
standardised methods of sample collection, preparation or method of identification
and quantification ofMPs.
MPs are described as intact phospholipids vesicles 0.1-1.0 pm in diameter expressing
surface antigens of their cell of origin[36, 87, 203]. Some investigators also use AV
positivity as a defining feature of MPs[78]; the latter can lead to significant
differences in the number ofMPs identified as explained later.
The published assay methods for MP analysis are very variable[71], making the
comparison of results from different laboratories very difficult. The reported levels
ofMPs vary significantly[36, 77, 78, 204], in some cases by as much as 3 to 4 orders
of magnitude. For example, Tesselaar et al[l 16], using light-scattering flow
cytometry, reported a median of 460 TF+ve MPs per pL of PPP, while Zwicker et
al[18], using impedance flow cytometry, reported TF+ve MPs of the order of 70,000
to 3,200,000/pL of PPP. While these differences may reflect the pathology of
underlying medical conditions, variations in methodology used for MP measurement,
and/or variable sample preparation are likely to be having a significant effect on the
observed differences. There is a need to standardize the definition of what
constitutes a MP and to standardize sample preparation and the assay protocols used
to identify and measure MPs, in order to allow inter-laboratory comparison and
meaningful and reproducible interpretation of absolute numbers ofMPs.
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2.2 PRE-ANALYTICAL VARIABLES
The pre-analytical methods used in obtaining and handling patient samples can
significantly influence the number of MPs detected[71, 78] due to the possible in
vitro activation of and MP release from platelets and other cells[121, 205], which
would invalidate the results obtained. The details of the pre-analytical processing of
samples need to be taken into consideration when comparing the results from
different laboratories.
2.2.1 Needle gauge
There seems to be no difference in the number of MPs detected when using either a
19-gauge needle or a 21-gauge needle (two samples taken concurrently from
different arms in the same individual using minimal venous stasis)[78]. However,
smaller gauge needles should be avoided, and only minimal venous stasis applied,
when taking blood samples to avoid the in vitro activation of platelets and
subsequent MP release as the blood is collected[206],
2.2.2 Anticoagulant
The effect of different types of anticoagulants on the number of MPs measured has
also been compared[78] (0.32% sodium citrate, 10% citric acid-sodium citrate-
dextrose (ACD), 17 units/ml sodium heparin, and 75 pM Phe-Pro-Arg-
chloromethylketone (PPACK)). Anticoagulants that preserve extracellular calcium
(heparin, PPACK) allow continuing in vitro microvesiculation and should therefore
be avoided when measuring MPs. Most investigators measure MPs in citrated
samples; the citrate chelates extracellular calcium limiting in vitro microvesiculation.
A few groups[98] use ACD, which also chelates extracellular calcium.
2.2.3 Sample processing
MP analysis can be done either directly on whole blood samples[73, 207] or on
plasma samples. Using whole blood has the advantage of leaving the MPs in a
physiological environment, without any pre-analytical processing steps. However,
such samples would need to be analysed as soon as possible to minimise the in vitro
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production of MPs from blood cells. Paraformaldehyde fixation is not possible due
to its effect on cell membranes (causes translocation of PS to the plasma membrane
outer layer)[208]. Most investigators instead measure MPs in PFP. This however is
a major source of variability due to the many and very different centrifugation
protocols in use to prepare PFP[11, 87, 209], either based on serial centrifugation of
citrated whole blood or using ultracentrifugation and re-suspension of the resultant
MP pellet.
Depending on the centrifugation protocol used there is the possibility of either a loss
of MPs (in the discarded sediment with blood cells and platelets, or in the
supernatant if MPs are sedimented), or activation of platelets and the in vitro
generation of MPs. Ultracentrifugation tends to avoid any platelet contamination,
however no amount of centrifugation will sediment 100% ofMPs because some MPs
are no more dense than plasma[87]. There are also concerns that the use of
ultracentrifugation results in the generation of MPs in vitro. The challenge of
accurately measuring the total number of circulating MPs is therefore still unmet.
Table 2.1 (page 40) is a summary of some of the more commonly used centrifugation
protocols published in the literature. The preparation of PFP is usually considered an
essential step prior to MP measurement and needs to be urgently standardised in
order to allow direct comparison of the results from different laboratories.
2.2.4 Sample storage
Another source of variability is whether plasma samples are analysed fresh or after a
freeze/thaw cycle. Limiting MP analysis to fresh samples is highly labour-intensive,
makes collaboration between laboratories difficult, decreases laboratory efficiency,
and increases sample-to-sample variation in large sample sizes. However on the
other hand there are concerns that the process of freezing itself generates MPs[73,
210]. During a freeze/thaw cycle a significant number of platelets have their cell
membranes destroyed producing cell fragments[71]. If this is extrapolated to MPs,
freeze/thaw cycles are likely to cause MP fragmentation, leading to false levels of
MPs being detected. Rectenwald[35] showed that snap freezing PPP and storing the
plasma for 2 weeks at -70°C consistently increased the total number of MPs by 90%
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compared to identical fresh samples, suggesting that snap freezing resulted in
fragmentation of MPs. Shah et al[78] also examined the effect of storage
temperature and duration on MP detection. They measured MPs by flow cytometry
either immediately or after storage at either 4°C or frozen for variable time intervals,
and found that the MP levels were significantly lower when samples were not
processed immediately, regardless of the duration or temperature of storage. The
reason for this is unclear, however it is unlikely to be caused by proteolysis or
shedding of cellular markers, since experiments with protease inhibitors failed to
prevent the disappearance ofMPs in samples stored at -80°C[78].
It is currently still unclear what effect a freeze/thaw cycle has on MPs. If it is not
possible to process samples in the desired short time frame and samples are to be
frozen prior to analysis it is important that true PFP and not platelet-poor plasma is
frozen to limit the generation of MPs from residual platelets as much as possible,
although this still does not prevent the theoretical possibility of MP fragmentation.
The actual freeze/thaw cycle used may further substantially affect the results of MP
analysis. Snap freezing ofPFP[98] in liquid nitrogen is recommended. Likewise the
process of thawing is as important: some investigators thaw MP samples on wet
ice[ 109]; others do a quick thaw at 37°C[98]. The latter should prevent intermediate
formation of large ice crystals, however prolonged incubation of a sample at 37°C
leads to the deterioration of MPs and the degradation of sensitive antigens. There is
no clear best method for thawing the plasma samples to ensure reliable MP results.
For each study it is important to establish how MPs of specific phenotypes of interest
are affected by a single freeze-thaw cycle. The freezing of MPs needs to be
investigated further, since the ability to freeze samples before analysis would
significantly increase the usefulness of the method for the diagnostic use of MP





Published studies Method of centrifugation Sample analysis
Pereira et al 2006[211]
2000g x 30mins twice +
20,800g x 45mins twice
frozen
Nantakomol et al 2008[203]
Combes et at 2004[70]
Robert et al 2009[77]
Faure et al 2006[212]
This study
1500g x 15mins +
13,000g x 2mins
fresh
Helley et al 2009[82] 2800gx 15mins twice frozen
Choudhury et al 2007[213] 2000g x 20mins fresh
Tesselaar et al 2007[ 116] 1550g x 20mins frozen
Kim et al 2002[121] 1550g x 15mins fresh
Trummer et al 2008[97] 1500g x 20mins frozen
Table 2.1: There is currently no standardised method of sample storage and
preparation for microparticle (MP) analysis. The table above is a summary of some
of the different centrifugation protocols in current use to isolate MPs. Different
) centrifugation protocols are a major source of variability between different
laboratories. Different investigators also vary as to whether MP analysis is carried
out on fresh platelet free plasma samples or after a freeze thaw cycle, another source
of variability.
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2.3 TYPES OF ASSAYS
MP assays vary, including: 1) measuring the total number ofMPs, 2) measuring MP
functional activity and 3) measuring other substances being carried on the MPs. MP
analysis is done either by using solid phase assays (functional or ELISA) or flow
cytometry, with the latter being used most commonly.
2.3.1 Solid Phase Assays
MPs may be analysed using solid-phase capture functional assays or ELISAs. In
functional assays the MPs are first isolated and immobilised from PFP using AV
(may underestimate MP levels, see page 47) or monoclonal antibodies to specific cell
surface antigens. The functional properties of the MPs are then measured using a
prothrombinase assay. Such functional assays give information on MP activity but
no details as to the absolute numbers ofMPs[36, 73],
Alternatively ELISA methods can be used to identify and quantify MP-bound
antigens. ELISAs are much more easily accessible laboratory techniques and can be
automated. However they give no information as to the functional properties of the
MPs (unlike functional assays) or the absolute numbers of MPs (unlike flow
cytometry). They use combinations of antibodies to specific cell surface antigens to
allow MP capture and detection in PFP. ELISAs will also detect soluble antigens not
bound to MPs (unlike flow cytometry), so that the results from flow cytometry and
ELISAs are not interchangeable[135, 214].
2.3.2 Flow cytometry
In flow cytometry, MPs are identified by gating on size (<1 pm) on forward scatter,
and fluorochrome positivity for cell specific antigens (using fluorochrome
conjugated monoclonal antibodies) - please refer to Figure 2.1, page 44. Flow
cytometry allows for the analysis of large numbers of MPs (to the order of tens of
thousands), collects information about their size and inner complexity and accurately
quantifies the number of circulating MPs (unlike ELISA and functional assays). It is
a relatively easy technique to carry out. However many clinical facilities do not have
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easy access to flow cytometers, and must instead rely on more conventional assay
methods such as ELISA. Also flow cytometry does not provide any information
about the functional properties of the measured MPs. There are now a number of
literature publications in which there was no correlation between the MP functional
assay results, the levels of antigen measured by ELISA, and the number of MPs
identified by flow cytometry in the same patient[116, 159], This is due to the fact
that MP numbers identified by flow cytometry do not give any information as to the
concentration of specific antigens on the individual MPs, or whether these antigens
(e.g. TF) being detected are active or not. It may well be that functional assays are a
better reflection of the patho-physiological effect of MPs, although the different
techniques are likely to be complementary.
Flow cytometry is the technique most commonly used to analyse MPs. However
there are a number of technical difficulties when using light-scattering flow
cytometry to identify MPs. The small size of MPs makes their accurate
identification difficult. Flow cytometers were designed to analyse cells many orders
ofmagnitude larger than MPs. When using currently available flow cytometers MPs
appear close to the electronic noise of the machine, together with cellular debris.
The minimal size of MPs has been defined as 0.1 pm mainly because commonly
used flow cytometers are unable to distinguish between smaller particles and
electronic noise. The limit of resolution on forward scatter between instrument noise
and MPs depends on fine optical adjustments and fluidics and optics cleanliness.
This may vary with time. It depends on maintenance for a single instrument, and
may be different between different instruments. The upper size limit of MPs has
been fixed at approximately 1.0 pm because a single bigger MP would be difficult to
distinguish from MP aggregates, platelets or MP-platelet aggregates[78].
To try and overcome some of the current technical limitations, Furie et al[5, 73] have
reported on a modified commercially available impedance flow cytometer.
Impedance flow cytometry is based on the Coulter principle[ 18]: it determines the
electronic volume of a particle based on the fact that the electronic volume is
proportional to the change in the impedance associated with the displacement of
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electrolyte in a flow cell by the particle of interest. Their modifications include: a
slower flow speed, electronic enhancement for a better sensitivity and less noise,
optimization of fluid management and ultrafiltration of buffers. With these changes
they were able to measure 520 nm beads with an accuracy of +/- 20 nm. It is likely
that as the technology advances the accurate identification and quantification ofMPs
will become easier and more reproducible. Other techniques currently being trialled
include the use of thinner laser beams[73], digital-acquiring flow cytometers,
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Figure 2.1: Flow cytometer dot plots: Forward scatter (FSC-H) v.s. side scatter (SSC-
H) dot plot (top image) showing all events <1 pm in size. Microparticles (MPs) are
further characterised by immunofluorescence with cell specific monoclonal
antibodies. For example in the lower dot plot platelet-derived MPs are being
identified by positivity with anti-CD41 FITC (in FL1-H); 1 pm size gate is being




Cell specific monoclonal antibodies are used to identify specific subtypes of MPs.
When detecting MPs by flow cytometry there are several requirements for target
antigens: cell specificity, an abundance of the antigen on the MPs, stability of the
antigen, and commercial availability of avid antibodies (preferably monoclonal) that
are conjugated to a fluorochrome. There are a wide range of antibodies that can be
(and are) used to label MPs prior to flow cytometry to determine their cell of
origin[97, 98], Table 2.2 (page 46) is a summary of some of the commonly used
antibodies.
The use of different antibodies to identify the same cell-specific MPs in an individual
often results in different quantities of MPs being identified by the different
antibodies[98], MPs originating from the same cell type express different surface
antigens according to the stimulus that led to their release. For example CD41+ve
PMP and CD42+ve PMP populations are not identical and reflect different
pathophysiological phenomena[78, 87, 121]. Different antigens are also likely to be
expressed at different concentrations, again leading to variability in their detection.
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MP cell of origin Antigen Alternative name of antigen
Red blood cell CD235a Glycophorin A
















Endothelial cells CD51 av integrin
CD105 Endoglin
CD144 VE-cadherin (most specific for EMPs)
CD 146 S-Endo/Muc 18
Table 2.2: Summary of commonly used antigens to identify the different subtypes of
microparticles (MPs) according to their specific cell of origin[98]. The antigens
shown in bold have been used in this study to identify LMPs, PMPs and EMPs.
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Some investigators include positivity for AV in their definition of what constitutes a
MP (besides gating on size and positivity for cell-specific antigens), and only analyze
MPs that are able to bind AV. AV binds to PS, and as mentioned in Chapter I not all
MPs express PS on their outer surface, this being dependent on the nature of the
stimulus leading to MP release. Several studies have now shown that AV negative
MPs can make up a significant proportion of all circulating MPs, and in some
individuals the concentration of AV negative MPs is 30 times higher than the
concentration of MPs that can be detected by AV[73, 87], Analysing only AV
positive MPs results in a significant population of MPs, particularly of endothelial
origin, being missed from the analysis[97, 98]. This needs to be taken into
consideration when comparing the results from different investigators. Various
methods using lipophilic fluorescent dyes, chromophore-labeled lectins, or
antibodies to ubiquitous antigens to try and identify the total number of MPs
independent of their cell of origin or stimulus leading to MP release have been
unable to provide satisfactory results to resolve this issue. At present the use of
different antibodies by different investigators to define the same population of MPs
is likely to lead to variable results. There is no current method available for the
identification of all MPs (irrespective of cell of origin) that allows us to calculate the
total number ofMPs accurately.
Another source of variability is whether washing steps are included before and after
immunolabelling of MPs with monoclonal antibodies. Including washing steps may
increase the specificity and minimize the formation of artifactual immunocomplexes;
however there is also the risk of losing MPs during several washing steps if this is
not done carefully. Such a protocol would require an experienced operator and is
time consuming. Several investigators use direct immunolabelling of plasma and
flow cytometry analysis without isolation and washing of MPs[217-219]. This




When using flow cytometry, the flow cytometer counts the number of events of a
particular fluorescence that pass through its detector. The events of interest are then
normally expressed as a percentage of the total number of cells present, allowing
their quantification. This however is not possible when PFP is used to identify MPs
due to the lack of cells in the PFP. In order to convert the number of events counted
into the absolute concentration of MPs in the patients' circulation most investigators
use commercially available fluorescent beads at predefined concentration as
reference standards. There are two ways of using such fluorescent beads: 1)
commercially available fluorescent counting beads of known concentration are added
to each patient plasma sample, or 2) the fluorescent beads are used to calculate the
volume (x) of sample analysed by the flow cytometer over a pre-defined collection
time - this value (x) is then used to calculate the MP concentration when the PFP
sample is analysed for the same length of time (flow based method).
In the first method, Flow-Count fluorospheres[121] (Beckman Coulter, Miami,
Florida, USA, supplied as a 10 pm-sized bead suspension of a known concentration),
or TRUCOUNT™ tubes[203] (Becton Dickinson, San Jose, California, USA, the
tubes contain a pre-dispensed lyophilized pellet of a known number of 4.2 pm
fluorescent beads) are used. The patient sample (with unknown numbers of MPs) is
added to one of the above, and the relative number of MPs detected by the flow
cytometer is assessed in comparison to the TRUCOUNT1M tube standard or the
Flow-Count fluorospheres. This allows the absolute number of MPs to be
calculated[220]. Both TRUCOUNT™ tubes and Flow-Count fluorospheres have
been found to be equally reliable[121]. This method is however expensive since
every sample has to be added to a TRUCOUNT™ tube, or have Flow-Count
fluorospheres added to it.
The alternative and significantly more cost effective method to quantify MPs is to
use a flow based method[203]. This method is based on the principle that a specific
volume of sample passes through the flow cytometer detector over a set period of
time (usually 120 seconds). Knowing the volume of sample that has been analysed
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in a given time frame allows the concentration of MPs in the patients' circulation to
be calculated. Different investigators[221, 222] have shown that the flow rate
through a flow cytometer is constant, so that the volume acquired in a fixed time
period will also be constant and can be determined by the use of TRUCOUNT™
beads at the same flow rate as that of sample acquisition. By running a
TRUCOUNT™ bead sample at a certain flow rate (the acquisition rate) over a
defined period of time (120 seconds), the exact volume that passes through the
detector can be easily derived from the number of counts divided by the
concentration of TRUCOUNT™ beads, as specified by the manufacturer. This
volume is then the reference volume to assess MP concentrations in unknown
samples. If the settings regarding flow rate remain the same, the MP count over the
same time period (120 seconds) corresponds to the same acquired sample volume, so
that the concentration ofMPs in the sample can be calculated. The number of events
counted in the same acquisition time period is then used to calculate the absolute MP
count per pL of test sample. This obviates the need to add reference beads to each
sample, and makes it a good method to use for quantification of MPs in serial
samples[203]. For accuracy frequent calibration checks should be undertaken at
least once at the start and again at the end of each batch of samples to ensure a
constant flow rate.
Using a flow rate based method to quantify MPs Storie et al[221] compared the
results obtained when using low, medium and high flow rates on the flow cytometer.
They found that a high flow rate was associated with the lowest CV and vice versa.
They speculate that this is because at the high flow rate, a larger volume is analysed
and hence more events are being counted in the 120 second acquisition period. They
recommend that a minimum of 100 events should be obtained to ensure reliability,
and therefore recommend that high flow rate acquisition is used. Alternatively if a
lower flow rate is used longer acquisition times would be necessary to ensure a
representative sample is analysed.
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2.4 CONCLUSION
There are still many unanswered questions in MP analysis. The current lack of
standardization ofMP assays means that it is very difficult to compare results in the
literature. There is an urgent need to reach an agreement on the methodology of the
various MP assays available, including sample handling, instrument settings for flow
cytometry and standard markers for quantification e.g. CD144 for EMPs, CD45 for
LMPs, CD41 for PMPs, each of defined target epitope (clone) and fluorescence, to
allow the reliable comparison of results. It is important to establish the details of
pre-analytical handling of samples and sample processing prior to comparing results
from different investigators.
Current identification and quantification of MPs is hampered by the limitation of the
technology available. Due to their small size it is currently difficult to accurately and
specifically identify and quantify MPs. We are still to establish a marker that will
satisfactorily identify all MPs irrespective of their cell of origin. However as the
technology advances (e.g. dynamic light scattering[215], electrochemical impedance
spectroscopy[216]) and the identification ofMPs becomes more accurate, MP assays
are likely to become clinically relevant in the future.
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CHAPTER III
DEVELOPMENT OF MICROPARTICLE ASSAY
FOR CURRENT STUDY
3.1 INTRODUCTION
As mentioned in the previous chapter there is currently no standardised method for
the identification and quantification of MPs in plasma. However the careful control
of experimental procedure would allow comparison between different samples
assayed at the same centre. 1 have devised a flow cytometry based method to
identify and quantify the number of circulating MPs derived from platelets, white
cells and endothelial cells. I also measured the total number of circulating TF+ve
MPs and AV+ve MPs. My method is based on previously published methods with
modifications to optimise the identification of the MPs.
3.2 Sample collection
A total of 9 mis of venous blood was collected into three 3.8% trisodium citrate BD
Vacutainer tubes (9 parts blood: 1 part citrate anticoagulant; Becton Dickinson, San
Jose, CA, USA) from an antecubital vein with a 21 gauge needle, using minimal or
no venous stasis. All samples were kept at room temperature and processed within
two hours of collection to minimize in vitro microvesiculation as a result of cell
death.
3.3 Microparticle assay
3.3.1 Preparation of PFP
After a review of the literature I compared 3 different centrifugation protocols[77,
97, 116, 203, 212, 220] in order to establish which protocol would be most effective
in producing PFP, with minimal platelet contamination - see Table 3.1, page 53. I
tested the 3 different centrifugation protocols on blood samples from 5 healthy
volunteers. Whole blood was collected into citrated vacutainer tubes (Becton
Dickinson, San Jose, California, USA) using a 21 gauge needle with minimal venous
stasis. Centrifugation was carried out within two hours at room temperature. In
protocol 1 whole blood was centrifuged at 1500g for 20 minutes, and the upper two
thirds of the supernatant used to measure the residual platelet count (using a Sysmex
XE-2100 analyser). In protocols 2 and 3, the supernatant after the first centrifugation
step was removed and centrifuged further as shown in Table 3.1, page 53. The upper
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two thirds of the supernatant after the second centrifugation step was then used to
measure the residual platelet count. Protocol 3 (1500g x 15 minutes + 13,000g x 2
minutes) consistently produced PFP with a residual platelet count of 5xl09/L or less.
I therefore used this centrifugation protocol in my study.
In the study cohort the residual platelet count in the PFP was in almost all cases less
than 5x109/L, with no residual detectable platelets in approximately half of the
samples - please refer to Table 3.2 for details.
Protocol number Centrifugation Protocol Residual platelet count (xl09/L)
1 1500g x 20 minutes 40-80
2 1500g x 20 minutes x2 1-15
3
1500g x 15 minutes +
13,000g x 2 minutes
0-5
I Table 3.1: The 3 different centrifugation protocols initially compared, showing the
centrifugal force used (g) and the duration of centrifugation. Protocol number 3










Table 3.2: The residual platelet count in the platelet free plasma of study samples.
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3.3.2 Immunophenotyping of MPs
Once the PFP was prepared small aliquots of it were labelled with the different
immunofluorescent monoclonal antibodies. As per published methods[82, 97, 121,
203] in the literature 20 pL of PFP were diluted in 100 pL of PBS and incubated
with 2 pL of immunofluorescent monoclonal antibody at room temperature for half
an hour in the dark. When staining with AV, 20 pL of PFP were diluted in 100 pL
of binding buffer (0.1M Hepes, 1.4M NaCl, 25mM CaCh, pH 7.4, (lOx concentrate),
BD Biosciences) and incubated with 5 pL of AV as above. Once the incubation
period was over PBS or binding buffer respectively was added to make up 1 mL of
volume, and the sample analysed on the flow cytometer (see later). For the first
twenty patients recruited, aliquots of 500pL of the PFP were also stored frozen at -
80°C (see section 3.5, page 64).
3.3.3 Flow cytometer
All samples were analysed using an unmodified BD FACScan flow cytometer using
CELL Quest software (Becton Dickinson Immunocytometry Systems, CA, USA).
The data generated was analysed using FCS express software (version 3, DeNovo
Software). The flow cytometer was cleaned on a daily basis as per the
manufacturer's instructions, and calibrated on a regular basis using Calibrite™ beads
(BD Biosciences).
3.3.4 Reagents and monoclonal antibodies
The list of antibodies used in this study is summarised in Table 3.3, page 56. I used
directly conjugated monoclonal fluorescent antibodies to identify cell-specific MP
subtypes. The antibodies I selected for this study are based on published
literature[98], I selected monoclonal antibodies against antigens with high cell
specificity. In order to ensure minimal disturbance from non-specific binding of the
antibodies, each patient sample was also incubated with non-specific FITC/PE/APC-
conjugated anti-mouse IgGl antibodies, to set a positive v.s. negative discrimination
limit.
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The different subtypes of MPs were defined as events <1 pm in size and positive
with the following antibodies:
PMPs positive with anti-CD41,
activated PMPs dual positive with anti-CD41 and anti-CD62P
EMPs positive with anti-CD 144
LMPs positive with anti-CD45
TF+ve MPs positive with anti-CD 142
AV+ve MPs positive with AV.
All the antibodies were titrated to determine the optimal saturating concentration for
MP labelling. I found that the optimal dilution for the different antibodies was as
follows:
anti-CD45 PE, anti-CD 144 PE, anti-CD 142 FITC and AV APC - neat;
anti-CD41 FITC and anti-CD62P PE diluted 1 in 2;
isotype controls diluted 1 in 4.
Examples of the titrations are shown in Figure 3.1, page 57-58.
The flow cytometer used in this study allows multi-colour labelling with up to 4
different colours. I had initially planned to use multi-colour flow cytometry to be
able to use combinations of antibodies in order to identify the MP subtypes that were
positive for TF and AV. However during my initial experiments I found that the
binding buffer, necessary for AV binding, was interfering with the binding of the
cell-specific antibodies. Similarly there was interference between anti-CD142 and
the other antibodies. I was therefore unable to use these antibodies in combination
with other antibodies, so that while I was able to measure the total number of TF+ve
(CD 142) MPs, and the total number of AV+ve MPs, I was unable to ascertain the
cell-specificity of these MPs. There was no adverse interaction between anti-CD41
and anti-CD62P, and these two antibodies were therefore used in combination to
further characterise the PMPs identified.
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Table 3.3: List of monoclonal antibodies and isotype negative controls used in this




















Figure 3.1a: An example of antibody titration using anti-CD41 FITC antibody. The
fluorescence histograms (images on the left) show the value for peak channel
fluorescence for each dilution; dot plots (images on the right) show anti-CD41
positive events (FL1-H), detecting platelet-derived microparticles. A 1 in 2 dilution




Figure 3.1b: Annexin V (AV) APC neat - fluorescence histogram (image on the left)
showing the peak channel fluorescence with AV neat; dot plot (image on the right)
showing AV positive microparticles (FL4-H).




NEGATIVE CONTROLS 1 in 4 dilution
Figure 3.1c: Negative controls 1 in 4 dilution: fluorescence histograms and dot plots
to establish the positive and negative gates for each fluorochrome.
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3.4 Flow cytometer protocol
3.4.1 Size calibration
The MP size gate was defined using 1 gin diameter latex beads (Duke Scientific
Corporation, Palo Alto, CA). These beads were diluted 1:10,000 in 0.5% albumin in
PBS. The flow cytometer settings were changed to MP settings (please refer to
Figure 3.3, page 60) and the data was acquired on a contour plot after sonication of
the 1 pm beads. This data was used to establish the 1 pm gate on log forward and
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Figure 3.2: 1 pm bead size calibration to set microparticle gate based on size.
The forward scatter and side scatter settings were set at logarithmic gain and the
settings were optimised to be able to identify events less than 1 pm in size, at the
same time minimising non-specific electronic noise. Fluorescence gates were set by
forward gating of samples labelled with monoclonal antibodies, using negative
isotype control samples for comparison to exclude non-specific background staining.
Please refer to Figure 3.3, page 60 for the flow cytometer settings used. Among the
events within the 1 pm gate, MPs were positively identified according to their
fluorescence positivity for cell-specific antigens.
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Detectors/Amps
Parameter Detector Voltage Amp gain Mode
PI FSc E00 9.99 Log
P2 SSc 350 1.58 Log
P3 FL1 540 1.0 Log
P4 FL2 590 1.0 Log
P7 FL4 600 1.0 Log
Threshold










Figure 3.3: Flow cytometer settings for microparticle analysis.
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3.4.2 Quantification of MPs
In order to be able to quantify the number of circulating MPs in the patient plasma I
used a flow based method. As per published methods[221] I used TRUCOUNT™
beads (BD Biosciences) of known concentration in order to establish the volume of
fluid analysed by the flow cytometer over a set period of time (120 seconds).
TRUCOUNT™ beads are supplied at a specific concentration (approximately 1000
beads/pL). They are 4 pm in diameter, and are labelled with both FITC and PE. 50
pL of such TRUCOUNT™ beads were diluted in 950 pL of PBS, using the
recommended reverse pipetting technique. The flow cytometer settings were
changed so as to optimise the detection of the TRUCOUNT™ beads according to the
advice given by the manufacturer (Figure 3.4, page 62 and Figure 3.5, page 63). The
beads were vortexed carefully immediately prior to analysis; a minimum of 10
seconds was allowed before commencing data acquisition to allow stabilization of
the sample flow rate. Data was then acquired at medium flow rate for 120 seconds
twice prior to and again twice at the end of each batch of patient samples (to ensure a
steady flow rate), and the mean bead count was calculated from these 4 sets of data.
Knowing the number of events measured by the flow cytometer over 120 seconds,
and the concentration of the TRUCOUNT™ beads, allowed me to calculate the
volume of fluid analysed by the flow cytometer over 120 seconds. There is
published evidence[221] that the flow rate through a flow cytometer is stable, so that
the same volume of fluid is analysed in the same time interval at the same flow rate,
confirmed also by my results. My mean bead count at medium flow rate over 120
seconds was 3744 beads with a standard deviation of 122 beads over 120 seconds,
and an overall inter-assay CV over 12 months of 3.2%.
Each patient sample was then analysed in the same manner as the TRUCOUNT™
beads i.e. for 120 seconds at medium flow rate, but changing the flow cytometer
settings to optimise MP identification (Figure 3.3, page 60) - this allowed me to then
calculate the concentration of MPs in patient plasma by the calculation shown in
Figure 3.6, page 63.
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Detectors/Amps
Parameter Detector Voltage Amp gain Mode
PI FSc E00 2.0 Log
P2 SSc 341 1.0 Log
P3 FL1 505 1.0 Log
P4 FL2 597 1.0 Log
Threshold





















Figure 3.5: Dot plot ofTRUCOUNT™ beads.
Final TRUCOUNT™ concentration (beads/pL) = Stated bead concentration (beads/uL) x 50 uL
1000 pL
Volume sampled in 120 seconds (pL) = Mean bead count in 120 seconds
Final TRUCOUNT™ concentration (beads/pL)
Final sample MP concentration (MP/pL) = MP count in 120 seconds
Volume sampled in 120 seconds (pL)
Original plasma MP concentration (MP/pL) = final sample MP concentration (MP/uL) x lOOOuL
20 pL
Figure 3.6: Method used to calculate the original microparticle (MP) concentration in
patient plasma. The above calculation is based on 50 pL of TRUCOUNT™ beads
being diluted in 950 pL of phosphate buffered saline (PBS), and 20 pL of patient
plasma being diluted to a final volume of 1000 pL of PBS or binding buffer prior to
flow cytometer analysis.
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3.5 Effect of freezing PFP on MP analysis
Limiting MP analysis to fresh samples is highly labour-intensive and significantly
limits the number of samples that can be run. It also makes inter-laboratory
collaboration difficult, decreases laboratory efficiency, and increases sample-to-
sample variation in large sample sizes. In view of this I assessed whether MP
analysis could be done on plasma samples that had been stored frozen until analysis
at a later date.
For the first twenty patients, I measured MPs on a fresh and again on a frozen aliquot
of the same PFP sample. The fresh sample of PFP was processed routinely. A
separate 500 pL aliquot of the same PFP sample was frozen and stored at -80°C until
analysis. This frozen sample was then thawed at room temperature, the number of
MPs measured as per the usual protocol and the results of the paired PFP patient
samples compared.
The two sets of results were significantly and variably different - Figure 3.7, page 65.
In the majority of cases the number of MPs detected after a freeze/thaw cycle was
greater than on fresh samples, except for EMPs and AV+ve MPs where the converse
was true. However for some patient samples the reverse was also true. While the
mechanisms behind these changes are difficult to explain, these results suggest that
freezing has the potential to introduce significant experimental artefacts. In view of
this in the rest of the patients MPs were measured on fresh plasma samples to ensure
that the results were comparable.
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PMPs in fresh v.s. frozen samples Activated PMPs in fresh v.s. frozen samples
I fresh sample
Ifrozen sample




EMPs in fresh v.s. frozen samples LMPs in fresh v.s. frozen samples
■fresh sample
ifrozen sample




TF+ve MPs in fresh v.s. frozen samples AV+ve MPs in fresh v.s. frozen samples
■fresh sample
■frozen sample




Figure 3.7: Comparison of results between fresh and frozen samples. The number of
microparticles detected after a freeze/thaw cycle did not correlate with the results
obtained from fresh plasma.
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3.6 D-dimers, TAT and PF1&2 Assays
3.6.1 Preparation of PFP
As for the MP analysis all the samples were processed at room temperature within
two hours of collection. In order to prepare PFP for the measurement of D-dimers,
TAT and PF1&2 one of the citrate tubes from each patient was centrifuged at 2500g
for 15 minutes, as per our local laboratory standard operating procedure for such
assays.
3.6.2 Storage of samples
An aliquot of PFP prepared as above from every patient recruited was stored frozen
at -80°C until a later date. At the end of patient recruitment all stored samples were
thawed at 37°C as per our local laboratory standard operating procedure and ELISAs
carried out.
3.6.3 Assays
The level ofD-dimers, TATs and PF1&2 were measured using ELISAs:
- HaemosIL D-Dimer HS, Instrument Laboratory UK Ltd (IL),
- Enzygnost TAT micro, Dade Behring, Marburg GMBH
- Enzygnost fl+2 micro (monoclonal), Dade Behring, Marburg GMBH
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3.7 FINAL PROTOCOL USED IN THIS STUDY
Sample Collection and Processing:
Venepuncture with no or minimal venous stasis from an antecubital vein, using a 21-
gauge needle.
9 mis of venous blood collected into 3 citrated tubes.
Samples kept at room temperature and processed within a maximum of two hours.
Centrifugation:
a) PFP preparation for MP analysis
Two citrate tubes from each patient were centrifuged at 1500g for 15 minutes; the
upper two thirds of the supernatant were removed and centrifuged further at 13,000g
for 2 minutes.
The resultant supernatant (PFP) was used to measure MPs. MP analysis was carried
out as soon as the PFP was prepared.
A small aliquot of the PFP was used to measure the residual platelet count in the
plasma.
b) PFP preparation for D-dimers, TAT and PF1&2
One citrate tube from each patient was centrifuged at 2500g for 15 minutes; the
resultant supernatant was stored at -80°C. These samples were later thawed at 37°C
and the levels of D-dimers, TAT and PF1&2 measured using ELISAs as the per
manufacturer's instructions.
Immunophenotyping:
For each patient sample 20 pL of PFP were diluted in 100 pL of PBS or binding
buffer and incubated with directly conjugated immunofluorescent monoclonal
antibody or AV as follows:
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Tube 1: 20 pL of PFP + 100 pL ofPBS + 2 \iL anti-mouse IgGl FITC + 2 pL
anti-mouse IgGl PE + 2 pL anti-mouse IgGl APC
Tube 2: 20 pL of PFP + 100 gL ofPBS + 2 gL anti-CD41 FITC + 2 gL anti-
CD62P PE
Tube 3: 20 gL of PFP + 100 gL of PBS + 2 gL anti-CD144 PE
Tube 4: 20 gL of PFP + 100 gL ofPBS + 2 gL anti-CD45 PE
Tube 5: 20 gL of PFP + 100 gL of PBS + 2 gL anti-CD142 FITC
Tube 6: 20 gL of PFP + 100 gL of binding buffer + 5 gL ofAV APC
The above test tubes were incubated in the dark at room temperature for half an hour.
The antibody dilutions used were as follows:
Isotype negative controls - 1 in 4 dilution
Anti-CD41 FITC, anti-CD62P PE - 1 in 2 dilution
Anti-CD 144 PE, anti-CD45 PE, anti-CD 142 FITC and AV APC - neat
When more than one patient sample was being analysed on a specific day, antibody
labelling of the different patient samples was staggered so that all samples were only
incubated for a total of half an hour ensuring uniformity.
Once the incubation period was over PBS or binding buffer was added to each test
tube to make up 1 mL of volume as follows:
Tube 1: 874 gL PBS
Tube 2: 876 gL PBS
Tube 3: 878 gL PBS
Tube 4: 878 gL PBS
Tube 5: 878 gL PBS
Tube 6: 875 gL binding buffer
The samples were then immediately analysed on the flow cytometer.
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Flow cytometer analysis:
While the patient samples were incubating, the flow cytometer was cleaned as per
the manufacturer instructions.
TRUCOUNT™ beads preparation:
50 pL of TRUCOUNT™ beads of known concentration (approximately 1000
beads/pL) were diluted in 950 pL of PBS.
TRUCOUNT™ beads analysis:
The flow cytometer settings were changed to optimise detection of the
TRUCOUNT™ beads (see Figure 3.4, page 62), the flow rate set to medium, the
beads vortexed and after at least 10 seconds of flow (to allow stabilization of the
sample flow rate) the beads were analysed for 120 seconds.
This was done twice prior to each batch of patient samples and twice again at the end
of patient sample analysis. The 4 event counts thus generated were used to calculate
the mean bead count over 120 seconds. This value was later used to calculate the
volume of fluid analysed by the flow cytometer over 120 seconds (see Figure 3.6,
page 63).
Patient sample analysis
The flow cytometer settings were then changed to MP settings (Figure 3.3, page 60),
the flow rate was kept at medium rate, the patient sample was vortexed, and after at
least 10 seconds of flow (to allow stabilisation of the sample flow rate) the patient
sample was analysed for 120 seconds.
69
3.8 DISCUSSION
At the time of writing there are still many unanswered questions about MPs. It is
still unclear how best to identify them accurately and specifically. This makes
comparison of results between different laboratories very difficult. Different
investigators use slightly different criteria to define what constitutes a MP, and there
is no currently standardised method to identity them. Accurate identification ofMPs
is hampered by their small size which challenges the currently available technology.
There are various methods by which MPs can be analysed. 1 have devised a method
based on light-scattering flow cytometry.
It is still unclear how best to process samples pre-analysis to ensure no loss or
generation of MPs in vitro during sample preparation. In order to produce
meaningful results and allow inter-patient correlations, I ensured that all the patient
samples were treated in an identical manner. All patients were sampled from an
antecubital vein with no or minimal venous stasis applied. All samples were kept at
room temperature and centrifuged within 2 hours. Incubation was always limited to
half an hour and all MP analysis on the flow cytometer was done immediately the
PFP was prepared. When more than one patient sample was being analysed on a
specific day, immunophenotyping of the plasma was done in a staggered fashion to
ensure uniform incubation and handling.
Flow cytometry is currently the commonest technique used to identify MPs. It
allows the analysis of tens of thousands of MPs, and the identification of the MP
subtype by positivity for cell specific antigens. However flow cytometry has a
number of limitations when used to measure MPs. MPs are generally defined as
intact phospholipid vesicles 0.1-1.0 pm in diameter[78], so that they are much
smaller than the cells which flow cytometers were initially designed to analyse. The
MPs appear close to the electronic noise and cellular debris in current flow
cytometers making their positive identification challenging. This is a limitation of
my study. In this study I defined MPs as events less than 1.0 pm in size that were
positive for the cell-specific antigens. I therefore set a 1.0 pm gate to capture all
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events 1.0 pm or less in size, minimising interference by any residual contaminating
platelets. On the other hand I set the forward scatter threshold at 20 to maximise
detection of the smallest MPs present while removing some of the machine noise.
Prior to processing patients samples 1 trialled out different centrifugation protocols to
establish how best to prepare PFP with minimal platelet contamination. I concluded
that based on current evidence ultra-centrifugation was probably best avoided due to
the real concern of "generating" MPs during the ultra-centrifugation process, and as
mentioned in the previous chapter even ultra-centrifugation cannot guarantee that all
the MPs are isolated. After reviewing the literature I tried out 3 different
centrifugation protocols. Based on my data the first two (please refer to Table 3.1,
page 53) did not adequately remove contaminating platelets from the plasma, while
protocol number 3 (1500gx 15 minutes + 13,000gx 2 minutes) produced PFP with a
residual platelet count consistently <5xl09/L. This was borne out in my study - none
of the patient PFP samples had a platelet count above 9xl09/L, 46.7% had no
residual contaminating platelets, another 46.7% had a residual platelet count of 1-
5x109/L and only 6.4% of all samples had a platelet count of 6-9xl09/L. This is
important because any residual platelets in the plasma sample are likely to interfere
with the accurate detection of PMPs.
In order to be able to accurately quantify the absolute number of circulating MPs I
made use of a flow based method, using TRUCOUNT™ beads of known
concentration to determine the volume of fluid analysed by the flow cytometer over a
specific period of time. There are published studies[221] showing that the flow rate
through a flow cytometer is constant. I have also confirmed this in my study. The
intra-assay variation in the bead count was low with only a small variation in the
flow rate over a single flow cytometry session and an overall method inter-assay CV
over 12 months of 3.2%. I found this method of quantifying MPs to be reproducible
and more cost-effective than if I had added Flow-Count fluorospheres to each patient
tube.
71
There are many different monoclonal antibodies that can be used to identify specific
subtypes of MPs. The antibodies I chose to use in my study (please refer to Table
3.3, page 56) were based on published literature[98], and were chosen because of
their reported specificity for a particular cell type. Anti-CD41 binds to GPIIb, an
antigen normally expressed on all platelets and specific to platelets. CD62P (P-
selectin) on the other hand is normally expressed on activated platelets and activated
endothelial cells. By using anti-CD62P together with anti-CD41 I was able to further
characterise the circulating PMPs (PMPs expressing both CD41 and CD62P being
released from activated platelets). CD 144, also known as VE-cadherin, is expressed
by most endothelial cells. Endothelial cells express many different surface antigens,
but CD 144 seems to be the surface antigen most specific to endothelial cells, the only
other cells expressing CD 144 being perineural cells. CD45, also known as the
common leucocyte antigen, is expressed on all white cells and is specific to white
cells, so that anti-CD45 identifies LMPs. CD 142 is the tissue factor antigen, while
AV binds to PS. The antibodies I used were titrated to determine their saturating
concentrations and optimal dilutions.
1 had initially planned to use combinations of up to 4 different antibodies using
multicolour flow cytometry to characterise the AV positivity and TF positivity of the
different subtypes of MPs. However in the initial experiments I found significant
interaction of the AV binding buffer with the other antibodies; anti-CD 142 also
interfered with the other antibodies leading to a lack of reproducibility. I therefore
elected to use all the antibodies singly (other than anti-CD41 and anti-CD62P which
did not interfere with each other) in order to ensure reproducible results. This
however meant that while I was able to measure the total number of PMPs, EMPs,
LMPs, TF+ve MPs and AV+ve MPs, I was unable to comment on the TF positivity
or the AV positivity of the PMPs, EMPs and LMPs. I also had no way of
establishing the cells of origin of the TF+ve and AV+ve MPs I was detecting.
A significant source of variability in the published literature is whether MP analysis
is carried out on fresh or frozen samples, with a number of investigators[82, 97, 116,
211] using frozen samples. This has the great advantage of being able to batch
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samples allowing greater efficiency in analysis, while limiting MP analysis to fresh
samples is highly labour intensive and makes inter-laboratory cooperation difficult.
However it is currently unclear what effect a freeze/thaw cycle has on MPs. In view
of this for the first 20 patients I measured the number of circulating MPs both on a
fresh sample and a separate aliquot of the same plasma that had been stored at minus
80°C prior to MP analysis. My results on fresh samples compared to the same
sample after a freeze/thaw cycle were very variable and significantly different. It is
difficult to explain the variability in these results, however it is likely that freezing
has the potential to introduce significant experimental artefact. As a result all MP
analysis in my study have been carried out on fresh samples within 2 hours of blood
collection to ensure that the results are comparable.
3.9 SUMMARY
I have designed a protocol for the measurement of MPs based on light-scattering
flow cytometry. MPs were identified based on size and expression of cell-specific
antigens, and their absolute numbers quantified using a flow-based method. The
limitation of my study is that MPs, by virtue of their small size, appear close to the
machine noise in current flow cytometers. There is currently no standardised method
for MP analysis, and it is likely that different pre-analytical variables and different
methods of analysis influence the number ofMPs detected. In view of this I ensured
that all my patient samples were treated in an identical manner to minimise any in







Patients with gynaecological malignancy have a significant risk of thrombosis,
together with its associated morbidity and mortality. Further, patients with both a
malignancy and a VTE event have a worse overall prognosis[19, 20, 47].
Thromboprophylaxis is known to reduce the incidence of VTE events, which in the
perioperative period translates into a reduced mortality rate[6, 62-64], However
there is very little data on the use of primary thromboprophylaxis in patients with
gynaecological malignancy outside the surgical setting. At present it is unclear what
the optimal thromboprophylaxis regimen in this patient group is, especially as they
also have a significant risk of bleeding. The risk factors for VTE are several.
However we are currently unable to predict the likelihood of a VTE event in an
individual. If patients at a higher risk of VTE events could be identified then
primary thromboprophylaxis in such patients could potentially reduce the incidence
of VTEs and improve the overall prognosis. Further studies to elucidate this are
required before primary thromboprophylaxis can be advised for all patients with
gynaecological malignancy.
MPs are thought to play an important role in haemostasis and thrombosis. They are
also considered important in the patho-physiology of cancer cell survival,
invasiveness and metastasis[99], The number of circulating MPs, and MP-dependent
function, have been variously reported to be increased in patients with underlying
prothrombotic conditions, including malignancy. Patients with malignancy
(with/without thrombosis) have also been found to have evidence of coagulation
system activation[36, 78], There are several published studies showing increased
levels of markers of haemostatic activation such as D-dimers, TAT and PF1&2 in
such patients[20, 142, 178],
It is therefore reasonable to assume that in patients with gynaecological malignancy
the number of circulating MPs is likely to be increased, and that there will be
evidence of coagulation system activation, with increased levels of D-dimers, TAT
and PF1&2. I hypothesised that the number of circulating MPs in individual patients
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with gynaecological malignancy may help identify patients at a significant risk of
thrombosis, allowing primary thromboprophylaxis to be tailored accordingly. As far
as I am able to ascertain there are no published studies looking at the number ofMPs
specifically in patients with gynaecological malignancy.
The aims and objectives of this research study are outlined in Chapter 1, section 1.6,
page 32. I have recruited patients presenting in the South East of Scotland Cancer
Network (SCAN) with a confirmed diagnosis of gynaecological malignancy, and a
control group of women with no underlying malignancy. I measured the number of
circulating PMPs, LMPs, EMPs, TF+ve MPs and AV+ve MPs to establish whether
MP levels are truly elevated in patients with gynaecological malignancy compared
with women with no malignancy and to assess whether the number of circulating
MPs can be used to establish the individual risk of thrombosis. I also measured D-
dimers, TAT and PF1&2 in the two patient groups as indirect markers of haemostatic
activation, and correlated their levels with the number of circulating MPs.
Statistical advice was obtained (Dr. Gillian Norrie BSc(Hons) Statistics) as to the
sample size required in order to establish whether plasma MP levels could be used to
assess the individual risk for VTEs. For MPs to be a useful predictor there would
need to be a clinically meaningful difference in the mean MP numbers in patients
with VTE compared to those with no VTE. The quoted incidence of VTE events in
patients with gynaecological cancer is very variable: 9.8-57% in endometrial
cancer[8], 0-34% in cervix cancer[9], 13.6-27% in ovarian cancer[7]. Based on these
reports we predicted that approximately 25% of women with gynaecological
malignancy would develop a VTE at some point during their investigation and
treatment for cancer. From Chirinos et al[23] we hypothesised that the mean number
of EMPs for patients with a VTE would be around 2000/pL, compared to
approximately 400/p.L for patients with no VTE. Assuming a common standard
deviation of 2500/pL, then a consecutive series of around 140 patients with
gynaecological malignancy would be expected to have around 35 women with a
VTE event and 105 with no VTE. Such a study would have around 90% power to
detect the hypothesised difference in mean EMP numbers between patients with a
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VTE and patients with no VTE, at a 5% level of significance using a two sample t-
test. Such a separation between patients with and without a VTE event may make
EMP numbers a useful predictor of VTE. The study was also planned to recruit a
similar number (n=140) of women without malignancy so that we could explore
whether EMP numbers are a superior predictor of VTE in women with
gynaecological cancer to those without.
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4.2 Methods
4.2.1 Recruitment ofmalignant group and control group
All patients with gynaecological malignancy in SCAN are initially discussed and
reviewed at the new patient gynae-oncology clinic at the Western General Hospital,
Edinburgh. During 2009, patients attending this clinic with a confirmed diagnosis of
gynaecological malignancy were invited to participate in this study (malignant
group). Women attending the clinic were given written information (Letter of
Invitation (Appendix A) and Patient Information Sheet for patients with
gynaecological malignancy (Appendix B)) about this study after their initial
consultation with the oncology team.
During the same period of time I also recruited a control group of women who were
attending hospital for pre-operative clerking prior to proceeding with benign
gynaecological surgery. This group of women (control group) did not have any
underlying malignancy. Women attending the gynaecology pre-operative clerking
clinic at the Royal Infirmary of Edinburgh were given written information (Letter of
Invitation (Appendix A) and Patient Information Sheet for patients with benign
gynaecological conditions requiring surgical treatment (Appendix C)) about this
study at the time of their clinic appointment for pre-operative clerking.
All patients attending the above-mentioned clinics were approached about the study
in a consecutive manner with no selection bias. A total of 69 patients with
gynaecological malignancy and 45 patients with no underlying malignancy were
invited to participate. Of these, 67 (97%) patients with gynaecological malignancy
and 42 (93%) patients with no underlying malignancy agreed to participate (see
Figure 4.1, page 79). The study was discussed with these patients in greater detail.
They were given the opportunity to ask questions, and written informed consent was
obtained from all patients enrolled in the study prior to any blood samples being
taken (Consent Form, Appendix D1 & D2).
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Total number of patients invited to participate in microparticle study
n=114
Patients with gynaecological malignancy





Patients with no malignancy





Figure 4.1: Recruitment tree
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4.2.2. Blood sampling and handling
All patients with gynaecological malignancy recruited to the study (n=67) had a
study blood sample taken as per study protocol at their first outpatient appointment
with the oncology team.
In 7 of the above patients follow up blood samples were also taken at the end of their
treatment to assess the effect of treatment on the number of circulating MPs.
However this proved difficult to co-ordinate with the patients and was not continued.
Six of these seven patients were treated with chemoradiotherapy or radiotherapy
alone - in these patients the second blood sample was taken in their 5th and final
week of treatment just before their final treatment session. The 7th patient was
treated with chemotherapy only, and in this patient the second blood sample was
taken in the 6th and final week of treatment, just before the final chemotherapy
session.
Of the patients with gynaecological malignancy who required surgery as part of their
treatment, 7 provided a second sample of blood 24 hours after surgery. The rest
declined a second blood sample post-operatively, mainly because they were not
feeling very well.
Patients in the control group (n=42) had a blood sample taken as per study protocol
at their pre-operative clerking appointment. In 18 of these patients a second blood
sample was also taken 24 hours after surgery. The rest of the patients in the control
group declined a second sample post-operatively, mainly because they were not
feeling very well.
All samples were kept at room temperature pre-analysis and processed within 2
hours as per study protocol. Please refer to chapter III for full details.
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4.2.3 Patient details
Patient details including histological diagnosis, disease stage, relevant past medical
history, treatment given and follow up information was obtained by reviewing the
patients' medical records. VTEs were defined as deep vein thrombosis and/or
pulmonary embolism occurring up to one year prior to, or concurrent with, the
diagnosis of malignancy, or during treatment and follow up of the malignancy in the
malignant group, and within 3 months of surgery in the control group.
4.2.4 Ethics
The study was submitted to and approved by the Lothian Local Research Ethics
Committee (REC reference number 08/S1103/51).
4.2.5 Statistics
Using the Shapiro-Wilk test, the parameters measured were found not to be normally
distributed. Values are therefore expressed as the median and interquartile range
(1QR). Comparisons between two independent groups of patients were carried out
using the Mann Whitney U test, while comparisons between three or more
independent groups were carried out using the Kruskal Wallis test. Multivariate
analysis was carried out to allow for age adjustment.
The correlation between different variables was assessed using Spearman's
nonparametric correlation coefficient (r). Paired samples were compared using the
Wilcoxon Signed Ranks test. All reported probability values are two-tailed.
Statistical significance was defined as a p value of < 0.05. Analyses were performed




Of the women with a confirmed diagnosis of gynaecological malignancy presenting
in SCAN during 2009, 67 agreed to take part in this study (malignant group). During
the same period of time I also recruited a control group of 42 women who were
attending hospital prior to proceeding with benign gynaecological surgery with no
underlying malignancy. Table 4.1 is a summary of the demographics of the two
groups of patients.
All the patients recruited in this study are women. The control group of women
tended to be younger than the women in the malignant group (p=0.02), although not
with a dissimilar age spread.





65 yrs (26-89yrs) 57 yrs (38-83yrs)
Diagnosis
n (%)
Ovarian cancer n=24 (36%)
Endometrial cancer n=24 (36%)
Cervical cancer n=13 (19%)
Vulval cancer n=5 (7.5%)
Vaginal cancer n=l (1.5%)
Prolapse n=18 (43%)
Benign fibroids n= 18 (43%)
Benign cysts n=6 (14%)
Table 4.1: Demographics of the two patient groups.
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4.3.2 Haematological and Renal Parameters
The haematological parameters (FBC) and renal function (EGFR) of the two patient
groups at the time of their recruitment to my study are summarised in Table 4.2, page
84. Using the Shapiro-Wiik test the FBC results were found not to be normally
distributed - Figure 4.2, page 85.
The malignant group tended to have a lower haemoglobin level, however this
difference did not reach statistical significance. The white blood count (wbc) was
higher in the malignant group, reaching statistical significance (p=0.001), while there
was no overall difference in the platelet count between the two groups. Patients with






























No. of pts with normal
EGFR(%)
(>60 mls/min)
54 (83%) 40 (95%) n/a






(52 & 57 mls/min)
n/a
Table 4.2: Summary of the haematological and renal parameters. Two of the patients
with gynaecological malignancy did not have a full blood count and renal function
checked at recruitment to the study (n=65 instead of 67). M refers to the patients
with gynaecological Malignancy, B refers to the control group with Benign
gynaecological conditions, p value result for 2-tailed significance testing using the
Mann Whitney U test for 2 independent samples. Haemoglobin (Hb), white blood
count (wbc), estimated glomerular filtration rate (EGFR), patients (pts), number
(no.).
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B=control cohort with benign gynaecological conditions; M=patient
group with gynaeoclogical malignancy
B=control cohort with benign gynaecological conditions; M=patient
group with gynaecological malignancy
B=coritroi cohortwilii benign gynaecological conditions; M=patient
group with gynaecological malignancy
Figure 4.2: Box plots showing the distribution of the haematological parameters.
85
4.3.3 Treatment
The women in the malignant group were treated with a variety of different protocols,
depending on their specific malignancy, disease stage and co-morbidities. The
surgical treatment of the control group also varied according to the specific condition









TAH BSO + Cisplatin + radiotherapy (3)





TAH BSO + radiotherapy (14)
TAH BSO + Carboplatin & Paclitaxel + radiotherapy (3)









TAH BSO + Carboplatin & Paclitaxel (10)
TAH BSO (6)
Carboplatin & Paclitaxel (6)
Hormone treatment (1)












Pelvic floor repair (10)





Table 4.3: Summary of the treatment delivered to the patients in the study.
Total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO)
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4.3.4 Incidence of Venous Thromboembolism
Any patients presenting with symptoms suggestive of venous thromboembolic events
were objectively and appropriately investigated by imaging techniques according to
their symptoms (CT scan and/or lower limb dopplers). Imaging (CT scan) was also
carried out on all women with malignancy to stage the cancer and assess response to
treatment. Routine imaging was not carried out in the control group, although
patients in the control group were investigated appropriately if they developed
symptoms suggestive ofVTE.
Of the 67 women in the malignant group, 5 were diagnosed with a VTE episode - 4
(2 ovarian carcinoma, 2 vulval carcinoma) at the time their malignancy was first
diagnosed on a staging scan, and one patient (ovarian carcinoma) while on
chemotherapy (Carboplatin and Paclitaxel), after investigation of symptoms
suggestive of a pulmonary embolism. None of the patients requiring surgical
treatment of their malignancy were diagnosed with a thrombotic event in the
perioperative period. Likewise, no patients receiving radiotherapy were diagnosed
with a thrombotic event. There were no arterial events.
Of the 4 patients diagnosed with a VTE event concurrent with their diagnosis of
malignancy, 1 had a coincidental diagnosis of both lower limb deep vein thrombosis
and pulmonary embolism on staging CT scan and 2 had a coincidental diagnosis of
only pulmonary embolism on staging CT scan. The 4th patient developed symptoms
suggestive of a pulmonary embolism a few days after her diagnosis of cancer (and
prior to commencing treatment) - the diagnosis of pulmonary embolism was
confirmed on CT pulmonary angiogram. The patient with a VTE event diagnosed
while on chemotherapy had a pulmonary embolus confirmed with CT pulmonary
angiography after developing symptoms suggestive of such a diagnosis.
All 4 patients who presented with a VTE at the same time their malignancy was
diagnosed had extensive disease and were only fit for palliative treatment, either by
virtue of the extent of their disease or because of general frailty. Two of these
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patients (40% of the patients with a VTE) passed away very quickly. Please refer to
Table 4.4, page 89 for a summary of the patients who developed VTE events.
None of the women in the control group were diagnosed with a thrombotic event
within 3 months of surgery. All surgical patients (both in the malignant group and in
the control group) were routinely managed with primary thromboprophylaxis with
low molecular weight heparin and TED stockings in the perioperative period.
4.3.5 Mortality rate
Of all the patients in this study, 4 (6%) of the malignant group (3 ovarian carcinoma
and 1 vulval carcinoma) died during the follow up period (median follow up of 11
months; range 5-17 months). Two of these patients had been diagnosed with venous
thrombosis at presentation with gynaecological malignancy, so that 40% (2 out of 5
patients with a VTE event) of the patients with a VTE event died, compared to 3.2%
(2 out of 62 patients with no thrombosis) of the patients with no thrombosis. None of








No. of pts with
VTE diagnosed










2 (8.3%) 1 (4.2%) 3 (12.5%) 0
Vulval ca
(5)
2 (40%) 0 2 (40%) 0
Cervical ca
(13)
0 0 0 0
Endometrial ca
(24)
0 0 0 0
Vaginal ca
(1)




4 (5.97%) 1(1.5%) 5 (7.5%) 0
Control group
(42)
0 0 0 0
Table 4.4: Summary of the thrombotic events in the study patients. VTE (venous
thromboembolism) refers to deep vein thrombosis (DVT) and/or pulmonary
embolism (PE). Number (no.), patients (pts), cancer (ca), cerebrovascular accident
(CVA), myocardial infarction (Ml).
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4.4 Study Results
4.4.1 Distribution of the measured parameters
Using the Shapiro-Wilk test, the number of circulating MPs and the level of D-
dimers, TAT and PF1&2 were found not to be normally distributed - please refer to
Figure 4.3, page 90.
TF+ve MPsAV+ve MPs
D-dimers ng/ml_
Figure 4.3: Box plots showing the distribution of the number of microparticles (MPs)
and the level of D-dimers and PF1&2 for the malignant group and the control group.
The thrombin-antithrombin results have not been included due to the fact that a very




The MP results are summarised in Table 4.5 and Figure 4.4, page 92. The number of
circulating MPs (PMPs, LMPs, EMPs, AV+ve MPs) was very similar between the
two groups with no statistically significant difference. There was also no difference
in the number of circulating TF+ve MPs between the two groups. This was also the
case when the MP levels were analysed according to tumour stage, specific cancer
diagnosis (i.e. cervical, endometrial, ovarian, vulval and vaginal cancer) and specific
reason for requiring benign gynaecological surgery (i.e. pelvic floor prolapse, benign
ovarian cysts, benign fibroids) - please refer to Figure 4.5, page 93.
MP subtype



















336 104-782 370 126-1091 0.3
EMPs
(anti-CD 144)
523 299-995 589 381-985 0.476
LMPs
(anti-CD45)
1315 844-2436 1510 950-2409 0.641
TF+ve MPs
(anti-CD 142)
981 478-1486 805 386-1169 0.214
AV+ve MPs 1609 998-2289 972 567-1938 0.051
Table 4.5: Number of microparticles (MPs) in the two patient groups according to
the specific cell of origin, tissue factor (TF) positivity and annexin V (AV) positivity.
There was no statistically significant difference, p value result for 2-tailed
significance testing using the Mann Whitney U test for 2 independent samples.
Interquartile Range (IQR), platelet-derived MPs (PMPs), endothelial-cell derived








Control group Malignant group
Figure 4.4: Box plot of the microparticle (MP) results. There is no statistically





































Figure 4.5: Box plots of the microparticle (MP) results by specific diagnosis. The
results of the patient with vaginal cancer are not shown above due to the fact that
there was only one patient with this diagnosis. There was no statistically significant
difference in the number of circulating MPs between the different groups, p value
ranging from 0.217 to 0.986, Kruskal Wallis test.
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There was a weak to moderate correlation amongst the different subtypes of
circulating MPs. Patients with increased levels of PMPs also had increased levels of
EMPs and LMPs. This was true for both the malignant patients and the control
group. Table 4.6 is a summary of these correlations.
Spearman's Correlation
MP subtypes p value Correlation coefficient r
PMPs & activated PMPs <0.001 0.96
PMPs & EMPs <0.001 0.404
activated PMPs & EMPs <0.001 0.398
PMPs & LMPs <0.001 0.342
activated PMPs & LMPs <0.001 0.339
EMPs & LMPs <0.001 0.478




4.4.3 Relative proportions of MP cell-specific subtypes
PMPs (anti-CD41) and LMPs (anti-CD45) together made up the majority of
measured MPs, with EMPs (anti-CD144) making up a smaller percentage - please









Table 4.7: The relative proportions of circulating microparticles (MPs) in the two
patient groups. The above results refer to the median percentage the different MP
subtypes make up when compared to the total number of cell specific MPs measured.
For example, PMPs are expressed as a percentage of PMPs+EMPs+LMPs. Platelet-




As mentioned in chapter III I measured the total number of AV+ve MPs, but was
unable to identify their cell of origin. The total number of AV+ve MPs was in the
majority of patients significantly less than the total number of MPs detected by the
cell-specific antigens (i.e. PMPs+EMPs+LMPs) in that patient. This means that a
significant number of the MPs measured were AV-ve (Figure 4.6). In a small
number of patients the total number of circulating AV+ve MPs was more than the
total number of PMPs, EMPs and LMPs measured together. In the latter patients
some of the AV+ve MPs must have been released by other cell types such as red











Control group Malignant group
Figure 4.6: Bar chart showing the total number of'AV+ve MPs in relation to the total
number of cell specific MPs identified i.e. PMPs+EMPs+LMPs. AV+ve MPs make
up a minority of all microparticles detected. Annexin V (AV), platelet-derived MPs
(PMPs), endothelial-cell derived MPs (EMPs), leucocyte-derived MPs (LMPs).
96
4.4.5 Correlation of MPs and age
Using Spearman's rank testing, there was no correlation between the number of
circulating MPs and the patients' age for both patient groups - Figure 4.7, page 98.
4.4.6 Correlation of MPs with haematological and renal parameters
There was a weak correlation (p=0.005, r=0.269) between the patients' peripheral
blood platelet count and the number of circulating PMPs. However there was no
correlation between the level of haemoglobin, white cell count or EGFR and the
number of circulating MPs (Figure 4.8, page 99-100).
97









o °D □ D6
o°B ^
o ° ° 0 □ Dp








age (years) age (years)








Correlation of TF+ve MPs with age
°o° 8n
- :ys:*° o8>°o ° of Rflfi Bo
age (years)
Correlation of AV+ve MPs with age
/•f $ 0P°°8> o°
CD° JO D ° n




Figure 4.7: Scatterplots of the
relationship between patient age and
the number of circulating PMPs,
EMPs, LMPs, TF+ve MPs and AV+ve
MPs. There is no correlation between
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Figure 4.8a: Scatterplots of haematological and renal parameters and the number of
circulating microparticles (MPs) (Spearman's correlation coefficient). There was a
weak correlation between the peripheral blood platelet count and the number of
circulating platelet-derived MPs (PMPs).
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Correlation of PMPs and EGFR Correlation of EMPs and EGFR




Figure 4.8b: Scatterplots of haematological and renal parameters and the number of
circulating microparticles (MPs) (Spearman's correlation coefficient). There was a
weak correlation between the peripheral blood platelet count and the number of
circulating platelet-derived MPs (PMPs).
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4.4.7 Residual platelet count in PFP
There was no correlation between the patients' peripheral blood platelet count and
the residual platelet count in the PFP (p=0.55), and no significant difference in the
residual platelet count in the PFP between the two patient groups (p=0.707). There
was however a statistically significant strong correlation between the residual platelet
count in the PFP and the number of PMPs detected by flow cytometry. This suggests
that the residual contaminating platelets (although at a low level in all samples) were
interfering with the PMP detection probably due to the presence of small platelets
being detected in the 1 pm gate - Figure 4.9.
Correlation of PFP residual platelet count and PMPs detected
Residual platelet count in PFP
Figure 4.9: Scatterplot showing the statistically significant strong correlation
between the residual platelet count (xl09/L) in the platelet free plasma (PFP) and the
number of platelet-derived microparticles (PMPs) measured (Spearman's correlation
coefficient).
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4.4.8 MPs and thrombosis
Five women from the malignant group and none from the control group were
diagnosed with a VTE during the follow up period (median follow up of 11 months,
range 5-17 months) - Table 4.4, page 89. There was no statistically significant
difference in the number of MPs between patients with a VTE and patients with no
VTE; however the numbers are too small to draw any final conclusion. The results
























506 364-3361 354 109-1060 0.265
EMPs
(anti-CD 144)
746 325-2193 546 354-967 0.505
LMPs
(anti-CD45)
1517 853-4784 1436 893-2402 0.602
TF+ve MPs
(anti-CD 142)
417 172-2450 850 456-1332 0.633
AV+ve MPs 615 492-3665 1357 649-2104 0.572
Table 4.8: Comparison of the number of microparticles (MPs) in patients with
venous thromboembolism (VTE) and patients with no VTE. There was no
statistically significant difference, p value for 2-tailed significance testing was
calculated using the Mann Whitney U test for 2 independent samples. Interquartile
Range (IQR), platelet-derived MPs (PMPs), endothelial-cell derived MPs (EMPs),
leucocyte-derived MPs (LMPs), tissue factor (TF), annexin V (AV).
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4.4.9 MPs and mortality
Four of the women in the malignant group and none of the patients in the control
group died during the observation period (median follow up of 11 months, range 5-
17 months). There was no statistically significant difference in the number of
circulating MPs in the patients who died (p value ranging from 0.204 to 0.895 for the
different MP subtypes, Mann Whitney U test), although the numbers are too small to
draw any firm conclusions.
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4.4.10 Effect of chemo/radiotherapy on MP levels
Seven of the women with gynaecological malignancy provided a second blood
sample on their last day of chemotherapy and/or radiotherapy treatment. The
demographics of these 7 patients are summarised in Table 4.9.
There was no statistically significant difference between the number of MPs
measured prior to starting treatment and the number of MPs at the end of treatment
(p value ranging from 0.091 to 1.0 for the different MP subtypes, Wilcoxon Signed
Ranks test). However there was an overall tendency for the number of circulating
PMPs, EMPs and LMPs detected at the end of treatment to be present in smaller
numbers than prior to starting treatment. At the same time these patients had a lower
number of platelets and white cells in their peripheral blood at the end of treatment
compared to their peripheral blood results at the time their first sample for MP
analysis was taken pre-treatment. This suggests that the trend in the number of
circulating MPs, particularly the PMPs and LMPs, may partly reflect the number of
circulating platelets and white cells in their peripheral blood respectively. The
results for TF+ve MPs and AV+ve MPs are more variable - Figure 4.10, page 105.
Patient Diagnosis Treatment given
1 Cervical ca Cisplatin and radiotherapy
2 Endometrial ca Radiotherapy
3 Endometrial ca Radiotherapy
4 Cervical ca Cisplatin and radiotherapy
5 Ovarian ca Carboplatin and Paclitaxel
6 Cervical ca Cisplatin and radiotherapy
7 Cervical ca Cisplatin and radiotherapy
Table 4.9: Demographics of patients with paired blood samples, one sample taken
prior to starting treatment and another sample taken at the end of treatment. Cancer
(ca)
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■ PMPs prior to
treatment





Case Number Case Number
•activated PMPs
prior to treatment






Case Number Case Number
aEMPs prior to
treatment







Figure 4.10: Bar charts of the number of microparticles (MPs) detected at the start of
cancer treatment and at the end of treatment. There was no statistically significant
difference between the number of MPs measured prior to starting treatment and the
number of MPs at the end of treatment (p=0.091-1.0, Wilcoxon Signed Ranks test).
There was however a trend for the number of circulating MPs detected at the end of
treatment to be fewer than prior to starting treatment.
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4.4.11 Postoperative levels ofMPs
In a number of patients with gynaecological malignancy, treatment included surgery.
Seven of these patients provided a second blood sample for MP analysis 24 hours
postoperatively, to assess the effect of surgery on the number of MPs. I also
obtained a second blood sample 24 hours postoperatively from 18 of the women in
the control group.
The number of MPs detected postoperatively compared to the number of MPs
preoperatively was very variable with no definite trend - in some patients the number
of MPs postoperatively was significantly higher than that preoperatively and vice
versa. Overall there was no statistically significant difference between the number of
circulating MPs preoperatively and postoperatively (p value ranging from 0.176 to
0.612 for the different MP subtypes, Wilcoxon Signed Ranks test) - please refer to
Figure 4.11, page 108 and 109.
4.4.12 Decision to stop study recruitment
As per statistical advice from Dr. Gillian Norrie, BSc(Hons) Statistics, the original
plan was to recruit 140 patients each in the malignant group and the control group in
order to have a 90% probability of detecting a difference in MP numbers between
patients with a VTE event and patients with no VTE (see page 76).
Interim statistical analysis was carried out after 12 months of recruiting patients
(n=67 patients with gynaecological malignancy; n=42 controls). There was no
statistically significant difference in the number of MPs measured between the
malignant group and control group for all subtypes of MPs. The number of patients
diagnosed with a VTE was too small to assess the relationship between VTEs and
MPs in any formal statistical analysis. As the assumptions made for the power
calculations were shown to be incorrect for this study population, it was unlikely that
we would be able to identify a difference in MP numbers between patients with a
VTE and patients with no VTE. It was also unlikely that a statistically significant
difference in MP numbers between cancer patients and controls would be
demonstrable. In view of this a decision was made to stop recruiting patients. It was
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decided to collect data on the incidence ofVTEs in the overall population of patients
diagnosed with gynaecological cancer in SCAN (the geographical area from where
the study patients were recruited) to establish whether the patients recruited to this
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Control group
Figure 4.11a: Comparison of the numbers of circulating micropanicies (MPs)
preoperatively and postoperatively in both patient groups. The number of MPs
detected postoperatively compared to the number of MPs preoperatively was very
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Control group
Figure 4.11b: Comparison of the numbers of circulating microparticies (MPs)
preoperatively and postoperatively in both patient groups. The number of MPs
detected postoperatively compared to the number of MPs preoperatively was very
variable with no definite trend.
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4.4.13 D-dimers, TAT and PF1&2 Results
The results for the markers of haemostatic activation are summarised in Table 4.10.
There was a statistically significant increased level of D-dimers (p<0.001) and
PF1&2 (p=0.009) in patients with gynaecological malignancy, evidence of































Table 4.10: Summary of the D-dimer, TAT and PF1&2 results for the two patient
groups. The D-dimer and PF1&2 results were increased in the malignant group,
reaching statistical significance. Interquartile range (IQR)
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Figure 4.12: D-dimer, TAT and PF1&2 levels in patients with gynaecological
malignancy compared to the control group. There was a statistically significant
increased level of D-dimers and PF1&2 in the patients with malignancy.
Ill
4.4.14 Correlation of markers of haemostatic activation and age
There was a moderate, statistically significant correlation between D-dimer levels
and age and between PF1&2 levels and age. There was no correlation between the
level ofTAT and age - Figure 4.13, page 113.
In view of the correlation between D-dimer and PF1&2 levels and age, multivariant
analysis was carried out to establish whether there was a statistically significant
difference in the level of these markers of haemostatic activation between patients
with gynaecological malignancy and the control group once the results were adjusted
for age. The results are presented in Figure 4.14, page 114. D-dimer levels
(p=0.004) and PF1&2 levels (p<0.001) were still statistically significantly increased
in the group of patients with malignancy when the results were age adjusted.
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Correlation between D-dimers and age
age in years





Correlation between PF1&2 and age
age in years
Figure 4.13: Scatterplots showing the relation between the markers of haemostatic










Figure 4.14: Scatterplots showing the age adjusted correlation between the markers
of haemostatic activation and malignancy.
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Correlation of D-dimer and TAT levels
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Figure 4.15: Correlation of the levels of D-dimers, PF1&2, TAT and the number of
circulating microparticles (MPs) (Spearman's correlation coefficient). There was a
weak correlation amongst the level of D-dimers, TAT and PF1&2, but no correlation
between the levels of the markers of haemostatic activation and the number of
circulating microparticles.
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4.4.15 Correlation of markers of haemostatic activation and MPs
There was a weak correlation amongst the levels of D-dimers, TAT and PF1&2.
However there was no correlation between the level of D-dimers, TAT and PF1&2
and the number of circulating MPs in individual patients - Figure 4.15, page 115.
4.4.16 Markers of haemostatic activation by diagnosis
There was no statistically significant difference in the measured levels of D-dimers,
TAT and PF1&2 between patients with different types of gynaecological malignancy
(i.e. cervical, endometrial, ovarian, vulval and vaginal cancer) and between control
patients with different reasons for requiring benign gynaecological surgery (i.e.
pelvic floor prolapse, benign ovarian cysts, benign fibroids), p value ranging from
0.089 to 0.764, Kruskall Wallis test - please refer to Figure 4.16.
■D-dimers ng/ml
IPF1&2 pmoM
benign fibroids pelvic floor prolapse benign ovarian cysts
I D-dimers ng/ml
SPF1&2 pmoll
cervix ca endometrial cal ca vulval ca
Figure 4.16: Box plots of the level of D-dimers and PF1&2 by specific diagnosis.
The results of the single patient with vaginal cancer have not been included. TAT
results are also not shown due to the requirement of a very different scale to show
these results. There was no significant difference between the patient subgroups
(p=0.089-0.764).
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4.4.17 Markers of haemostatic activation and thrombosis
Five women from the malignant group and none from the control group were
diagnosed with a VTE event during the follow up period (median follow up of 11
months, range of 5-17 months) - Table 4.4, page 89. There was a statistically
significant increase in the D-dimer levels in the patients with a VTE (p=0.007, Mann
Whitney U test), but no statistically significant difference in the level of TAT and
PF1&2 between patients with/without a VTE (p=0.183, p=0.078 respectively, Mann
Whitney U test).
4.4.18 Markers of haemostatic activation and mortality
The level of D-dimers was statistically significantly increased in the 4 patients with
gynaecological malignancy that died during the study follow up period (p value
0.003, Mann Whitney U test). There was no significant difference in the level of
TAT and PF1&2 between patients who died and patients who were alive at the end
of the follow up period (p value 0.25 and 0.322 respectively, Mann Whitney U test).
4.4.19 Effect of treatment on markers of haemostatic activation
Seven of the women with gynaecological malignancy provided a second set of blood
samples on their last day of chemotherapy and/or radiotherapy treatment. The
demographics of these 7 patients are summarised in Table 4.9, page 104. There was
no statistically significant difference between the level of D-dimers, TAT and PF1&2
measured prior to starting treatment and at the end of treatment (p value ranging











Figure 4.17: Bar charts comparing the level of D-dimers, TAT and PF1&2 prior to
starting treatment and at the end of treatment in patients with gynaecological
malignancy. There was no significant difference in the paired results of individual
patients (p=0.176-0.735)
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4.4.20 Markers of haemostatic activation pre- and post-operatively
Seven patients with gynaecological malignancy and 18 women from the control
group provided a second blood sample 24 hours after surgery. The level of D-dimers
was statistically significantly increased postoperatively compared to the preoperative
results (p<0.001, Wilcoxon Signed Ranks test). There was no significant difference
in the level of TAT and PF1&2 between pre- and post-operative samples (p value
0.277 and 0.94 respectively, Wilcoxon Signed Ranks test) - please refer to Figure
4.18, page 120.
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Figure 4.18: Comparison of the level of the markers of haemostatic activation preoperatively
and postoperatively. The level of D-dimers was statistically significantly increased
postoperatively (p<0.001). There was no significant difference in the level of TAT and
PFI&2 between the pre- and post-operative results (p=0.277 and 0.94).
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4.5 DISCUSSION
I recruited a total of 67 women with gynaecological malignancy and a control group
of 42 women with no underlying malignancy over a 12 month period (2009), and
measured the number of circulating MPs in the two groups of women using light-
scattering flow cytometry.
4.5.1 Demographics
The women in the control group tended to be younger than the women in the
malignant group, however with a similar age distribution. This difference in median
age is likely to reflect the fact that gynaecological malignancy is commoner in older
women. On the other hand symptomatic benign gynaecological conditions such as
pelvic floor prolapse are more likely to be managed surgically in younger patients,
and conservatively in older women who are more likely to have co-morbidities. This
age difference is however unlikely to have made a difference to the MP results, there
being no correlation between the patients' age and MP numbers measured.
The women in the malignant group tended to have a slightly lower haemoglobin and
higher white cell count than the women in the control group, while there was no
significant difference in the peripheral blood platelet count between the two groups.
Some of the women in the malignant group also had slightly impaired renal function
with a reduced EGFR, although in the majority of patients the renal function was
normal. These differences in the full blood count and renal function between the two
groups are an expected finding in patients with underlying malignancy and may be
due to a variety of reasons such as bleeding, the effect of chemo/radiotherapy and
renal obstruction by the tumour. I found no correlation between the level of
haemoglobin, white cell count and EGFR results and the number of circulating MPs
so that these differences between the two groups are unlikely to have influenced the
MP results. There was a weak correlation between the patients' peripheral blood
platelet count and the number of PMPs measured. However as there was no overall
difference in the number of platelets in the peripheral blood between the two patient
groups this has not influenced the MP results.
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^ 4.5.2 MP results
The number of circulating MPs (all subtypes) in the patients with gynaecological
malignancy was very similar to the number ofMPs in the control group who had no
malignancy. The total number of TF+ve MPs was also very similar between the two
patient groups. As far as I can establish this is the first study looking specifically at
patients with gynaecological malignancy. My results are different to a number of
studies[164, 165] published earlier where investigators have reported increased
numbers of circulating MPs in patients with various prothrombotic conditions
including malignancy. However more recent studies[23, 81, 159] have, like me,
found very similar numbers of circulating MPs in patients with malignancy
compared to healthy individuals.
^ Some investigators[18, 81, 165] have reported increased levels of TF+ve MPs in
patients with malignancy, while others found similar numbers of circulating TF+ve
MPs but increased TF+ve MP-dependent function[l 16, 159]. There are now a
number of published studies where the results of MP assays using different
techniques (i.e. flow cytometry, ELISA and functional assays) do not correlate,
underlying the fact that these assays are not interchangeable. For example Tesselaar
^
et al[l 16] reported similar levels of TF+ve MPs in healthy controls and patients with
metastatic cancer, but increased MP dependent TF activity. Similarly Haubold et
al[ 159] found significantly increased TF activity in the cancer patient group, but the
TF antigen levels and TF+ve MP levels did not correlate with TF activity. It is
possible that I did not find a difference in the number of circulating TF+ve MPs
I between patients with malignancy and the control group because I measured the
TF+ve MPs by flow cytometry. The latter measures the number of events but does
not give any information as to the concentration of TF on the individual MPs or
whether the TF being detected is active or not. It is hypothesised that functional
assays of MPs may better reflect their patho-physiological effect. In the future
performing parallel assays looking at both the number of MPs present and the MP-
I
dependent activity may be more informative.
There is a correlation between the number of circulating MP subtypes in individual
patients. Patients with increased numbers of PMPs also tended to have increased
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levels of EMPs and LMPs, and vice versa. This was true for both the patients with
gynaecological malignancy and the control group of women. This may reflect a
generalised stimulus leading to MP release from various different types of cells, or
may reflect a reduced rate of excretion ofMPs in an individual.
PMPs and LMPs together made up the majority of circulating MPs, with EMPs
making up a smaller percentage (see Table 4.5, page 91). This is different from the
relative proportions of MP subtypes detected by other investigators. There are a
number of publications[71, 76, 77, 79, 204] where PMPs make up the majority of
circulating MPs. On the other hand Shah[78] found EMPs to be the predominant
subtype of circulating MPs. These differences may partly reflect the underlying
medical condition in the various patient groups. However since both the malignant
group and the control group in this study had very similar proportions of MP
subtypes, these differences in the published literature and in my study could also be
the result of different handling and processing of samples for MP analysis.
I measured the total number of circulating AV+ve MPs, but was unable to establish
their cell of origin, mainly due to the binding buffer needed for AV binding
interfering with the monoclonal antibodies binding to MPs. When I compared the
total number of AV+ve MPs, with the total number of cell specific MPs i.e.
PMPs+EMPs+LMPs, in the vast majority of patients AV+ve MPs made up a much
smaller number than the total number of cell-specific MPs (PMPs+EMPs+LMPs). In
the majority of patients in this study most of the MPs being measured were AV
negative. A number of investigators still use AV positivity as one of the defining
criteria when identifying MPs. However this would have resulted in the majority of
MPs being missed in this study. There are now a number of published reports[87,
98] indicating that AV negative MPs make up a significant proportion of all
circulating MPs. Care must therefore be taken when comparing the results from
different investigators to establish the exact criteria used to identify MPs. On the
other hand in a small number of the study patients the number of AV+ve MPs was
greater than the total number of cell-specific MPs measured (PMPs+EMPs+LMPs)
in the individual. Such patients must have a significant number of MPs being
released by other cell types such as red cells or tumour cells.
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4.5.3 MPs and thrombosis
Out of the 67 women with gynaecological malignancy, 5 (7.5%) were diagnosed
with a VTE event within the follow up period (median follow up of 11 months, range
5-17 months). An incidence of 7.5% of VTE is not dissimilar to the quoted
incidence rates in the literature of VTE in patients with gynaecological
malignancy[8, 9, 23, 25, 44], Three out of the 5 episodes of VTE occurred in
patients with ovarian cancer (12.5% of the patients with ovarian cancer), the latter
group of patients often being considered to have the highest risk of thrombotic events
in patients with gynaecological malignancy[20], The other 2 VTE events occurred in
patients with vulval cancer (40% of the patients with vulval cancer). None of the
patients with cervical cancer, endometrial cancer or vaginal cancer was diagnosed
with a thrombotic event.
Four of the VTE events occurred on diagnosis of the underlying malignancy
suggesting that the prothrombotic state was a manifestation of the malignancy itself
secondary to a physical and/or systemic effect of the tumour. All four patients who
presented with a VTE at the same time as their malignancy was diagnosed were only
eligible for palliative treatment, either due to generalised frailty of the patient or
because of tumour extent. The fifth VTE event occurred on treatment with
Carboplatin and Paclitaxel. Treatment with platinums is a well known risk factor for
thrombosis[223-225], and Paclitaxel has also been linked with an increased incidence
of thrombosis[226, 227].
The absolute number of patients diagnosed with a VTE event was too small to look
at VTEs in any formal statistical analysis; however there was no apparent trend
between the occurrence of thrombosis and the number of circulating MPs. The
power calculations done prior to study recruitment had been based on approximately
25% of women being diagnosed with a VTE at some point during their investigation
and treatment for cancer, as per previous publications[7-9] of VTE incidence in
patients with gynaecological malignancy. At the interim statistical analysis carried
out after 12 months of recruiting patients it was clear that the incidence of VTE
events in the study patients was significantly lower at 7.5% (this was later confirmed
to be representative of the overall population of patients diagnosed with
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gynaecological malignancy in SCAN; see Chapter V). This meant that it would have
necessitated a much larger study group than originally planned in order to identify
any difference between patients with a VTE and patients with no VTE. It was
therefore decided to stop recruiting patients at that point, particularly as there was
also no difference in MP numbers between patients with cancer and patients without
cancer. It may be that had I continued to recruit patients and/or followed them up for
longer (so that potentially more would have been diagnosed with a VTE event) 1 may
have identified a difference in the number of MPs between patients with/out a VTE
event.
None of the women in the control group were diagnosed with a thrombotic event
within 3 months of surgery. This is likely to reflect the routine use ofTED stockings
and thromboprophylaxis with low molecular weight heparin perioperatively in all
patients undergoing major gynaecological surgery. A number of studies have been
published confirming that such thromboprophylaxis is protective against
perioperative VTE events[228].
4.5.4 MPs and prognosis
Of all the patients in this study 4 of the women with gynaecological malignancy
(6%) and none of the women in the control group died during the follow up period
(median 11 months, range 5-17 months). The numbers are too small for formal
statistical analysis, however there was no difference in MP numbers in the patients
that died. Of the 4 patients who died, two had also been diagnosed with a VTE
event, so that 40% of patients with both gynaecological malignancy and a VTE event
died during the study period, compared to 3.2% of women with gynaecological
malignancy but no thrombosis. The number of patients is too small to draw firm
conclusions; however it is suggestive that patients with malignancy who also have a
venous thrombotic event have a worse outcome compared to patients with a similar
malignancy but no associated thrombosis. Similar findings have been reported by
other investigators[6, 12, 19, 20]. It is currently unclear whether the worse prognosis
is simply a result of the presence of a VTE (unlikely since the majority of VTE
events are not fatal), or whether the occurrence of a VTE in a patient with
malignancy is a manifestation of a more aggressive tumour.
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4.5.5 MPs and treatment
The treatment in different patients varied according to the specific type of
gynaecological malignancy, disease stage and grade and any co-morbidities present.
Seven of the patients with gynaecological malignancy provided a second blood
sample on their last day of treatment with chemotherapy and/or radiotherapy (week 5
or 6 of treatment, please refer to Pg 78). There was no significant difference in the
numbers of circulating MPs in individual patients between blood samples taken prior
to starting treatment and blood samples taken at the end of treatment. There was
however a trend for the level of PMPs, EMPs and LMPs to be lower at the end of
treatment (the results of TF+ve MPs and AV+ve MPs were very variable with no
overall trend). At the same time these patients had lower circulating platelet and
white cell counts in their peripheral blood at the end of treatment compared to the
number of peripheral blood platelets and white cells prior to starting treatment. It
may be that the trend for the PMPs, LMPs and EMPs to be lower at the end of
treatment may partly reflect the lower number of peripheral blood platelet and white
cells, or may be due to the effect that chemo- and/or radio-therapy may have on the
rate of MP release. One could also hypothesise that the lower number of MPs
detected may be partly due to MPs being recruited to sites of inflammation secondary
to the effects of chemoradiotherapy, leaving fewer MPs in the circulation. The
numbers are however too small to draw firm conclusions. There was also no
significant difference in the level of the markers of haemostatic activation between
the blood samples taken prior to treatment and the blood samples at the end of
treatment.
4.5.6 Markers of haemostatic activation
I measured the level of D-dimers, TAT and PF1&2 as indirect markers of
haemostatic activation. Their levels have been reported to be increased in patients
with malignancy and other prothrombotic conditions[20, 170]. In my group of
patients there was a statistically significant increase in the level of D-dimers and
PF1&2 in patients with gynaecological malignancy even after adjusting for age, and
a statistically significant weak correlation between the level of D-dimers, TAT and
PF1&2. However there was no correlation between the level of the markers of
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haemostatic activation and the number of circulating MPs. This is in keeping with
the fact that I found no difference in the number of circulating MPs between the two
patient groups.
The results in the literature are variable. Hron et al[81] found a correlation between
the number of circulating TF+ve PMPs and the level of D-dimers. However several
other investigators have failed to show a correlation between the number of
circulating MPs and the level of markers of haemostatic activation[79, 140]. This
variability in results may be due to the use of different methods to analyse the
number of circulating MPs by different investigators. Given the role MPs are
thought to play in coagulation activation and propagation it would be reasonable to
expect that the number of circulating MPs and the level of the markers of
haemostatic activation would be correlated. The current variability in results with
most investigators failing to show a correlation is likely to partly reflect the lack of
standardisation of MP assays. It may also be that measuring MP-dependent activity
rather than MP numbers would better reflect the role of MPs in coagulation
activation. The relationship between the level of circulating MPs (and/or their
function) and the markers of haemostatic activation needs to be re-assessed once the
assays for MP analysis are standardised.
There was a statistically significant increase in the level of D-dimers in the patients
who had had a thrombotic event, reflecting haemostatic activation with fibrin
generation in these patients. There was also a statistically significant increase in the
level of D-dimers in the 4 patients that died during the follow up period. Two of
these 4 patients had also been diagnosed with a thrombotic event. Increased levels of
haemostatic activation secondary to the presence of advanced malignancy is likely to
have contributed to the increased levels of D-dimers in these 4 patients.
In a number of patients I measured the number of MPs and the markers of
haemostatic activation both pre- and post-operatively. The number of circulating
MPs postoperatively was very variable and difficult to interpret with no particular
trend. On the other hand there was a statistically significant increase in the level of
D-dimers in the postoperative samples. The latter can be explained due to the trauma
of surgery and the necessary haemostatic activation to control bleeding
postoperatively.
4.5.7 Limitations of the study
This is a single centre relatively small study including patients with all types of
gynaecological malignancy. This has lead to a heterogeneous population of cancer
patients, different subtypes of gynaecological malignancy having different prognoses
and being associated with different degrees of thrombotic risk. The absolute number
of study patients diagnosed with a thrombotic event is too small to allow generalised
conclusions regarding the prothrombotic nature or otherwise ofmeasured MPs.
I have analysed MPs using light-scattering flow cytometry. This is currently the
commonest technique to characterise MPs. However it has a number of limitations,
mainly due to the small size of MPs so that the MPs appear close to the electronic
noise of current flow cytometers. This makes their accurate identification difficult.
Further, flow cytometry does not given any information as to the functional activity
of the measured MPs. There is considerable research currently taking place with the
aim ofmaking the identification ofMPs more specific and accurate.
The variability in the results from different investigators is likely to be partly due to
the lack of a standardised method by which to identify and measure MPs. There are
still many variables and problems, not least the small size of MPs which challenges
the currently available technology, and the lack of a universal definition of what
constitutes a MP. Comparing results between different investigators is therefore
difficult. The different protocols used by different laboratories to analyse MPs are
likely to significantly affect the absolute number of MPs measured. In this study all
the patient samples were analysed by a single operator, using a tightly controlled
protocol, so that although the results from this study may not be comparable with the
results from other laboratories using a different technique, they are comparable for
this cohort of patients.
One of the main reasons for result variability between different laboratories is the use
of different centrifugation techniques with the risk of either removing MPs or
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"generating" MPs by fragmentation during sample processing. In view of the real
concern of "generating" MPs during ultra-centrifugation I decided to instead use
serial centrifugation to prepare PFP. The centrifugation protocol I used in my study
produced PFP with a residual platelet count of 5xl09/L or less in the majority of
samples. I still however had a few patient samples with detectable residual platelets
in the PFP, albeit at low numbers. There was a statistically significant strong
correlation between the residual platelet count in the PFP and the number of PMPs
measured by the flow cytometer. This is likely to be due to the residual platelets
interfering with PMP identification such that small platelets (<1 pm) were being
measured in the MP gate by the flow cytometer, underlying the current problems
with the available technology. The cut-off of 1 pm for the upper size limit ofMPs is
arbitrary so that some MPs will be larger than 1 pm and by using my method of
gating on size some of the larger MPs will be missed. However it is difficult to
resolve this issue at present since both platelets and MPs are on a continuum of size
and some platelets will be <1 pm and some MPs will be larger than 1 pm, making
the accurate and specific measurement ofMP numbers difficult.
4.6 CONCLUSION
I found no difference in the number of circulating PMPs, EMPs and LMPs between
the group of patients with gynaecological malignancy and the control group. There
was also no difference in the number of circulating TF+ve MPs. The incidence of
VTE events in the study cohort was 7.5%, similar to the overall incidence of VTEs in
patients with gynaecological malignancy in SCAN (please refer to Chapter V). The
absolute number of patients with thrombosis was too small to be able to make
generalised conclusions, however there was no statistically significant difference in
the number of MPs in the patients with gynaecological malignancy who also had a
VTE. This means that MP numbers cannot at present be used to help identify
patients with malignancy at a higher risk of venous thrombotic events.
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CHAPTER V
COHORT OF PATIENTS DIAGNOSED WITH
GYNAECOLOGICAL MALIGNANCY




I wanted to establish whether the cohort of patients recruited to the study on MPs
was representative of the overall population of patients being diagnosed with
gynaecological malignancies in the South East of Scotland Cancer Network (SCAN),
in order to determine whether the results of the MP study could be extrapolated to the
rest of the patients with gynaecological malignancy in SCAN.
I have therefore carried out an audit of all the patients presenting to SCAN with a
confirmed gynaecological malignancy over one calendar year (2009 - the same time
period during which 1 recruited patients to the MP study) in order to establish the
overall incidence of the different gynaecological malignancies and the incidence of
thromboses in this patient group. Here 1 describe the demographics and clinical
characteristics of these patients, and correlate my audit findings with the




All patients who are likely to have a diagnosis of gynaecological malignancy are
discussed in a weekly gynae-oncology multidisciplinary meeting (MDM) in SCAN.
I was therefore able to identify all patients with a confirmed diagnosis of
gynaecological malignancy from the weekly MDM discussion lists for the relevant
period of time. The audit was registered with the Clinical Governance Support
Team. Prior to commencing data collection, permission was sought and obtained
from the chairperson of the SCAN gynae-oncology multidisciplinary team and all the
gynaecology and oncology consultants who treat patients with gynaecological
malignancy.
5.2.2 Data collection
The list of patients discussed in the weekly gynae-oncology MDM meetings during
2009 was obtained from the MDM co-ordinator. Patient details, including tumour
site, histological diagnosis, disease stage, treatment, past medical history, evidence of
VTE (DVT and/or pulmonary embolism) or arterial events, smoking history and
overall outcome were collected by going through the patients' medical records on the
Lothian NHS IT system.
5.2.3 Statistics
The audit data was analysed and the descriptive statistics are reported in this chapter.
The findings have been compared between patient subgroups using the Mann
Whitney U test, with two-tailed significance testing. Statistical significance was
defined as a p value of < 0.05. Analyses were performed with the statistical package




During 2009 a total of six hundred and eighty one (681) patients were discussed at
the gynae-oncology MDM meetings. Of these patients five hundred and eighty four
(584) were confirmed to have a current diagnosis of gynaecological malignancy or
gynaecological pre-malignant condition (CIN, VIN, VAIN or borderline ovarian
tumours). Another 17 patients had a previous history of gynaecological malignancy
but no recurrence was confirmed during 2009. A further 80 patients did not have a
diagnosis of gynaecological malignancy confirmed, often having instead a benign
gynaecological condition or a malignancy arising elsewhere.
The population living in SCAN is made up of approximately 1.45 million people, 0.7
million of whom are women (General Register Office for Scotland mid-2009
population estimate)[3]. The patients treated by the SCAN team are referred from a
large geographical area which includes the Lothian area, as well as Dumfries &
Galloway, The Borders and Fife. All these patients are discussed in the weekly
gynae-oncology SCAN MDM so that treatment is uniform across the whole region.
The details of all patients managed by the SCAN team are recorded electronically on
the Lothian NHS IT system. The data for the audit (including diagnosis, treatment
planned and complications) was gathered by going through the individual patients'
medical records on this computer system. This computer system is however not
linked up to hospitals outside Lothian i.e. Dumfries & Galloways, The Borders and
Fife. Patients with gynaecological malignancy living in the latter geographical areas
of SCAN are still managed by the same multidisciplinary team for their malignancy,
however in the case of an acute emergency such as a DVT or pulmonary embolism,
they would normally present to their local hospital.
Of the 584 patients with a confirmed diagnosis of gynaecological malignancy
referred to SCAN, 375 were living in Lothian i.e. these patients would use one of the
hospitals within Lothian as their local hospital. For this group of patients (group A) I
had access to all their medical records i.e. detailing both the management of their
gynaecological malignancy and any other reason for attending hospital. The
remaining 209 patients lived outside Lothian (group B). For these patients I had
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access to their medical records detailing the management of their malignancy,
however I did not have access to their records detailing acute admissions to their
local hospitals for the management of complications such as DVT/pulmonary
embolism. In the majority of cases I was still able to ascertain the occurrence of such
events by reviewing all correspondence sent to the oncology team. However, there is
the possibility that some such events will have been missed purely because of a lack
of such correspondence, for example in patients who had already finished treatment
for their malignancy, or patients who were being palliated locally and no longer
requiring active treatment. In view of this I have analysed the data I gathered for the
whole patient group (n=584), and also analysed the two subgroups of patients
separately (patients living within Lothian (n=375 - group A) and patients living
outside Lothian (n=209 - group B)) to establish whether there were any significant
differences in the documented occurrence of complications (such as VTEs) between
the two groups of patients and thus determine how robust my data collection has
been.
5.3.2 Patient demographics
The patient demographics of the women diagnosed with gynaecological malignancy
or a gynaecological pre-malignant condition (CIN, VIN, VAIN, borderline ovarian
tumours) in SCAN in 2009 are detailed in Table 5.1, page 135. Of the 584 patients
diagnosed with gynaecological malignancy, 504 (86%) were new diagnoses, while
the remaining 80 (14%) had a history of gynaecological malignancy diagnosed in the
past and had re-presented again in 2009 with relapsed disease. The relative
proportions did not change when I considered only the 375 patients living within
Lothian (324 (86%) new diagnoses and 51 (14%) with a history of gynaecological
malignancy re-presenting in 2009), or the 209 patients living outside Lothian (180
(86%) new diagnoses and 29 (14%) with a history of gynaecological malignancy re¬
presenting in 2009). The pathological subtypes of the different gynaecological
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Unknown primary 3 (0.5%) 1 (0.26%) 2 (0.96%) n/s
Peritoneal
mesothelioma
1 (0.17%) 1 (0.26%) 0 n/s
Bartholin's gland 1 (0.17%) 1 (0.26%) 0 n/s
Table 5.1: Details of the number of patients diagnosed with the different subtypes of
gynaecological malignancy. Comparison is made between the whole patient group
diagnosed with gynaecological malignancy treated in SCAN, and the two patient
subgroups according to geographical areas i.e. patient group A, living within Lothian
and patient group B, living outside Lothian, but still in SCAN. The patient subgroups
have a very similar incidence of the different subtypes of gynaecological
malignancies so that the group living within Lothian is representative of the whole
patient cohort overall, p value for 2-tailed significance testing was calculated using
the Mann Whitney U test for 2 independent samples. Cervical intraepithelial
neoplasia (CIN), vulval intraepithelial neoplasia (VIN), vaginal intraepithelial
neoplasia (VAIN), number (no.), not statistically significant (n/s), patient (pt).
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Squamous carcinoma 66 (62.9%)
Adenocarcinoma 14(13.3%)
Neuroendocrine carcinoma 2 (1.9%)
Endometrioid carcinoma 2 (1.9%)
Adenosquamous carcinoma 1 (0.95%)
Clear cell carcinoma 1 (0.95%)
Serous carcinoma 1 (0.95%)
CIN 16(15.2%)
Information missing 2 (1.9%)
Table 5.2a: Cervical malignancy patients - histological subtypes. Cervical intra¬
epithelial neoplasia (CIN)




Endometrioid carcinoma 156 (72.6%)
Serous papillary carcinoma 26(12.1%)
Carcinosarcoma 10(4.7%)
Clear cell carcinoma 5 (2.3%)
Leiomyosarcoma 5 (2.3%)
Stromal sarcoma 3 (1.4%)
Squamous carcinoma 1 (0.5%)
Information missing 9 (4.2%)
Table 5.2b: Endometrial malignancy patients - histological subtypes.
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Serous carcinoma 83 (41.5%)
Mucinous carcinoma 22(11%)
Endometrioid carcinoma 19 (9.5%)
Primary peritoneal adenocarcinoma 17(8.5%)
Clear cell carcinoma 10(5%)
Granulosa cell carcinoma 7 (3.5%)
Fallopian tube serous papillary carcinoma 3 (1.5%)
Malignant teratoma 3 (1.5%)
Carcinosarcoma 2 (1%)
Cystadenocarcinoma 1 (0.5%)
Pseudomyxoma peritonei 1 (0.5%)
Borderline ovarian tumours 9 (4.5%)
Information missing 23 (11.5%)
Table 5.2c: Ovarian malignancy patients - histological subtypes.




Squamous carcinoma 43 (82.7%)
Melanoma 3 (5.8%)
Verrucous carcinoma 1 (1.9%)
Basal cell carcinoma 1 (1.9%)
VIN 4 (7.7%)
I












Bartholin's gland ca Adenoid cystic carcinoma (n=l)
Peritoneal mesothelioma Mesothelioma (n=l)
Table 5.2e: Miscellaneous gynaecological malignancies - histological subtypes.
Vaginal intra-epithelial neoplasia (VAIN), cancer (ca)
5.3.3 Management of gynaecological malignancies
The treatment offered to the different patients varied according to the specific
diagnosis and histological subtype, disease stage, any previous treatment and pre¬
existing patient co-morbidities. Many of the treatment modalities used in patients
with gynaecological malignancy contribute to a prothrombotic state e.g. surgery and
chemotherapy, especially Cisplatin[223-225], I have therefore summarised the
different treatment modalities used according to cancer type (see Table 5.3a-f, page
139-143) to assess whether there was a particular treatment associated with a
significantly increased incidence of venous or arterial events (see later).
Cervical malignancy n=105
Treatment Details of chemotherapy
Number of
patients
Cisplatin & Etoposide 1




Cisplatin & Topotecan 2
Surgery only n/a 26
Surgery & chemotherapy Cisplatin & Topotecan 1
Surgery, chemotherapy & Cisplatin 6
radiotherapy Carboplatin & Paclitaxel 1
Radiotherapy only n/a 12
LETZ n/a 18
Patient declined treatment n/a 3
Table 5.3a: Summary of the treatments used in patients with cervical malignancy.
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Endometrial malignancy n=215






Carboplatin & Paclitaxel 3
Chemotherapy & radiotherapy Carboplatin 1
Surgery only n/a 90
Surgery & chemotherapy








Carboplatin & Paclitaxel 17
Carboplatin 2
Surgery & radiotherapy n/a 58
Hormone treatment n/a 11
Radiotherapy only n/a 3
Patient declined treatment n/a 4
Unfit for treatment n/a 8




Treatment Details of chemotherapy
Number of
patients
Surgery only n/a 46
Surgery & chemotherapy
Carboplatin & Paclitaxel 48
Carboplatin 14
Cisplatin & Etoposide 2







Carboplatin & Paclitaxel 18
Cisplatin & Etoposide 1
Topotecan 1
Radiotherapy only n/a 2
Hormone treatment n/a 5
Watch & wait n/a 5
Patient declined treatment n/a 8
Unfit for treatment n/a 18
Information missing n/a 1
Table 5.3c: Summary of the treatments used in patients with ovarian malignancy.
141
Vulval malignancy n=52
Treatment Details of chemotherapy Number of patients
Chemotherapy & radiotherapy Cisplatin 2
Radiotherapy only n/a 8
Surgery only n/a 33
Surgery & radiotherapy n/a 4
Patient declined treatment n/a 1
Unfit for treatment n/a 4
Table 5.3d: Summary of the treatments used in patients with vulval malignancy.
Vaginal malignancy n=7
Treatment Details of chemotherapy Number of patients
Surgery only n/a 2
Chemotherapy only Cisplatin 1
Chemotherapy & radiotherapy Cisplatin 2
Radiotherapy only n/a 2
Table 5.3e: Summary of the treatments used in patients with vaginal malignancy.
Miscellaneous
Diagnosis Treatment Number of patients
Unknown primary
Surgery, Carboplatin & Paclitaxel 1
Surgery only 1
Radiotherapy only 1
Bartholin's gland tumour Surgery, Cisplatin & radiotherapy 1
Peritoneal mesothelioma Surgery only 1
Table 5.3f: Summary of the treatments used in patients with various gynaecological
malignancies.
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5.3.4 Incidence of thrombosis
I gathered information on the number of patients who were diagnosed with a
thrombotic event in the year prior to or concurrent with the diagnosis of malignancy,
and also subsequent to this, either while still on treatment or in the follow up period.
The data presented is correct as of June 2010 (median follow up of 11 months, range
5-17 months).
In view of the fact that patients living outside Lothian would not normally present to
one of the hospitals within Lothian for acute events (i.e. DVT, pulmonary embolism,
MI, CVA) I looked at the patient cohort as a whole and also at the two subsets of
patients according to geographical location i.e. patients living within Lothian (group
A) and patients living outside Lothian (group B), and compared my findings between
the two subgroups. In the case of patient group A, i.e. patients living within Lothian,
I had easy access to all their hospital records, and I was therefore confident that I had
a complete picture of any complications from the malignancy or its treatment. On
the other hand in the case of patient group B, i.e. patients living outside Lothian, but
still within SCAN, I did not have access to their local hospital medical records.
There is therefore the possibility that I may have missing data on the occurrence of
thrombotic events. By comparing the two subgroups of patients I was able to
establish how robust my data collection for the whole cohort of patients has been.
The data is summarised in Table 5.4, page 145-146.
When calculating the incidence of thrombotic events I did not include any patients
with a pre-malignant condition, i.e. CIN, VIN, VAIN and borderline ovarian
tumours, but focused instead on patients with invasive malignancies. Pre-malignant
conditions are normally completely removed surgically, and are not generally
considered to be associated with an increased risk of thrombosis. In fact in this
















































































































































































































































0 0 0 0 0 0 n/a
Mesothelioma
(n=l)
0 0 0 0 0 0 n/a
Unknown
primary (n=3)










































Table 5.4: Summary of the incidence of all thrombotic events, including both venous
thromboembolic (VTE) events (pulmonary embolism and deep vein thrombosis) and arterial
events (myocardial infarctions (MI) and cerebrovascular accidents (CVA)). Results are
presented for the whole patient cohort diagnosed with gynaecological malignancy in SCAN,
and also for the two patient subgroups according to geographical locations - group A:
patients living within Lothian and group B: patients living outside Lothian. There was no
statistically significant difference in the incidence of either venous or arterial events
between the two subgroups, implying that my data collection for the whole patient group
(which was made up of the two patient subgroups) was robust. The results for the whole
patient cohort are presented in bold, the results in normal font refer to the group of patients
living within Lothian (group A) and the results in italics refer to the group of patients living
outside Lothian (group B). Patients with a diagnosis of a pre-malignant condition (CIN,
VIN, VAIN and borderline ovarian tumours) have been excluded from this analysis. The
data is correct as of June 2010; median follow up of 11 months, range 5-17 months, p value
for 2-tailed significance testing was calculated using the Mann Whitney U test for 2
independent samples. Diagnosis (Dx), cancer (ca), not applicable (n/a), not statistically
significant (n/s)
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5.3.5 Correlation of thrombotic events with treatment
I have analysed the audit data to establish whether the incidence of thrombotic events
correlates with a specific treatment modality. The results are summarised in Table
5.5, page 148. The highest incidence of thrombotic events (DVT, pulmonary
embolism, CVA, MI) was in the group of patients with extensive metastatic disease
who were too unfit to be treated (30% (9 of 30) of this group of patients were
diagnosed with a thrombotic event). Patients on chemotherapy also had a significant
number of thrombotic events (6.5%, 15 of 230), with the highest incidence seen in
patients treated with Carboplatin and Paclitaxel in combination (9.8%, 10 of 102) or
Carboplatin alone (10%, 5 of 50). Of all the patients undergoing surgery, only 1.1%
(4 of 372) were diagnosed with a thrombotic event in the perioperative period (up to
3 months postoperatively), and only one (0.6% (1 of 158)) of all patients being




















None - extensive disease,
pt unfit for treatment
(n=30)
Cervical Ml 1
All events: 9 (30%)
VTE: 5 (16.7%)





Postoperatively Endometrial VTE 1 All events: 4 (1.1%)
(up to 3 months) Ovarian MI 2 VTE: 1 (0.3%)
(n=372) Vulval CVA 1 Arterial events: 3 (0.8%)
Carboplatin
&











Ovarian CVA 4 (6.5%)










Vulval VTE 1 1 (0.6%)
Table 5.5: Summary of thrombotic events according to treatment given. This table does
not include the thrombotic events occurring prior to, or concurrent with, the diagnosis of
malignancy. The patient who was diagnosed with a venous thromboembolic (VTE) event
while being treated with radiotherapy had very extensive disease and was being treated
with palliative radiotherapy to control her symptoms. Her extensive disease is therefore a
more likely risk factor for her thrombotic event. Patient (pt), number (no.), treatment (Rx),
myocardial infarction (MI), cerebrovascular accident (CVA)
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5.3.6 Prognosis in patients with thrombotic events
I analysed the number of patients who died between their initial presentation in 2009
and June 2010 (time of writing). The median length of follow up was 11 months
(range 5-17 months). Once again in view of the possibility of having missing
information from patients who did not live within Lothian I analysed the data both
for the whole group of patients treated in SCAN and also for the two subgroups of
patients according to geographical locations (group A living within Lothian, group B
living outside Lothian, but still in SCAN), and compared the latter two subgroups to
assess how robust my data collection has been.
Of all the patients with a gynaecological malignancy (excluding pre-malignant
conditions) treated in SCAN (553 patients), 78 (14.1%) died during the follow up
period. Twenty five (32%) of these patients had also had a thrombotic event, 23
(29.5%) a VTE and 2 (2.5%) an arterial event.
Out of the whole group of patients with gynaecological malignancy (excluding pre-
malignant conditions) 57 had had a thrombotic event (44 a VTE and 13 an arterial
event). Of all the patients who had had a venous thrombotic event 52% died in the
follow up period, compared to 15% of patients with an arterial event and 11% of
patients with no thrombosis. This suggests that patients with gynaecological
malignancy who are also found to have a venous thrombosis may have a worse
outcome when compared with patients with gynaecological malignancy but no
thrombosis. However on multivariate analysis this finding was not found to be
statistically significant (beta=-0.57, p=0.531).
On subgroup analysis, of the 351 patients living within Lothian (group A; excluding
pre-malignant conditions), 46 (13.1%) patients died during the follow up period; 15
(32.6%) of these patients had also had a thrombotic event, 14 (30.4%) a VTE and 1
(2.2%) an arterial event. Of all the patients in group A (excluding pre-malignant
conditions) 30 had been diagnosed with a thrombotic event, 23 a VTE and 7 an
arterial event; of the patients with a VTE, 61% died during the follow up period,
compared to 14% of patients with an arterial event and 10% of patients with no
thrombosis (Table 5.6, page 151).
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Of the 202 patients living outside Lothian (group B; excluding pre-malignant
conditions), 32 (15.8%) died during the follow up period; 10 (31.2%) of these
patients had also had a thrombotic event, 9 (28.1%) a VTE and 1 (3.1%) an arterial
event. Of all the patients in group B (excluding pre-malignant conditions), 27 had
been diagnosed with a thrombotic event, 21 a VTE and 6 an arterial event; of the
patients with a VTE, 43% died during the follow up period, compared to 17% of
patients with an arterial event and 13% of patients with no thrombosis (Table 5.6,
page 151).
Subgroup analysis confirms that the two patient subgroups are very similar with no
significant difference (p=0.317). This means that my data collection is robust,
allowing me to conclude that the statistics for the overall patient cohort are truly
representative.
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Table 5.6: Summary of the number of patients who died in the follow up period
(median 11 months, range 5-17 months), and correlation with outcome. The data for
the whole patient group is shown in bold, in normal font for the subgroup of patients
living within Lothian (group A) and in italics for the subgroup of patients living
outside Lothian, but still in SCAN (group B). Venous thromboembolism (VTE)
refers to deep vein thrombosis and pulmonary embolism, while arterial events refer
to cerebrovascular accidents or myocardial infarction. Patients with pre-malignant
conditions are excluded from this analysis.
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5.3.7 Smoking history
Information about the patients' smoking history was available in just under half of all
the patients (n=272). Of these, 81 were smokers (currently smoking or having
stopped smoking less than a year prior to cancer diagnosis), 141 were life long non-
smokers and 51 were ex-smokers (defined as having stopped smoking at least one
year prior to presenting with gynaecological malignancy). The demographics of this
group of patients are summarised in Table 5.7. Unfortunately there is no way of
confirming whether the patients with available smoking history are representative of
the whole group. However in the patients where the smoking history is available, the
incidence of smoking was highest in patients with cervical cancer (54%; not taking
into account the single patient with a Bartholin's gland tumour in view of the rarity
of this tumour site).
Of the patients with a known smoking history a thrombotic event was diagnosed in 5
(3.55%) non-smokers, 3 (3.7%) smokers and 3 (5.88%) ex-smokers. It is difficult to
comment on this incidence of thrombotic events according to the smoking history
with so many patients having missing information.
Number of patients with available smoking history n=272
Diagnosis Non-smokers Smokers Ex-smokers
n=141 n=81 n=51
Cervical ca 23 (34%) 36 (54%) 8 (12%)
Endometrial ca 72 (65%) 15 (13%) 24 (22%)
Ovarian ca 29 (51%) 13 (23%) 15 (26%)
Vaginal ca 2 (40%) 2 (40%) 1 (20%)
Vulval ca 13 (45%) 14 (48%) 2 (7%)
Bartholin gland ca 0 1 (100%) 0
Unknown primary 1 (50%) 0 1 (50%)




Information about the extent of disease (stage) was available in 73% (402 out of 553
patients; patients with pre-malignant conditions are not included in this analysis) of
patients. There was an increased incidence of thrombotic events (p<0.001) and a
worse prognosis (increased mortality rate; p<0.001) with more extensive disease
stage. This data is summarised in Table 5.8.
Variable compared










Total number of VTE
events
5 (2.4%) 2 (2.8%) 8 (13.1%) 11 (18%)
Total number of
arterial events
3 (1.4%) 2 (2.8%) 2 (3.3%) 0
Mortality rate 3 (1.4%) 5 (7%) 8 (13%) 22 (18%)
Table 5.8: Summary of the incidence of thrombotic events and mortality rate
according to disease stage. Patients with pre-malignant conditions (CIN, VIN, VAIN
and borderline ovarian tumours) have been excluded. Venous thromboembolism
(VTE) refers to deep vein thrombosis and pulmonary embolism, arterial events refer




I have collected data on all patients presenting with gynaecological malignancy in
the South East of Scotland Cancer Network (SCAN) over one calendar year. All
patients with a probable or confirmed diagnosis of gynaecological malignancy in
SCAN are discussed at the gynae-oncology multidisciplinary meeting on a weekly
basis. The patients' details, including their diagnosis and management plan, are
recorded electronically onto the Lothian NHS IT system and were thus available to
me for the purposes of the audit. I am therefore confident that my list of patients
with a diagnosis of gynaecological malignancy is complete and truly representative
of the gynae-oncology activity in SCAN.
All patients with gynaecological malignancy in SCAN are treated by the same team
of gynae-oncologists based in Lothian. However the geographical area of SCAN is
large (includes Lothian, Dumfries and Galloway, fife and The Borders), so that
while the management of the gynaecological malignancies is uniform across the
whole region, acute complications such as VTE events are managed at the patients'
local hospitals. Such hospitals outside Lothian are not linked up electronically to the
Lothian NHS IT system, so that my data gathering of such acute events may be
incomplete. I was dependent on timely correspondence being sent to the oncology
team taking care of the patients' malignancy for information on the occurrence of
such acute events. In view of the potential of having such information missing I
analysed the data I gathered both as a whole group and also compared the two
subgroups of patients according to the geographical area - group A being patients
living within Lothian, and group B patients living outside Lothian but still within
SCAN. In the case of patients in group A I am confident that I had full access to all
their medical records through the Lothian NHS IT system and thus complete
information as to the incidence of thrombotic events. When I compared the two
subgroups of patients the incidence of the different types of gynaecological
malignancies, thrombotic events and the mortality rate were very similar between the
two subgroups, so that I am confident that my data gathering is in fact robust and
truly reflects the patient population with gynaecological malignancy throughout
SCAN - please refer to Table 5.1, page 135 and Table 5.4, page 145-146.
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5.4.1 Incidence of gynaecological malignancies
The population living in SCAN is made up of approximately 1.45 million people, 0.7
million of whom are women (General Register Office for Scotland mid-2009
population estimate)[3]. During 2009 four hundred and seventy three women
(excluding patients with pre-malignant conditions and with relapsed disease)
presented with a new diagnosis of gynaecological malignancy, making the crude rate
incidence for all types of gynaecological malignancies in SCAN 67.6 per 100,000
women. The details of the incidence for the different types of gynaecological
malignancies are summarised and compared with the incidence in England in Table
5.9, page 161. There was a higher incidence of cervical, endometrial, ovarian and
vulval cancer in SCAN when compared to England, although this difference did not
reach statistical significance (p=0.317). These differences in the incidence rate may
reflect different population demographics and risk factors for gynaecological
malignancies in SCAN - for example smoking and obesity are two well
established[229] risk factors for gynaecological malignancy. It would be useful to
assess whether there are any significant differences in the population demographics
and the population risk factors between SCAN and the rest of the UK that could
explain the trend in the incidence rates of the gynaecological cancers.
The histological subtypes of the different gynaecological malignancies are described
in Table 5.2, page 136-138. The distribution of the different histological subtypes in
SCAN is similar to that reported in the published literature[230],
5.4.2 Incidence of thrombotic events
10.3% of all patients presenting with a gynaecological malignancy in 2009 in SCAN
were diagnosed with a thrombotic event (8% VTEs, 2.3% arterial thromboses
(CVA/MI)). The results are summarised in Table 5.4, page 145-146. The highest
incidence of thrombosis was in patients with vaginal cancer: 40% of 5 patients.
However the total number of patients diagnosed with vaginal cancer (5 patients) is
very small so that it may be difficult to extrapolate these results to a bigger
population of patients with vaginal cancer. Of the commoner gynaecological
malignancies the patients with the highest incidence of thromboses were patients
with ovarian cancer: 19.9% of 191 patients (14.7% VTE and 5.3% arterial events),
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followed by patients with vulval cancer, 8.3% of 48 patients (6.3% VTE and 2.1%
arterial events), patients with cervical cancer, 4.5% of 89 patients (3.4% VTE and
1.1% arterial events) and finally patients with endometrial cancer, 4.2% of 215
patients (3.7% VTE and 0.47% arterial events). This suggests that ovarian cancer
tends to be more prothrombotic than other gynaecological malignancies.
There is very little in the way of prospective data in the literature assessing the
incidence of thrombotic events in patients with gynaecological malignancy. The
quoted incidence rates of VTEs are very variable, potentially reflecting the difficulty
of collecting such data: 13.6-27% of patients with ovarian cancer[23], 9.8-57% of
patients with endometrial cancer[8, 24, 25] and 0-34% of patients with cervical
cancer[9]. Arterial thromboembolism occurs much less frequently than venous
thrombosis in patients with malignancy[10, 231]. The incidence of thrombosis in the
cohort of patients with gynaecological malignancy in SCAN is not dissimilar to the
incidence rates published in the literature.
5.4.3 Patients not fit for treatment
In the SCAN patient cohort 30% of the thirty patients not eligible for treatment
(either due to extensive disease, and/or patient co-morbidities) were diagnosed with a
thrombotic event - Table 5.5, page 148. This thrombotic rate is likely to reflect the
prothrombotic state of such patients as a result of the extent of disease, patient co¬
morbidities (e.g. renal disease, obesity) or concurrent illness (e.g. sepsis)[223, 224,
232],
5.4.4 Treatment
Oncology treatment can also contribute to the pro-thrombotic state of patients with
cancer. The treatment offered to different patients varies, depending on the specific
site of origin and histological subtypes, disease stage, any prior oncology treatment
and patient fitness. Treatment consists of surgery, chemotherapy or radiotherapy




Cancer patients being treated with chemotherapy have been found to have a two- to
six-fold increased risk of VTE compared to the general population[43, 223, 233].
There is also an increased risk of arterial events (CVA and MI) in such patients[231,
234], In the SCAN patient cohort, patients being treated with chemotherapy had a
significant incidence of thrombotic events: 6.5% for all chemotherapy regimens;
9.8% of patients treated with the combination ofCarboplatin and Paclitaxel and 10%
of patients treated with Carboplatin alone were diagnosed with a thrombotic event -
Table 5.5, page 148. None of the 54 patients treated with a Cisplatin regimen were
diagnosed with thrombosis while on treatment.
This incidence rate of thrombotic events is likely to reflect both the presence of the
underlying disease as well as the effect of treatment with chemotherapy. Specific
chemotherapeutic agents may be associated with higher rates of thrombosis than
others. Platinum-based regimens have been significantly associated with
thrombosis[223-225]. Cisplatin has been associated with platelet activation in vitro,
elevated von Willebrand factor levels and hypomagnesaemia-induced vasospasm,
which have been proposed as potential mechanisms for thrombosis[20, 235], There
are a number of publications linking Cisplatin treatment with thrombotic events, both
venous and arterial[236]. All platinums have in fact been associated with an
increased incidence of thrombosis, although most of the data available relates to
Cisplatin. Paclitaxel has also been linked to an increased risk of thrombosis; it
enhances the thrombin-induced TF expression in endothelial cells in a concentration
and time dependent manner[226, 227], It has been suggested that chronomodulation
could result in a reduced incidence of thrombosis[223, 237],
Further studies are required to assess the risk:benefit ratio of primary
thromboprophylaxis in patients being treated with chemotherapeutic agents that are
known to be associated with an increased risk of thrombosis (such as platinums),
especially because such patients also have a significant risk of bleeding.
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5.4.4.2 Surgery
Surgery is a well known high risk setting for thrombotic events as a result of the
trauma of surgery and immobility after surgery amongst other reasons. This is
especially so in the presence of gynaecological cancer[17]. The presence of
undiagnosed clinically silent DVT prior to surgery which extends and becomes
symptomatic postoperatively may partly explain the high incidence of VTE events
diagnosed postoperatively in this patient group. Thromboprophylaxis with TED
stockings and low molecular weight heparin in the perioperative period has been
shown to reduce the incidence of VTE events by approximately 15%[ 17, 38, 238-
240], which in turn translates into a reduced mortality rate in the perioperative setting
in patients with cancer[17]. Such thromboprophylaxis is recommended in all
patients undergoing surgery for gynaecological malignancy.
In the SCAN audit cohort, of all the patients who required surgery as part of their
management, only 4 (1.1% of all patients having surgery) were diagnosed with a
thrombotic event (1VTE, 2MI, 1CVA) within 3 months of surgery. Of these 4
patients only one (0.3% of all patients having surgery) had a venous thrombosis -
Table 5.5, page 148. This is a very low incidence of perioperative thrombotic events
and is likely to reflect the routine use of thromboprophylaxis as described above in
all patients having surgery for gynaecological malignancy, unless contraindicated.
5.4.4.3 Radiotherapy
Only one patient (0.6% of all patients receiving radiotherapy) was diagnosed with a
VTE event while being treated with radiotherapy - Table 5.5, page 148. This patient
had very extensive disease and radiotherapy was being used in a palliative setting to
control her symptoms (pain and bleeding), making it likely that her disease extent
was a more important contributing factor towards her thrombotic event.
Radiotherapy is generally not considered to be a risk factor for thrombosis, although
there are only a small number of studies looking at this[223, 233, 241], Treatment
with radiotherapy can be associated with a number of risk factors for thrombosis,
including potential dehydration secondary to torrential diarrhoea, immobility either
as a result of treatment with brachytherapy or secondary to excessive fatigue and a
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postulated prothrombotic effect on the endothelium. More studies are warranted to
assess the thrombotic rate associated with radiotherapy treatment. The low incidence
rate of thrombosis associated with radiotherapy in the audit cohort is likely to reflect
the aggressive management of radiotherapy induced toxicities and the use of primary
thromboprophylaxis in brachytherapy patients in SCAN.
5.4.4.4 Smoking
Unfortunately the data 1 have regarding the patients' smoking history is incomplete.
It is unclear whether the group of patients with a documented smoking history is
representative of the whole group of patients or not. However from the data
available the incidence of smoking (54%) was highest in patients with cervical
cancer. There is a postulated causal effect between smoking and cervical cancer.
Smoking appears to enhance the progression of in-situ carcinomas to invasive
carcinomas, and smokers tend to have a poorer response to radiotherapy and an
increased incidence of radiotherapy associated toxicity[242].
There was no significant difference in the incidence of thrombotic events according
to the smoking history (please refer to Table 5.7, page 152). However it is unclear
whether this would still be the case if the data regarding the patients' smoking
history was more complete.
5.4.5 Disease stage
There was an increased incidence of thrombotic events (p<0.001) and an increased
mortality rate (p<0.001) in the audit cohort with more advanced disease - Table 5.8,
page 153. Large cohort studies have identified disease stage as a major risk factor for
thrombosis[223, 243-245], Advanced stage disease is associated with poor
performance, and is more likely to be associated with disease related complications
so that such patients are more likely to be unfit for treatment, or if eligible for
treatment are more susceptible to treatment related complications. This translates
into an increased mortality rate as the disease advances, a measure of the
aggressiveness of the underlying malignancy. For example Stage I cervical cancer is




The overall mortality rate during the observation period (median follow up of 11
months, range of 5-17 months) was 14.1%. While there was a trend for patients
found to have a VTE event to have a worse outcome compared to patients with no
thrombosis, the difference was not statistically significant.
Other studies have reported a significantly worse prognosis for cancer patients who
were also found to have a VTE[6, 12, 19, 20], especially so if the latter occurred at
the same time as the malignancy was diagnosed. The relationship between cancer
and arterial thrombosis is less clear, with very little data in the published literature;
Li et al.[231] reported very short survival times after ischaemic strokes in cancer
patients being treated with chemotherapy.
There are some studies which have shown that heparin treatment may improve the
prognosis of malignancy[58]. Elowever this has not been confirmed by all studies
and it is currently unclear what the role of heparin should be in patients with
malignancy but no thrombosis, especially considering the risk of bleeding in such
patients. It is currently unclear whether the worse prognosis associated with
thrombotic events in patients with cancer is due to the thrombosis itself, or whether it

















Endometrial cancer 199.0 28.4 24.0
Ovarian cancer 160.0 22.9 20.3
Cervical cancer 75.0 10.7 8.8
Vulval cancer 35.0 5.0 3.6
Vaginal cancer 2.0 0.3 0.8
Unknown primary 1.0 0.14 not available
Bartholin's gland
cancer
1.0 0.14 not available
All types 473.0 67.6 not available
Table 5.9: Comparison of the incidence rate of the different gynaecological
malignancies between SCAN and England. The total population living in SCAN is
approximately 1.45 million, 0.7 million of whom are women. Patients with pre-
malignant conditions (CIN, VIN, VAIN and borderline ovarian tumours) and patients
with relapsed disease are excluded. Data for England was obtained from the Cancer





5.5 COMPARISON OF MP STUDY COHORT AND SCAN AUDIT
COHORT
I have compared the demographics of the patients recruited to the MP study with
those of the SCAN audit cohort to establish whether the group of patients recruited to
the MP study is representative of the whole population of patients with
gynaecological malignancy treated in SCAN in 2009. The data is summarised in
Table 5.10, page 163-164.
The relative proportions of the different types of gynaecological malignancy were
very similar in the MP study cohort and the audit cohort (p=0.275, Mann Whitney U
test). The incidence of venous thrombotic events (7.5% in MP study, 8% in SCAN
audit, p=0.352, Mann Whitney U test) and the mortality rate (6% in MP study,
15.2% in SCAN audit, p=0.099, Mann Whitney U test) were also comparable. This
suggests that the group of women in the MP study is representative of the overall
population ofwomen with gynaecological malignancy in SCAN.
It is not possible to comment on treatment related thrombosis in the patients in the
MP study. Of the 5 patients diagnosed with a thrombotic event in this study, 4
presented with a thrombosis at the time their malignancy was first diagnosed, and




Proportion of pts in
MP study cohort





Endometrial cancer 36 39 n/s
Ovarian cancer 36 34 n/s
Cervical cancer 19 16 n/s
Vulval cancer 7.5 9 n/s
Vaginal cancer 1.5 0.8 n/s
Unknown primary 0 0.6 n/s
Peritoneal mesothelioma 0 0.2 n/s
Bartholin's gland cancer 0 0.2 n/s
Table 5.10a: The proportion of patients diagnosed with the different gynaecological




























Endometrial ca 0 2.6 0 1.6 0 4.2 n/s
Ovarian cancer 8.3 10.2 4.2 4.8 12.5 15 n/s
Cervical cancer 0 1.3 0 2.6 0 3.9 n/s
Vulval cancer 40 0 0 2.3 40 2.3 n/s
Vaginal cancer 0 25 0 25 0 50 n/s
All types 6 4.9 1.5 3.1 7.5 8 n/s
Table 5.10b: Comparison of the proportion of patients with a venous thromboembolic (VTE)
event in the MP study cohort and the audit cohort.
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Study cohort Audit cohort p value
Proportion of patients who died (%) 6 15.2 n/s
Proportion of patients with a venous
thrombotic event who died (%)
40 59 n/s
Table 5.10c: Comparison of the proportion of patients who died by June 2010 (median follow
up of 11 months, range 5-17 months).
The 67 patients in the MP study have been removed from the audit cohort (n=584) for the
purposes of the above comparisons; patients with pre-malignant conditions (n=31) have also
been excluded. This means that for the above comparisons n=486 (584 minus 67 minus 31)
for the audit cohort. There is no significant difference in the above relative proportions, so
that the cohort of patients in the MP study is representative of the overall population of
patients with gynaecological malignancy in SCAN.
Cancer (ca), patients (pts), diagnosis (Dx), not statistically significant (n/s). The p value for




From the SCAN audit data I have found that the incidence rate of thrombosis in the
patient cohort diagnosed with gynaecological malignancy in SCAN was 10.3% (8%
VTE and 2.3% arterial events) in 2009. Of the commoner subtypes of
gynaecological malignancy, patients with ovarian cancer were most at risk of a
thrombotic event. The highest incidence of thrombosis was in patients too unfit for
treatment (30%). Patients being treated with chemotherapy also had a significant
incidence (6.5%) of thrombosis, likely reflecting the prothrombotic nature both of the
underlying disease, and also treatment with chemotherapy agents. There was no
significant increase in thrombosis associated with radiotherapy (0.6%) or surgery
(1.1%). In the latter case the low rate of thrombosis is likely to be a reflection of
routine primary thromboprophylaxis in the perioperative period in patients having
surgery for gynaecological malignancy.
I have compared the group of patients recruited to the MP study with the SCAN audit
cohort and found that the MP study cohort is representative of the SCAN audit
cohort. This suggests that the results of the study on MPs can be extrapolated to the




The aim of this research project was to test the hypothesis that the number of MPs is
raised in patients with gynaecological malignancy with thrombosis and that they are
a useful marker of thrombotic risk. I also wanted to compare the number of plasma
MPs in patients with gynaecological malignancy and a control group of women
without malignancy. This required the establishment of a robust, reproducible and
practical method to measure plasma MPs. I also wanted to establish whether there
was any correlation between the number of plasma MPs and established markers of
haemostatic activation such as D-dimcrs.
6.1 Measurement of plasma microparticles
Despite a plethora of published articles in the peer reviewed literature indicating that
MPs are likely to be important contributors in many different patho-physiological
processes, there is still no universally accepted definition of what constitutes a MP,
nor any standardised method ofMP identification and measurement.
MPs are generally considered to be anucleate structures, 0.1 -lpm in diameter,
surrounded by a phospholipid bilayer, released by microvesiculation from the plasma
membrane of cells[73, 76, 79], They contain various different cytoplasmic
components and also express surface antigens, proteins and receptors of their parent
cell. They circulate throughout the body and transfer receptors, genetic information
(mRNA) and second messengers to recipient cells, allowing intercellular
communication between far removed cells. They are also able to support
haemostasis on their surface phospholipids.
MPs are released from cells either secondary to cell activation or cell
stress/apoptosis. The release of MPs is a physiological process. During cell
activation or apoptosis there is an increase in intracytoplasmic calcium which leads
to the activation of various different enzymes (please refer to Figure 1.1, page 11)
resulting in membrane budding and MP shedding by microvesicualtion. Blood cells
can continue to release MPs after blood sampling. It is well recognised that variable
pre-analytical handling of samples can significantly affect the number of MPs
detected. These pre-analytical variables have not yet been fully characterised.
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It is important to avoid cell/platelet activation/stimulation during blood sampling.
The use of minimal or no stasis when sampling blood and the use of at least a 21
gauge needle is therefore recommended[78]. Blood sampled into anticoagulants that
preserve extracellular calcium e.g. heparin, PPACK allow the continuing release of
MPs post blood sampling[78]. This happens to a lesser degree when blood is
sampled into anticoagulants that chelate calcium e.g. citrate, ACD. In the majority of
published studies MPs have been measured from samples taken into citrate tubes[74,
81, 82, 116, 142], Given that MP release in vitro can happen, samples need to be
handled in as uniform a manner as possible to ensure that results are comparable. In
this study all samples were handled by one operator. Blood was withdrawn with
minimal or no venous stasis using a 21 gauge needle, and collected into citrate tubes
to minimise the in vitro release ofMPs.
The interval between blood sampling and MP analysis is also likely to contribute to
variable results due to the potential for continuing in vitro release of MPs. Many
investigators[81, 116, 142, 159] do not specify the length of time between blood
sampling and either freezing the samples or analysing MPs in fresh plasma. Variable
lengths of storage times are likely to contribute significantly to the variability of
results in the published literature. I addressed this by ensuring that the method used
was tightly controlled and that all samples were analysed within two hours of blood
sampling.
It is also unclear what effect a freeze-thaw cycle has on the number of MPs, with
different investigators reporting different and sometimes opposite effects. For
example Rectenwald[35] reported increased number of MPs when the PFP had been
stored frozen prior to analysis, while Shah[78] found that MP numbers decreased
after storage irrespective of whether the PFP was stored at room temperature or
frozen. The majority of published studies have analysed MPs on samples stored
frozen [35, 81, 82, 116, 140, 142, 159, 164] and then thawed by a variety of different
methods prior to analysis, with few studies reporting on MP numbers in fresh
plasma[212, 213], This makes the meaningful comparison of results published in the
literature difficult and is likely to be contributing to significant variation in the results
published. Limiting MP analysis to fresh samples significantly limits the usefulness
168
of the assay, prevents sample batching and makes inter-laboratory collaboration and
comparison difficult. However it is clear from the published results that a freeze -
thaw cycle has an as yet undefined effect on MPs. At the start of patient recruitment
I compared the number of MPs identified in fresh plasma and a frozen aliquot of the
same plasma. The results obtained from plasma that had gone through a freeze/thaw
cycle did not correlate with the results from fresh plasma (please refer to section 3.5,
page 64). In view of this I measured MPs on fresh plasma to avoid any effect a
freeze-thaw cycle may have on MP numbers. Further research to clarify the effect a
freeze-thaw cycle has on MP numbers is important since the ability to carry out MP
analysis on plasma that has been stored frozen would greatly enhance the clinical
usefulness of this assay.
It is equally important that the in vitro release and loss of MPs secondary to
centrifugation or washing is minimized. The centrifugation protocols used vary
significantly between different laboratories (please refer to Table 2.1, page 40). This
is likely to be contributing to variable published results. The speed and duration of
centrifugation may lead to either the potential "generation" of MPs, when plasma is
ultra-centrifuged, or to the loss of MPs which are not sedimented out. If washing is
also used this may further contribute to MP loss. There is no single centrifugation
protocol that will guarantee that all MPs are isolated, particularly as some MPs are
no denser than plasma. I prepared PFP using serial centrifugation. I avoided the use
of ultracentrifugation due to the concern of potentially "generating" MPs during such
high speed centrifugation. After a literature review I compared 3 different serial
centrifugation protocols to establish which protocol would allow me to prepare PFP
with a residual platelet count consistently less than 5xl09/L. I confirmed the residual
platelet count in all the PFP samples and in 93.4% of the samples there were no or
<5x109/L residual platelets. Seven (6.4%) of the samples had a residual platelet
count of 6-9x109/L. 1 found a statistically significant correlation between the number
of residual platelets in the plasma and the number of PMPs measured after
centrifugation (please refer to section 4.4.7, page 101). It is likely that some of the
residual small platelets were being measured with the PMPs. Most investigators[35,
74, 81] do not quantify the number of residual platelets in the PFP. This is likely to
partly explain the variable results from different investigators using different
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centrifugation protocols, particularly as the number of residual contaminating
platelets will vary according to the centrifugation protocol used, therefore having a
variable effect on the number of MPs detected. So in the absence of any
standardised protocol, 1 have selected procedures to minimise in vitro generation or
loss ofMPs, and have used a consistent approach to allow intra-study comparability.
A further source of variable results is the specificity of antibodies used to identify
different MP subtypes. Initially MPs were thought to universally bind AV which
could therefore be used as a marker for all subtypes of MPs, irrespective of their cell
of origin. There are now a number of published articles[73, 87] indicating that AV
negative MPs can make up a significant, and in some cases the majority, proportion
of all plasma MPs. Unfortunately there is again variability between investigators as
to whether AV positivity is used as a defining criteria for MPs or not. For example
Hron et al[81] and Toth et al[l64] only analysed AV positive MPs, while Helley et
al[82] and Rectenwald et al[35] analysed all MPs, irrespective of AV positivity. In
view of the fact that it is now clear that AV negative MPs may make up a significant
proportion of plasma MPs, using AV positivity to define MPs could potentially result
in a significant and variable proportion of plasma MPs being not identified, again
making the meaningful comparison of results between different investigators
difficult. In my study AV+ve MPs made up a minority of all MPs detected, so that
measuring only AV+ve events would have meant that the majority of MPs would
have been missed (please refer to section 4.4.4, page 96). When comparing results in
the literature, this needs to be taken into account.
The choice of cell-specific antibody to identify different subtypes of MPs also
contributes to variable results. The specific antigens and the concentration at which
they are expressed by MPs vary according to the stimulus that leads to the release of
MPs. For example CD41+ve PMP and CD42+ve PMP populations are not identical
and reflect different pathophysiological phenomena. Depending on which cell-
specific antibody (e.g. anti-CD41, anti-CD41a, anti-CD42, anti-CD61) is used to
identity PMPs, different subgroups of PMPs are measured, leading to different
results. For example Toth et al[ 164] used CD61 to identify PMPs, while Hron et
al[81] identified PMPs using CD41a. Unfortunately there is currently no universal
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marker for MPs irrespective of cell of origin and no marker that will identify all MPs
released from a particular cell type irrespective of the stimulus that lead to their
release. This will contribute to different results published by different investigators.
Standardising the specificity of antibodies used would facilitate the meaningful
comparison of results between different laboratories. The antibodies I have used to
identify the cell-specific MPs were identified after a literature review and chosen due
to their specificity for the particular cell types (please refer to section 3.3.4, page 54-
56). The choice of antibodies used needs to be taken into consideration when
comparing results from different investigators.
When I initially designed the study I planned to use combinations of antibodies
(using multicolour flow) in order to be able to identify the cell of origin of AV+ve
MPs and TF+ve MPs. In my initial experiments I realised that the binding buffer
necessary for AV binding was interfering with the binding of the cell-specific
antibodies. Likewise anti-CD 142 was also interfering with other antibodies. I
therefore elected to use AV and anti-CD142 singly, so that while I was able to
measure the total number of AV+ve MPs and the total number of TF+ve (CD142)
MPs, I have been unable to identify their cell of origin. It would be valuable to be
able to characterise such MPs further. It would be particularly interesting to
establish the cell of origin of TF+ve MPs since this may be of therapeutic
significance; for example to establish whether the TF+ve MPs are originating from
tumour cells or other cells. This could be studied further by using other antibody
combinations so as to better characterise AV+ve and TF+ve MPs.
There are a number of different assays that can be used to analyse MPs. The
technique used most often is flow cytometry. This has the advantage of analysing
tens of thousands ofMPs and gives information regarding the size and complexity of
the MPs being analysed. It however gives no information as to the concentration of
the antigen being measured on individual MPs or the functional properties of the
MPs, unlike ELISAs and functional assays (see later).
When measuring MPs using flow cytometry, MPs are identified based on size and
antigen positivity. MPs are most often defined as being 0.1 -lpm in diameter[74, 81,
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82], The lower size limit was chosen due to the fact that smaller particles cannot
readily be distinguished from electronic noise when using flow cytometry. Current
flow cytometers were intended to measure cells much larger in size than MPs. Their
small size means that most MPs appear close to the electronic noise of current flow
cytometers. The accuracy ofmeasuring such small particles with currently available
flow cytometers is highly dependent on fine optical adjustments and fluidics and
optics cleanliness of the machine. This will vary from one machine to the next and
depends on maintenance for a single instrument. This was borne out in the results of
the International Society on Thrombosis and Haemostasis SSC Collaborative
workshop[247], where it was shown that standardization of PMP enumeration by
flow cytometry is feasible, but is dependent on intrinsic characteristics of both the
flow cytometer and the calibration strategy. It is now clear that most current flow
cytometers are unable to accurately and specifically identify and measure particles
less than 0.5pm in diameter. This means that a significant and variable proportion of
the circulating plasma MPs will be missed by current flow cytometers.
The upper size limit of MPs is also arbitrary, mainly due to the fact that flow
cytometers are unable to distinguish between PMPs larger than 1pm and platelets
smaller than 1pm in diameter, both platelets and MPs being on a continuum of size.
This invariably contributes to variable results. Using size as one of the defining
criteria of MPs (as in my study) necessarily results in some MPs being missed and
some small platelets being measured with the PMPs. At present there is however no
easy solution to this problem.
There is currently a significant amount of research being carried out to try and
improve the accuracy and specificity of MP identification, looking at the use of
impedance based flow cytometers and digitally acquiring flow cytometers amongst
other techniques. As the technology evolves and is better able to identify such small
structures it may well be that MP assays will become much more accurate and easier
to standardise. My method of analysing MPs was based on flow cytometry. I
defined MPs as events <lpm in size that were positive for a particular cell specific
antigen. To maximise the specific identification of MPs I set a lower threshold on
forward scatter such that small MPs would not be missed while at the same time
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removing some of the electronic noise of the machine. To avoid any variability in
results due to technique all analyses were carried out on a single instrument using a
constant setup everytime.
MPs may also be analysed using ELISAs or functional assays. When using such
assays MPs are first isolated and immobilised from PFP using specific monoclonal
antibodies or AV. In ELISAs a second monoclonal antibody is used to identify and
quantify MP-bound antigens, while in functional assays, the functional properties of
the MPs are assessed using a prothrombinase assay. In such assays the antibodies
used will capture MPs irrespective of their size (unlike in flow cytometry). ELISAs
and functional assays however still have the same problems as flow cytometry of
potentially loosing/generating MPs according to the technique used to prepare PFP
and similar problems regarding the specificity of the antibodies used to identify the
MPs since there is currently no universal marker that will identify all MPs
irrespective of cell of origin. It is now clear that the results from flow cytometric
analysis of MPs are not interchangeable with the results obtained from ELISAs or
functional assays. There are several publications[81, 116, 159] where the results of
the various types of assays did not correlate. For example Flaubold et al[ 159]
reported significantly increased TF activity in cancer patients, but the TF antigen
levels and TF+ve MP levels did not correlate with TF activity. It would be valuable
to set up a functional based assay to assess the procoagulant activity of the MPs, and
compare the results of such assays with the number of MPs measured by flow
cytometry.
In order to quantify the absolute number of MPs in cell free plasma I used a flow
based method using TRUCOUNT™ beads (please refer to section 3.4.2, page 61). A
number of studies have reported that the flow rate through a flow cytometer is
constant[221]. This was borne out in my study too. The volume of fluid analysed by
the flow cytometer over 120 seconds was very stable over a session of analysis, and
the overall inter-assay CV over the twelve month period of analysing patient samples
was 3.2%. With this method TRUCOUNT™ beads are only required at the start and
again at the end of each session of patient samples, making it a more cost-effective
method than adding such or similar beads to each patient tube.
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It is clear that while there is currently a tremendous amount of research being carried
out and many peer-reviewed articles being published on MPs there are still many
important unanswered questions, not least how best to analyse MPs to ensure
reproducible results. It is very important that any laboratory carrying out research on
MPs is meticulous in standardising their protocol used to analyse MPs. This would
at least ensure that their results are comparable for their samples and would be
comparable with another laboratory's results using the same protocol. Unfortunately
the pre-analytical details are not always described in a such way as to accurately
establish their effects on published data, but will contribute to the variability of
published results. In order to ensure that my results from different patients are
comparable I standardised the pre/analytical process. All samples were analysed by
me using a tightly controlled protocol (please refer to chapter III) to ensure that any
variability secondary to pre/analytical handling was kept to a minimum. This means
that while my results may not be comparable with those published using different
pre-analytical and analytical techniques, they are comparable between themselves.
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6.2 Study results
As far as I can ascertain this is the first study measuring MPs in patients with
gynaecological malignancy. I measured the number of plasma MPs in a cohort of
women diagnosed with gynaecological malignancy and a control group of women
without malignancy. Gynaecological malignancy was chosen due to the fact that
gynaecological malignancies are associated with a significant incidence of
thrombosis. Although the different gynaecological malignancies have diverse
pathologies they are all managed by the same clinical team in Edinburgh, so that the
data collected would be comprehensive and consistent.
The control group of women was on average younger than the malignant group.
However this is unlikely to have affected the MP results, there being no correlation
between age and MP numbers (please refer to section 4.3.1, page 82 and 4.4.5, page
97). Control groups in the published literature have varied. Hron et al[81] measured
MPs in 20 patients with colorectal cancer and compared the results with 20 healthy
control subjects matched for age and sex. On the other hand in the study by
Rectenwald et al[35], the control group was significantly younger than the patient
group with no analysis made as to whether MP numbers were correlated with age.
MPs have been measured in many different patient groups by other investigators.
There are several reports[18, 164, 165] in the published literature indicating that the
number of plasma MPs is increased in various different prothrombotic conditions
including malignancy. There are however also studies where the number of MPs
measured was similar between patients with cancer and a control group without
cancer, but have at the same time reported an increased numbers of TF+ve MPs[81]
or increased MP associated TF function[l 16]. For example Hron et al[81] reported
increased numbers of TF+ve MPs in cancer patients compared to healthy controls,
however the absolute number of MPs in plasma did not signficantly differ between
patients and controls. The protocol used by Hron et al was significantly different to
that used in my research study. PFP was prepared by a one-step centrifugation at
2600g for 15 minutes (vs 1500gxl5minutes + 13,500gx2minutes); plasma samples
were stored frozen rather than processed fresh; the MPs were defined by positivity to
both AV and cell-specific antibodies thus exluding AV negative MPs (unlike in my
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study, please refer to chapter III for study protocol). Tesselaar et al[248] reported
that AV+ve MP numbers did not differ in patients with cancer with VTE compared
to cancer patients without VTE, but found increased TF-dependent MP activity in the
cancer patients with VTE. The protocol used in this study is again different. PFP
was prepared with a one-step centrifugation at 1550g for 20 minutes (vs
1500gxl5minutes + 13,500gx2minutes) and plasma samples were stored frozen
rather than processed fresh. Kanazawa et al[249] on the other hand reported
increased numbers of PMPs in lung cancer patients compared to healthy controls. In
this latter study the centifugation protocol used to prepare PFP was different again,
this time including washing steps; the plasma samples were analysed fresh (as in my
study), but the PMPs were identified using different cell specific antibodies
compared to my study. The studies described above are all significantly different in
between themselves and different from my study protocol. There isn't one easily
identifiable confounding variable that could readily explain the variable published
results. It is more likely that a combination of pre/analytical variables contribute to
the different results. It may also be that differences in the underlying pathologies are
contributing to the variability in the published literature.
Although all the patients in my study had a diagnosis of gynaecological cancer, they
are in fact a relatively diverse group due to the fact that different types of
gynaecological cancer have a different prognosis and behave differently biologically.
Other investigators have however reported a difference in the number of plasma MPs
between a diverse group of cancer patients and control groups without cancer[18,
140, 144], For example Tesselaar et al[ 116] reported increased AV+ve MPs in a
group of patients with pancreatic (n=23) and breast (n=27) cancer compared to a
group of healthy control (n=37), and Zwicker et al[ 18] reported increased TF+ve
MPs in patients with pancreatic (n=39) and colorectal (n=12) cancer compared with
cancer-free controls (n=31). There is increasing evidence that MPs are likely to
contribute to cancer cell survival, invasiveness and metastases[99, 109]. Given this,
it is reasonable to hypothesise that plasma MPs would be present in increased
numbers in patients with cancer. The fact that I did not find a difference in plasma
MPs between the malignant group and the control group should not have been
influenced by the specific type of gynaecological cancer present, although it is
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possible that a more uniform and bigger group of cancer patients may have allowed a
difference in MP numbers to be identified. It is however also likely that the lack of a
standardised method of analysis, particularly in the pre-analytical handling of
samples, is contributing to the variable reports in the literature.
Given the fact that MPs express surface negatively charged phospholipids and also
carry TF, other clotting factors, vWF and receptors for clotting factors[84, 147, 148],
MPs are generally considered to be important components of normal haemostasis and
to contribute to thrombosis when present in increased numbers. Indeed MPs have
been reported to be 50-100x[ 146] more procoagulant than an identical surface of
activated platelets. In view of this it would be reasonable to speculate that MPs can
in fact contribute towards thrombosis.
In this study I wanted to establish whether measuring MP numbers in patients with
gynaecological malignancy would be helpful in identifying patients at an increased
risk of thrombosis. The statistical advice obtained prior to study recruitment
suggested that assuming approximately 25% of women with gynaecological cancer
would develop a VTE at some point during their treatment for cancer (as per quoted
incidence rates in the literature[6, 8, 9, 20, 24, 27, 250]), a consecutive series of
around 140 women with gynaecological cancer would have a 90% probability of
detecting a difference in the mean number ofMPs between patients with a VTE and
patients with no VTE. We also aimed to recruit a similar number (n=140) of women
without malignancy to explore whether MP analysis is a superior predictor ofVTE in
women with gynaecological cancer compared to women without cancer. Interim
study analysis after 12 months of study recruitment indicated that the incidence of
VTE in the study (7.5%) was significantly lower than expected so that the planned
study was underpowered to identify a difference in MP numbers in patients with
VTE compated to patients with no VTE. Furthermore the number of plasma MPs in
the patients with VTE was indistinguishable from the number of MPs in patients
without a VTE event. Neither was there any difference or trend in the number of
plasma MPs in patients with gynaecological cancer as a group compared to the
control group. It was therefore decided at that point to stop study recruitment since it
was unlikely that there would be a statistically significant difference in MP numbers
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between the identified patient groups. It is possible that a much larger study or
longer follow up may have resulted in more of the study patients being diagnosed
with a VTE, allowing any difference that may have been present in MP numbers to
be identified.
Due to the fact that the number of patients diagnosed with a VTE event in the study
was much smaller than initially expected, I audited all the patients diagnosed with
gynaecological malignancy within SCAN (the geographical area from where the
study patients were recruited) over one calendar year, with the aim of establishing
the incidence of the various types of gynaecological malignancy in the overall
population being treated in SCAN and the incidence of VTEs in this patient group.
All the patients treated for gynaecological malignancy in SCAN are managed by one
team of gynae-oncologists. All such patients are discussed at a weekly multi-
disciplinary meeting and their details are captured on a local IT system. This
allowed me to identify all patients presenting with gynaecological malignancy within
one calendar year. After analysing all the data (please refer to chapter V) it was clear
that the group of patients recruited to my study was in fact representative of the
overall population within SCAN. The incidence of VTE events was very similar in
the overall population of patients diagnosed with gynaecological malignancy in
SCAN (8%) to that of the study patients (7.5%). This suggests that the results of this
study can be extrapolated to the SCAN population of patients diagnosed with
gynaecological malignancy. The results of the SCAN audit confirmed that I would
have needed to recruit a much larger number of patients than originally planned in
order to detect any statistically significant difference in the number ofMPs measured
in cancer patients with a VTE compared to cancer patients without VTE. This
SCAN data, previously unavailable, has been presented as an abstract at the 17th
International Meeting of the European Society ofGynaecological Oncology.
I also measured indirect markers of haemostatic activation as a surrogate marker in
the patients with cancer and the control group. Similar to other publications in the
literature[ 171] the levels of D-dimers and PF1&2 were statistically significantly
increased in the patients with gynaecological malignancy (even after adjusting for
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age), evidence of haemostatic activation in patients with malignancy (please refer to
sections 4.4.13-4.4.20, pages 110-120). The level of D-dimers was also statistically
significantly increased in the small group of patients with a VTE event. The level of
TATs was not statistically significantly different between the two groups. The latter
is likely to reflect the lower sensitivity of TATs[50] and their shorter half life in
circulation.
The different markers of haemostatic activation were statistically significantly
correlated, however there was no correlation between the level of D-dimers, TATs
and PF1&2 and the number of MPs measured. This is in keeping with the fact that
there was no difference detectable in MP numbers measured between the two groups
of patients. My results therefore do not support the hypothesis that the number of






Some of the limitations of the study have already been touched on in the preceeding
discussion. This is a single institute study, with a relatively short follow up (median
11 months, range 5-17 months). Although all the patients recruited had a diagnosis
of gynaecological cancer, the latter types of cancer have a varied biological course
with different prognoses and outcomes depending on the specific type of
gynaecological cancer present. This means that the patient group recruited was not
uniform. However as already discussed, other studies (see previously) have
previously reported a statistically significant difference in the number of MPs
measured between cancer patients (variable diagnosis) and patients with no
underlying cancer, in some cases with smaller numbers recruited than in this study.
Although the incidence of VTEs in the study cohort was similar to that of the overall
population of patients presenting with gynaecological cancer in SCAN, the absolute
number of such patients was too small to be able to form any definitive conclusions
as to the usefulness of measuring MP numbers as a marker of thrombotic potential.
A much larger study is needed in order to have enough patients diagnosed with a
VTE event.
Due to logistical reasons patients were not recruited in a consecutive manner;
however there was no perceived bias and when comparing the incidence of the
various types of gynaecological cancer and the incidence of VTEs in the study group,
this was comparable with the overall population of patients presenting with
gynaecological cancer in SCAN (please refer to chapter V).
The MPs were measured using light scattering flow cytometry. While this is the
most commonly used technique to measure MPs it is clear that the technology
currently struggles to accurately and specifically measure MPs, particularly ones
smaller than 0.5pm in diameter. I have not looked at the functional properties of the
MPs measured; published studies[140, 248] indicate that such an assay may be more
helpful in assessing the thrombotic potential of individual patients.
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Due to difficulties with antibody interference I have been unable to identify the cell
of origin of the TF+ve MPs and of the AV+ve MPs. This could be studied further by
using other antibody combinations. It would be very helpful to be able to identify
which cells are releasing the TF+ve MPs, particularly if the TF+ve MPs are
originating from cancer cells.
6.4 Conclusion
I have set up an assay using light-scattering flow cytometry to measure plasma MPs.
All samples were analysed using a tightly controlled protocol on fresh plasma. My
results may not be readily comparable to other studies due to differences in
methodology. Keeping in mind the limitations of the study, there was no difference
in plasma MP numbers between patients with gynaecological malignancy and a
control group of women without malignancy. The number of patients in the study
diagnosed with a VTE is too small to draw any firm conclusions; however the lack of
correlation with surrogate markers of haemostatic activation, and the current
difficulty of accurately measuring the number of plasma MPs, would suggest that






Following your consultation in hospital with Dr , I would like to
invite you to take part in a research project we are carrying out. I would be very
grateful if you were to read the attached information sheet giving you details of our
research project and what your involvement would be should you decide to help us
with this research project.
Thank you for your time and help.
Best regards,
SHARON ZAHRA
Clinical Lecturer in Haematology
University of Edinburgh
Department ofHaematology
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh EH 16 4AC
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APPENDIX B
Patient information sheet - Gynaecological malignancy
patients
MICROPARTICLES AND THROMBIN GENERATION IN
PATIENTS WITH GYNAECOLOGICAL MALIGNANCY
I. Invitation
You are being invited to take part in a research study. Please take time to read the
following information carefully and discuss it with others if you wish. Ask us if there
is anything that is not clear or if you would like more information. Take time to
decide whether or not you wish to take part in the study.
II. Introduction
You have recently been diagnosed with cancer. Patients vary widely in the incidence
of side-effects from cancer and its treatment, in particular the incidence of blood
clots. If a test could be developed to accurately predict the patients at high risk of
developing blood clots then those patients may in the future be offered medication to
try and reduce this risk, while patients thought to be at low risk of developing a blood
clot could be spared unnecessary medication.
III. Standard Management
As part of your normal management, you will be offered treatment with one or more
of surgery, chemotherapy, radiotherapy and brachytherapy depending on the exact
nature of your cancer. During your treatment your doctors will be taking blood
samples at regular intervals to monitor your response to the treatment you are
receiving.
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IV. Participation in the Study
This study is aimed at establishing what happens to the level of microparticles (very
small particles in the blood) and to thrombin generation (the rate of production of a
protein in the blood) in patients with gynaecological cancer, and whether these
change during the course of the disease and its treatment. We will also be looking to
see whether we can establish a link between the level of microparticles, thrombin
generation and the onset of blood clots. This will be done by analysing blood
samples from patients. We hope to enrol 140 patients in the study over 2 years.
Microparticles are small particles that are found circulating in everybody's blood.
They are known to be involved in inflammation and blood clotting, and while they
are present in healthy individuals, their levels tend to increase significantly in many
disease states, including cancer. Microparticles may therefore represent novel
markers of disease activity. They may also be involved in several disease processes
such as the development of blood clots.
Thrombin generation is a relatively new technique that allows us to measure an
individual's ability to stop bleeding or to develop blood clots.
• By taking part in this study you will get exactly the same treatment as you would
otherwise.
• We will ask you for a small blood sample (12mls - approximately the size of a
table spoon) over and above the blood samples that will be taken as part of your
normal management, for us to analyse in the laboratory
• The number of blood samples that we would need will vary according to the
treatment you will receive. Depending on which type of cancer you have you
may be treated with any or all of surgery, chemotherapy, radiotherapy and
brachytherapy - depending on your treatment we would like to take blood
samples just before and after surgery, at regular intervals during chemotherapy
and radiotherapy, before and after brachytherapy, and should you develop a
blood clot. In view of this the total number of blood samples that we would need
from you will vary from just two samples up to a maximum of ten samples.
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• We will endeavour to time our blood samples so that they are done at the same
time as the blood samples that you will need to have done as part of your usual
management. You will be free to stop having blood samples taken for our study
at any time.
• The blood samples that we will take will be stored in our laboratory and analysed
as necessary to establish the level of microparticles and thrombin generation, and
other markers of activation of the clotting mechanism. The blood samples will be
disposed of at the end of our research project.
• We would like to contact you for a further blood sample should you require
further treatment for your cancer.
• We would like to send a letter to your GP to inform him/her of your participation.
• If you have private medical insurance, you should contact your insurance
company to ensure that your participation will not affect your insurance in any
way.
• Participation in the study is entirely voluntary. By agreeing to take part in the
study you will remain completely free to opt out at any stage, and to withdraw
your consent to any part of the process, without having to give a reason. The
decision not to participate or to withdraw from the study will not affect the
standard of care you receive.
• If you choose not to participate in the study your treatment will be unaffected and
will go ahead entirely as normal.
• Please let us know if you are participating in any other research projects.
V. What happens if something goes wrong?
If you are harmed by taking part in this research study, there are no special
compensation arrangements. If you are harmed due to someone's negligence, then
you may have grounds for legal action but you may have to pay for it. Regardless of
this, if you wish to complain, or have any concerns about the way you have been
approached or treated during the course of this study, the normal National Health
Service complaints mechanisms are available to you.
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VI. Confidentiality
If you consent to take part in this study, your medical records will be inspected by
the investigators conducting this study. All information that is collected about you
will be kept strictly confidential. Any information leaving the hospital will have your
name and address removed so that you cannot be recognised.
^ VII. Funding of the Study
This study is supported by funds through the University of Edinburgh.
VIII. Results of the Study
1 The initial results of the research will be available about 2 years from the start of the
study and will be published in peer reviewed medical journals. We do not expect our
findings to alter the management of current patients; however it is hoped that they
might reveal important correlations between blood clots and the level of
microparticles, which may be of clinical relevance to patients in the future. We
would thus like to be able to use the results we obtain from this study to compare
^ with the results from other potential future studies. We will be happy to let you
know our overall results at the completion of our study. If you would like to be
informed in writing please let us know.
IX. New Information
^
If any new information becomes available during the course of this study, which




X. Contact for further information
If you require further information about this study, please contact Dr. Sharon Zahra
at the New Royal Infirmary of Edinburgh on 0131 242 6096.
Thank you for taking the time to read this information sheet. Your participation
in the study would be greatly appreciated and highly valued, as it would allow
us to further our knowledge and help us treat future patients.
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APPENDIX C
Patient information sheet - Patients with benign
gynaecological conditions requiring surgical treatment
MICROPARTICLES AND THROMBIN GENERATION
I. Invitation
You are being invited to take part in a research study. Please take time to read the
following information carefully and discuss it with others if you wish. Ask us if there
is anything that is not clear or if you would like more information. Take time to
decide whether or not you wish to take part in the study.
II. Introduction
You have been chosen because you are about to undergo surgery for a
gynaecological condition. We need to recruit a group of people like yourself as
controls for a study we are carrying out in patients with various different
gynaecological conditions.
We are looking at the level of microparticles and thrombin generation. We need to
compare these results in different patient groups, and need to recruit a group of
patients about to undergo surgery for a benign gynaecological condition such as
yourself as one of our control groups.
III. Standard Management
As part of your normal management, you will be offered gynaecological surgery, and
your doctors will monitor your blood tests.
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IV. Participation in the Study
Our aim is to compare the level ofmicroparticles and thrombin generation in patients
requiring treatment for various different gynaecological conditions. We will be
looking to see whether we can establish a link between the level of microparticles,
thrombin generation and the onset of blood clots. This will be done by analysing
blood samples from patients. We hope to enrol a group of 140 patients similar to
yourself into the study over a 2 year period.
Microparticles are small particles that are found circulating in everybody's blood.
They are known to be involved in inflammation and blood clotting, and while they
are present in healthy individuals, their levels tend to increase significantly in many
disease states. Microparticles may therefore represent novel markers of disease
activity. They may also be involved in several disease processes such as the
development of blood clots.
Thrombin generation is a relatively new technique that allows us to measure an
individual's ability to stop bleeding or to develop blood clots.
• By taking part in this study you will get exactly the same treatment as you would
otherwise.
• We will ask you for a small blood sample (12mls - approximately the size of a
table spoon) over and above the blood samples that will be taken as part of your
normal management, for us to analyse in the laboratory.
• The blood samples that we need will be taken just before and after your surgery.
We will also ask you for a further blood sample should you develop a blood clot
around the time of surgery or in the subsequent three months.
• The total number of blood samples that we would require would thus be two in
the majority of cases, or a total of five should you develop a blood clot.
• We will endeavour to time our blood samples so that they are done at the same
time as the blood tests that you will need to have done as part of your usual
management.
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• We would like to contact you by telephone at one month and three months after
your surgery to check on your progress.
• The blood samples that we will take will be stored in our laboratory and analysed
as necessary to establish the level of microparticles and thrombin generation, and
other markers of activation of the clotting mechanism. The blood samples will be
disposed of at the end ofour research project.
• We would like to send a letter to your GP to inform him/her of your participation.
• If you have private medical insurance, you should contact your insurance
company to ensure that your participation will not affect your insurance in any
way.
• Participation in the study is entirely voluntary. By agreeing to take part in the
study you will remain completely free to opt out at any stage, and to withdraw
your consent to any part of the process, without having to give a reason. The
decision not to participate or to withdraw from the study will not affect the
standard of care you receive.
• If you choose not to participate in the study your treatment will be unaffected and
will go ahead entirely as normal.
• Please let us know if you are participating in any other research projects.
V. What happens if something goes wrong?
If you are harmed by taking part in this research study, there are no special
compensation arrangements. If you are harmed due to someone's negligence, then
you may have grounds for legal action but you may have to pay for it. Regardless of
this, if you wish to complain, or have any concerns about the way you have been
approached or treated during the course of this study, the normal National Health
Service complaints mechanisms are available to you.
VI. Confidentiality
If you consent to take part in this study, your medical records will be inspected by
the investigators conducting this study. All information that is collected about you
will be kept strictly confidential. Any information leaving the hospital will have your
name and address removed so that you cannot be recognised.
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VII. Funding of the Study
This study is supported by funds through the University of Edinburgh
VIII. Results of the Study
The initial results of the research will be available about 2 years from the start of the
study and will be published in peer reviewed medical journals. We do not expect our
findings to alter the management of current patients; however it is hoped that they
might reveal important correlations between blood clots and the level of
microparticles, which may be of clinical relevance to patients in the future. We
would thus like to be able to use the results we obtain from this study to compare
with the results from other possible future studies. We will be happy to let you know
our overall results at the completion of our study. If you would like to be informed
in writing please let us know.
IX. New Information
If any new information becomes available during the course of this study, which
might affect your willingness to continue taking part, your doctor will inform you
immediately.
X. Contact for further information
If you require further information about this study, please contact Dr. Sharon Zahra
at the New Royal Infirmary of Edinburgh on 0131 242 6096.
Thank you for taking the time to read this information sheet. Your participation
in the study would be greatly appreciated and highly valued, as it would allow
us to further our knowledge and help us treat future patients.
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APPENDIX D
CONSENT FORM Study Number:
MICROPARTICLES AND THROMBIN GENERATION IN PATIENTSWITH
GYNAECOLOGICAL MALIGNANCY





1. I confirm that I have read and understood the information sheet regarding the
above-mentioned study, and have had the opportunity to ask questions.
2. I understand that my participation is entirely voluntary and I am free to
withdraw at any time without giving a reason, without my medical and legal
rights being affected.
3. I understand that the investigators of this study will inspect my medical records.
4. I agree to take part in this study.
5. 1 give permission for images and other information obtained in the course of
this study to be used in any future publications.
6. 1 agree to the notification ofmy GP regarding my participation in this study.
7. I would like to be informed in writing of the overall findings of this study at its
completion.
Name of patient Date Signature
Name of Researcher Date Signature
Copyfor patient, copyfor researcher, copy to be kept with hospital notes
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APPENDIX E
CONSENT FORM Study Number:
MICROPARTICLES AND THROMBIN GENERATION IN PATIENTS WITH
BENIGN GYNAECOLOGICAL CONDITIONS





1. I confirm that I have read and understood the information sheet regarding the
above-mentioned study, and have had the opportunity to ask questions.
2. I understand that my participation is entirely voluntary and I am free to
withdraw at any time without giving a reason, without my medical and legal
rights being affected.
3. I understand that the investigators of this study will inspect my medical records.
4. I agree to take part in this study.
5. I give permission for images and other information obtained in the course of
this study to be used in any future publications.
6. I agree to the notification ofmy GP regarding my participation in this study.
7. I would like to be informed in writing of the overall findings of this study at its
completion.
Name of patient Date Signature
Name of Researcher Date Signature
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1. Levels of circulating microparticles in patients with gynaecological
malignancy - a case control study
Zahra S, Anderson JAM, Stirling D, Ludlam CA
Abstract and Poster
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2. Circulating microparticles in patients with gynaecological
malignancy
Zahra S, Anderson JAM, Stirling D, Ludlam CA
Abstract and Poster
15th Congress of the European Hematology Association, 2010
3. Microparticles malignancy and thrombosis - review
Zahra S, Anderson JAM, Stirling D, Ludlam CA
British Journal of Haematology 2011 Mar;152(6):688-700
4. Plasma microparticles are not elevated in fresh plasma from patients with
gynaecological malignancy - an observational study
Zahra S, Anderson JAM, Stirling D, Ludlam CA
Gynecologic Oncology 2011 Oct; 123( 1): 152-6
5. Study of the incidence of thrombotic events in patients with invasive
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